Bifunctional molecules containing E3 ubiquitin ligase binding moiety linked to BCL6 targeting moiety

By developing bifunctional compounds containing the E3 ubiquitin ligase binding part and the target protein binding part, the problem of difficulty in regulating BCL6 in the prior art has been solved, targeted degradation and inhibition of BCL6 has been achieved, and a wide range of therapeutic applications have been provided.

CN119019369APending Publication Date: 2024-11-26ARVINAS OPERATIONS INC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411130777.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-10-17
Filing Date
2020-10-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art is difficult to effectively target and regulate B-cell lymphoma 6 protein (BCL6), leading to challenges in the treatment of diseases related to BCL6 overexpression or aggregation.

Method used

Bifunctional compounds containing the E3 ubiquitin ligase binding moiety and the target protein binding moiety were developed to regulate BCL6 expression by recruiting the target protein to the E3 ubiquitin ligase.

Benefits of technology

Targeted degradation and inhibition of BCL6 is achieved, with broad-spectrum pharmacological activity, and can be used to treat a variety of cancers, including lymphoma and non-small cell lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019369A_ABST
    Figure CN119019369A_ABST
Patent Text Reader

Abstract

The present invention describes bifunctional molecules containing an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety. In particular, the present invention describes bifunctional compounds that can be used as a polymer of B cell lymphoma 6 protein (BCL6; a target protein). Specifically, the bifunctional compounds of the present disclosure contain, on one end, a Hilegel-forest, cerebellar, apoptosis inhibitor protein, or a mouse double minute homolog 2 ligand that binds to the corresponding E3 ubiquitin ligase, and on the other end, a moiety that binds to the target protein such that the target protein is disposed in proximity to the ubiquitin ligase, the degradation (and inhibition) of the target protein is realized. The bifunctional compounds of the present disclosure exhibit a wide range of pharmacological activities associated with degradation / inhibition of a target protein. The compounds and compositions of the present disclosure are used to treat or prevent diseases or conditions resulting from aggregation or accumulation of target proteins.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese patent application No. 202080088004.3, with an application date of October 16, 2020 and an invention name of “Bifunctional molecules containing an E3 ubiquitin ligase binding portion connected to a BCL6 targeting portion”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority to U.S. Provisional Patent Application No. 62 / 916,588, filed on October 17, 2019, entitled MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE, which is incorporated herein by reference in its entirety for all purposes.

[0004] Incorporated by reference

[0005] U.S. patent application serial number 15 / 230,354, filed on August 5, 2016, published as U.S. patent application publication number 2017 / 0065719; and U.S. patent application serial number 15 / 206,497, filed on July 11, 2016, published as U.S. patent application publication number 2017 / 0008904; and U.S. patent application serial number 15 / 209,648, filed on July 13, 2016, published as U.S. patent application publication number 2017 / 0037004; and U.S. patent application serial number 15 / 730,728, filed on October 11, 2017, published as U.S. patent application publication number 2018 / 0099940; and U.S. patent application serial number 14 / 686,640, filed on April 14, 2015, published as U.S. patent application publication number 2015 / 0291562; and U.S. patent application serial number 15 / 209,648, filed on July 13, 2016, published as U.S. patent application publication number 2017 / 0037004; No. 14 / 792,414, filed on July 11, 2014, published as U.S. Patent Application Publication No. 2016 / 0058872; and U.S. Patent Application Serial No. 14 / 371,956, filed on July 11, 2014, published as U.S. Patent Application Publication No. 2014 / 0356322; and U.S. Patent Application Serial No. 15 / 074,820, filed on March 18, 2016, published as U.S. Patent Application Publication No. 2016 / 0272639; and U.S. Patent Application Serial No. 15 / 885,671, filed on January 31, 2018, published as U.S. Patent Application Publication No. 2018 / 0215731A1; and International Patent Application No. PCT / US2016 / 023258, filed on March 18, 2016, published as International Patent Application Publication No. WO2016 / 149668, are all incorporated herein by reference in their entirety. Furthermore, all references cited herein are hereby incorporated by reference in their entirety. Technical Field

[0006] This specification provides bifunctional compounds comprising a target protein binding portion and an E3 ubiquitin ligase binding portion, and related methods of use. The bifunctional compounds can be used as modulators targeting ubiquitination, such as B-cell lymphoma 6 protein (BCL6), which is degraded and / or otherwise inhibited by the bifunctional compounds according to the present disclosure. Background Art

[0007] Most small molecule drugs bind enzymes or receptors in a tight and well-defined pocket. On the other hand, protein-protein interactions are notoriously difficult to target using small molecules due to their large contact surface and the shallow grooves or flat interfaces involved. E3 ubiquitin ligases (hundreds of which are known in humans) confer substrate specificity for ubiquitination, and therefore, due to their specificity for certain protein substrates, are more attractive therapeutic targets than general proteasome inhibitors. The development of E3 ligase ligands has proven challenging, in part due to the fact that they must destroy protein-protein interactions. However, recent developments have provided specific ligands that bind to these ligases. For example, since the discovery of the first small molecule E3 ligase inhibitor, nutlin, other compounds targeting E3 ligases have been reported, but this field is still underdeveloped.

[0008] One E3 ligase with exciting therapeutic potential is the von Hippel-Lindau (VHL) tumor suppressor, the substrate-recognition subunit of the E3 ligase complex VCB, which also consists of elongins B and C, Cul2, and Rbx1. VHL's primary substrate is hypoxia-inducible factor 1 (HIF-1α), a transcription factor that upregulates genes such as the pro-angiogenic growth factor VEGF and the red blood cell-inducing cytokine erythropoietin in response to low oxygen levels. The first small-molecule ligand of VHL that targets the substrate-recognition subunit of the E3 ligase was generated, and a crystal structure was obtained, demonstrating that the compound mimics the binding mode of the transcription factor HIF-1α, a major substrate of VHL.

[0009] Cerebellin is a protein encoded by the CRBN gene in humans. CRBN orthologs are highly conserved from plants to humans, underscoring its physiological importance. Cerebellin forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1), Cullin-4A (CUL4A), and regulator of cullin 1 (ROC1). This complex ubiquitinates numerous other proteins. Through mechanisms not yet fully elucidated, cerebellin ubiquitination of target proteins leads to increased levels of fibroblast growth factor 8 (FGF8) and fibroblast growth factor 10 (FGF10). FGF8, in turn, regulates numerous developmental processes, such as limb and auditory vesicle formation. The net result is that this ubiquitin ligase complex is important for limb growth in the embryo. In the absence of cerebellin, DDB1 forms a complex with DDB2, which acts as a DNA damage binding protein.

[0010] Bifunctional compounds, such as those described in U.S. Patent Application Publication Nos. 2015-0291562 and 2014-0356322 (incorporated herein by reference), are used to recruit endogenous proteins to E3 ubiquitin ligases for degradation. Specifically, this disclosure provides bifunctional or proteolytic targeting chimeric (PROTAC) compounds that are useful as targeted ubiquitination modulators of a variety of polypeptides and other proteins that, following targeted ubiquitination, are degraded and / or otherwise inhibited by the bifunctional compounds.

[0011] There is a continuing need in the art for effective treatments for diseases associated with overexpression or aggregation of the B-cell lymphoma 6 protein (BCL6). However, nonspecific effects and the inability to target and modulate BCL6 continue to hinder the development of effective therapeutics. Therefore, small molecule therapeutics that target BCL6 and influence or enhance the substrate specificity of E3 ubiquitin ligases (such as VHL and cerebellin) would be very useful. Summary of the Invention

[0012] The present disclosure describes bifunctional compounds and methods of use thereof, which are used to recruit endogenous proteins to E3 ubiquitin ligases for degradation. Specifically, the present disclosure provides bifunctional or proteolytic targeting chimeric compounds that are suitable for use as targeted ubiquitination regulators of a variety of polypeptides and other proteins, which are degraded and / or otherwise inhibited by the bifunctional compounds as described herein after targeted ubiquitination. An advantage of the compounds provided herein is that a broad spectrum of pharmacological activity can be present, consistent with the degradation / inhibition of targeted polypeptides from virtually any protein class or family. In addition, the present specification provides methods of using an effective amount of the compounds described herein to treat or ameliorate disease conditions, such as cancer, for example, lymphoma, B-cell non-Hodgkin's lymphoma, large B-cell lymphoma, Burkitt's lymphoma, follicular lymphoma, intravascular large B-cell lymphoma, B-cell leukemia, acute B-cell lymphocytic leukemia, chronic myeloid leukemia, and non-small cell lung cancer.

[0013] Thus, in one aspect, the present disclosure provides a bifunctional compound comprising an E3 ubiquitin ligase binding moiety (i.e., a ligand for an E3 ubiquitin ligase or "ULM" group) and a target protein binding moiety (i.e., a protein / polypeptide targeting ligand or "PTM" group), such that the target protein / polypeptide is placed in proximity to the ubiquitin ligase to achieve degradation (and inhibition) of the protein. In a preferred embodiment, the ULM (ubiquitination ligase modulator) can be a VHL-Lindau E3 ubiquitin ligase (VHL) binding moiety (VLM), or a cerebellum E3 ubiquitin ligase binding moiety (CLM). For example, the structure of the bifunctional compound can be depicted as:

[0014]

[0015] The corresponding positions of the PTM and ULM moieties (e.g., VLM or CLM) as shown herein and their number are provided by way of example only and are not intended to limit the compounds in any way. As will be appreciated by those skilled in the art, bifunctional compounds as described herein can be synthesized such that the number and position of the various functional moieties can vary as desired.

[0016] In certain embodiments, the bifunctional compound further comprises a chemical linker ("L"). In this example, the structure of the bifunctional compound can be depicted as:

[0017]

[0018] wherein PTM is a protein / peptide targeting moiety, L is a linker, such as a bond or chemical group that couples the PTM and the ULM, and the ULM is a VHL-binding moiety (VLM) or a cerebellum E3 ubiquitin ligase binding moiety (CLM).

[0019] For example, the structure of a bifunctional compound can be depicted as:

[0020]

[0021] wherein: PTM is a protein / polypeptide targeting moiety; "L" is a linker (e.g., a bond or chemical linker group) that couples PTM and at least one of VLM, CLM, or a combination thereof; VLM is a Hippel-Lindau E3 ubiquitin ligase binding moiety that binds to VHL E3 ligase; and CLM is a cerebellum E3 ubiquitin ligase binding moiety that binds to cerebellum.

[0022] In certain embodiments, the compounds as described herein comprise a plurality of independently selected ULMs, a plurality of PTMs, a plurality of chemical linkers, or a combination thereof.

[0023] In further embodiments, the VLM may be hydroxyproline or a derivative thereof. Additionally, other contemplated VLMs are contained in U.S. Patent Application Publication No. 2014 / 03022523, which, as noted above, is incorporated herein in its entirety.

[0024] In one embodiment, the CLM comprises a chemical group derived from an imide, a thioimide, an amide, or a thioamide. In a specific embodiment, the chemical group is a phthalimide group or an analog or derivative thereof. In certain embodiments, the CLM is thalidomide, lenalidomide, pomalidomide, an analog thereof, an isostere thereof, or a derivative thereof. Other contemplated CLMs are described in U.S. Patent Application Publication No. 2015 / 0291562, which is incorporated herein in its entirety.

[0025] In certain embodiments, "L" is a bond. In other embodiments, the linker "L" is a linker having a linear number of non-hydrogen atoms in the range of 1 to 20. The linker "L" may include, but is not limited to, functional groups such as ethers, amides, alkanes, alkenes, alkynes, ketones, hydroxyls, carboxylic acids, thioethers, sulfoxides, and sulfones. The linker may include aromatic, heteroaromatic, cyclic, bicyclic, and tricyclic moieties. Halogen substitutions such as Cl, F, Br, and I may be included in the linker. In the case of fluorine substitution, single or multiple fluorines may be included.

[0026] In certain embodiments, the VLM is a derivative of trans-3-hydroxyproline, wherein both the nitrogen and the carboxylic acid of trans-3-hydroxyproline are functionalized as amides.

[0027] In certain embodiments, CLM is a derivative of piperidine-2,6-dione, wherein piperidine-2,6-dione may be substituted at the 3-position, and the 3-substitution may be a bicyclic heteroaromatic having a CN bond or a CC bond. Examples of CLM may be, but are not limited to, pomalidomide, lenalidomide, and thalidomide, and derivatives thereof.

[0028] On the other hand, the present specification provides a therapeutic composition comprising an effective amount of a compound as described herein or a salt form thereof and a pharmaceutically acceptable carrier. The therapeutic composition regulates protein degradation and / or inhibition in a patient or subject (e.g., an animal, such as a human) and can be used to treat or improve a disease state or condition regulated by a protein that is degraded / inhibited. In certain embodiments, the therapeutic composition as described herein can be used to achieve degradation of a protein of interest to treat or improve a disease, such as cancer. In yet another aspect, the present disclosure provides a method for ubiquitination / degradation of a target protein in a cell. In certain embodiments, the method comprises administering a bifunctional compound as described herein, comprising a PTM and a VLM, or a PTM and a CLM, preferably connected by a linker moiety, as described elsewhere herein, wherein the VLM / CLM is coupled to the PTM via a linker to target a protein bound to the PTM for degradation. Similarly, the PTM can be coupled to a VLM or CLM via a linker to target a protein or polypeptide for degradation. When the target protein is placed near an E3 ubiquitin ligase, degradation of the target protein will occur, resulting in degradation / inhibition of the action of the target protein and control of protein levels. The control of protein levels provided by the present disclosure provides for the treatment of disease states or conditions that are modulated by the target protein by reducing the levels of that protein in the patient's cells.

[0029] In another aspect, the present disclosure provides a method for treating or improving a disease, disorder, or symptom thereof in a subject or patient (e.g., an animal, such as a human), the method comprising administering to a subject in need thereof a composition comprising an effective amount (e.g., a therapeutically effective amount) of a compound described herein or a salt form thereof, and a pharmaceutically acceptable carrier, wherein the composition is capable of effectively treating or improving the disease, disorder, or symptom thereof in the subject.

[0030] In another aspect, the present description provides methods of identifying the effects of degradation of a protein of interest in a biological system using compounds according to the present disclosure.

[0031] The aforementioned general practical areas are given for illustrative purposes only and are not intended to limit the scope of the present disclosure and the appended claims. Based on the claims, description, and examples, one of ordinary skill in the art will understand the additional objects and advantages associated with the compositions, methods, and methods of the present disclosure. For example, various aspects and embodiments of the present disclosure may be utilized in numerous combinations, all of which are explicitly contemplated by this specification. These additional aspects and embodiments are explicitly included within the scope of the present disclosure. Publications and other materials herein that are used to illustrate the background of the present disclosure and to provide additional details about practice in certain circumstances are incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] The accompanying drawings, which are incorporated into and constitute a part of this specification, illustrate several embodiments of the present disclosure and, together with the description, serve to explain the principles of the present disclosure. The accompanying drawings are only for the purpose of illustrating the embodiments of the present disclosure and should not be construed as limiting the present disclosure. Further objects, features, and advantages of the present disclosure will become apparent from the following detailed description taken in conjunction with the accompanying drawings, which illustrate exemplary embodiments of the present disclosure, wherein:

[0033] Figure 1A and Figure 1B . Schematic representation of the general principle of PROTAC function. ( Figure 1A ) An exemplary PROTAC comprises a protein targeting moiety (PTM; dark shaded rectangle), a ubiquitin ligase binding moiety (ULM; light shaded triangle), and optionally a linker moiety (L; black line) that couples or tethers the PTM to the ULM. ( Figure 1B ) illustrates the functional use of PROTACs as described herein. Briefly, ULMs recognize and bind to specific E3 ubiquitin ligases, and PTMs bind and recruit target proteins into close proximity with the E3 ubiquitin ligases. Typically, E3 ubiquitin ligases complex with E2 ubiquitin-binding proteins and, alone or through an E2 protein, catalyze the attachment of ubiquitin (dark circles) to lysines on target proteins via an isopeptide bond. Polyubiquitinated proteins are then targeted (far right) for degradation by the cell's proteasome machinery.

[0034] Figure 2A and Figure 2B . ( Figure 2A) Western blot showing BCL6 protein degradation in FaRAGE cells 24 hours after treatment. Protein lysates were electrophoresed on a 4-12% Bis Tris gel. BCL6 was detected using an anti-BCL6 antibody (PG-B6P, sc-56625) at a 1:500 dilution in 5% BSA-TBS-T and normalized to β-actin. β-actin was detected using an anti-β-actin antibody (CST, 8H10D10) at a 1:10,000 dilution in 5% BSA-TBS-T. ( Figure 2B )exist Figure 2A Figure 5. Quantification of BCL6 protein in western blots. The numbers above each bar indicate the % of BCL6 degradation. DETAILED DESCRIPTION

[0035] The following is a detailed description provided to help those skilled in the art practice the present disclosure. Those skilled in the art may make modifications and variations in the embodiments described herein without departing from the spirit or scope of the present disclosure. All publications, patent applications, patents, drawings, and other references mentioned herein are expressly incorporated by reference in their entirety.

[0036] The present invention describes compositions and methods that relate to the surprising and unexpected discovery that E3 ubiquitin ligase proteins (e.g., VHL or cerebellin) ubiquitinate target proteins upon proximity to the target protein via bifunctional or chimeric constructs that bind the E3 ubiquitin ligase protein and the target protein. Accordingly, the present disclosure provides such compounds and compositions comprising an E3 ubiquitin ligase targeting moiety ("ULM") coupled to a protein target binding moiety ("PTM") that will cause ubiquitination of a selected target protein, thereby leading to degradation of the target protein by the proteasome (see Figure 1A and Figure 1B ). The present disclosure also provides a composition library and its use.

[0037] In certain aspects, the present disclosure provides compounds comprising a ligand such as a small molecule ligand (i.e., a molecular weight of less than 2,000, 1,000, 500 or 200 Daltons) that is capable of binding to a ubiquitin ligase such as cerebellin or VHL. The compound further comprises a portion capable of binding to a target protein in such a way that the target protein is placed near the ubiquitin ligase to achieve degradation (and / or inhibition) of the protein. In addition to the above, a small molecule can also mean that the molecule is non-peptidyl, i.e., it is not generally considered a peptide, for example, comprising less than 4, 3 or 2 amino acids. According to the present specification, a PTM, ULM or bifunctional degradation molecule can be a small molecule.

[0038] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terms used in this specification are for describing particular embodiments only and are not intended to be limiting of the disclosure.

[0039] Where a range of values ​​is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise (e.g., in the case of a group containing multiple carbon atoms, in which case each number of carbon atoms falling within the range is provided), between the upper and lower limits of the range, and any other stated or intervening value within the stated range is encompassed within the disclosure. The upper and lower limits of these smaller ranges, which may independently be included in smaller ranges, are also encompassed within the disclosure, subject to any specifically excluded limitations in the stated range. Where the stated range includes one or both of the limits, ranges excluding either of these limits are also included in the disclosure.

[0040] The following terms are used to describe the present disclosure. Where a term is not specifically defined herein, the term is given the art-recognized meaning as applied by persons of ordinary skill in the art in the context of its use in describing the present disclosure.

[0041] As used herein and in the appended claims, the articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article, unless the context clearly dictates otherwise. For example, "an element" means one element or more than one element.

[0042] As used herein in the specification and claims, the phrase "and / or" should be understood to mean "either or both" of the elements so combined, i.e., elements that are present in combination in some cases and separately in other cases. Multiple elements listed with "and / or" should be interpreted in the same manner, i.e., "one or more" elements so combined. In addition to the elements specifically identified by the "and / or" clause, other elements may optionally be present, whether related or unrelated to those specifically identified. Thus, as a non-limiting example, a reference to "A and / or B," when used in conjunction with open language such as "comprising," may refer to A alone (optionally including elements other than B) in one embodiment; to B alone (optionally including elements other than A) in another embodiment; to both A and B (optionally including other elements) in yet another embodiment; and so on.

[0043] As used herein in the specification and claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating the items in a list, "or" or "and / or" should be interpreted as inclusive, i.e., including at least one, but also including more than one of a number of elements or a list of elements, and optionally, additionally unlisted items. Only when the contrary term is clearly indicated, such as "only one" or "exactly one", or, when used in the claims, "consisting of..." refers to exactly one element of a number of elements or a list of elements. In general, when preceded by an exclusive term such as "either", "one of", "only one" or "exactly one", as used herein, the term "or" should only be interpreted as indicating exclusive alternatives (i.e., "one or the other but not both").

[0044] In the claims and the foregoing description, all transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," "having," "consisting of," and the like are to be construed as open-ended, i.e., meaning including, but not limited to, "consisting of." Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively, as set forth in Section 2111.03 of the United States Patent Office Manual of Patent Examining Procedures.

[0045] As used herein in the specification and claims, referring to a list of one or more elements, the phrase "at least one" should be understood to mean at least one element selected from any one or more elements in the list of elements, but does not necessarily include at least one of each and every element specifically listed in the list of elements, and does not exclude any combination of elements in the list of elements. This definition also allows that in addition to the elements specifically identified within the list of elements to which the phrase "at least one" refers, elements, whether related or unrelated to those specifically identified, may optionally be present. Thus, as a non-limiting example, in one embodiment, "at least one of A and B" (or equivalently, "at least one of A or B," or equivalently, "at least one of A and / or B") may mean at least one, optionally including more than one A, with no B (and optionally including elements other than B); in another embodiment, at least one, optionally including more than one B, with no A (and optionally including elements other than A); in yet another embodiment, at least one, optionally including more than one A, and at least one B, optionally including more than one B (and optionally including other elements); and so on.

[0046] It should also be understood that in certain methods described herein that include more than one step or action, the order of the steps or actions of the method are not necessarily limited to the order in which the steps or actions of the method are recited unless the context dictates otherwise.

[0047] The term "co-administration" or "combination therapy" refers to concurrent administration (administration of two or more therapeutic agents at the same time) and timed administration (administration of one or more therapeutic agents at a different time than administration of other therapeutic agents or agents), as long as the therapeutic agents are present in the patient simultaneously, preferably in effective amounts, to some extent. In certain preferred aspects, one or more compounds of the invention described herein are co-administered in combination with at least one other biologically active agent (especially including anticancer agents). In particularly preferred aspects, co-administration of the compounds produces synergistic and / or therapeutic (including anticancer) activity.

[0048] Unless otherwise indicated, as used herein, the term "compound" refers to any specific compound disclosed herein and includes its tautomers, regioisomers, geometric isomers and, where applicable, stereoisomers, including optical isomers (enantiomers) and other stereoisomers (diastereomers), and, where applicable, pharmaceutically acceptable salts and derivatives thereof (including prodrug forms). Contemplated deuterated small molecules are those in which one or more hydrogen atoms contained in the drug molecule have been replaced by deuterium.

[0049] In its use in this context, the term compound generally refers to a single compound, but may also include other compounds, such as stereoisomers, regioisomers and / or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of the disclosed compounds. In this context, the term also refers to prodrug forms of the compounds that have been modified to facilitate administration and delivery of the compound to the active site. It should be noted that in describing the compounds herein, many substituents and variables associated therewith are described, among others. It will be understood by those of ordinary skill that the molecules described herein are stable compounds as generally described below. When bonds are shown, both double and single bonds are represented or understood within the context of the compounds shown and the well-known rules for valence interaction.

[0050] The term "ubiquitin ligase" refers to a family of proteins that facilitate the transfer of ubiquitin to specific substrate proteins to target them for degradation. For example, the cerebellum protein E3 ubiquitin ligase, alone or in combination with an E2 ubiquitin conjugating enzyme, causes the attachment of ubiquitin to lysines on target proteins and subsequently targets specific protein substrates for degradation by the proteasome. Therefore, E3 ubiquitin ligases, alone or in combination with an E2 ubiquitin conjugating enzyme, are responsible for the transfer of ubiquitin to target proteins. Typically, ubiquitin ligases involve polyubiquitination, where a second ubiquitin is attached to a first ubiquitin; a third ubiquitin is attached to a second ubiquitin, and so on. Polyubiquitination marks proteins for degradation by the proteasome. However, there are some ubiquitination events that are limited to monoubiquitination, in which only a single ubiquitin is added to the substrate molecule by the ubiquitin ligase. Monoubiquitinated proteins are not targeted for degradation by the proteasome, but can be altered in their cellular location or function, for example, by binding to other proteins with domains capable of binding ubiquitin. To complicate matters further, different lysines on ubiquitin can be targeted by E3s to make chains. The most common lysine is Lys48 on the ubiquitin chain. This is the lysine used to make polyubiquitin that is recognized by the proteasome.

[0051] The term "patient" or "subject" is used throughout the specification to describe an animal, preferably a human or domesticated animal, to whom treatment, including prophylactic treatment, is provided with a composition according to the present disclosure. For treatment of those infections, conditions, or disease states that are specific to a particular animal (e.g., a human patient), the term patient refers to that particular animal, including domesticated animals such as dogs or cats or farm animals such as horses, cattle, sheep, etc. In general, in this disclosure, unless otherwise specified or implied by the context in which the term is used, the term patient refers to a human patient.

[0052] The term "effective" is used to describe an amount of a compound, composition, or component that, when used in the context of its intended use, achieves the intended result. The term effective encompasses all other effective amount or effective concentration terms otherwise described or used in this application.

[0053] Compounds and compositions

[0054] In one aspect, the present disclosure provides a compound comprising an E3 ubiquitin ligase binding moiety ("ULM"), which is a cerebellum E3 ubiquitin ligase binding moiety ("CLM") and / or a VHL-Lindau E3 ubiquitin ligase (VHL) binding moiety (VLM). In an exemplary embodiment, the ULM is coupled to a target protein binding moiety (PTM) via a chemical linker (L) according to the following structure:

[0055] (A)PTM-L-ULM

[0056] Wherein L is a bond or chemical linker group, ULM is an E3 ubiquitin ligase binding moiety, and PTM is a target protein binding moiety. The number and / or relative positions of the moieties in the compounds shown herein are provided for example only. As will be appreciated by those skilled in the art, the compounds described herein can be synthesized with any desired number and / or relative positions of the various functional moieties.

[0057] Unless the context indicates otherwise, the terms ULM, VLM, and CLM are used in their inclusive sense. For example, the term ULM includes all ULMs, including those that bind cerebellum (i.e., CLM) and those that bind VHL (i.e., VLM). Furthermore, the term VLM includes all possible VHL binding moieties, and the term CLM includes all cerebellum binding moieties.

[0058] On the other hand, the present disclosure provides bifunctional or multifunctional compounds that can be used to modulate protein activity by inducing degradation of a target protein. In certain embodiments, the compound comprises a VLM or CLM coupled (e.g., covalently, directly or indirectly connected) to a portion that binds to a target protein (i.e., a protein targeting portion or "PTM"). In certain embodiments, VLM / CLM and PTM are joined or coupled via a chemical linker (L). VLM binds to VHL, and CLM binds to cerebellum protein E3 ubiquitin ligase, PTM recognizes the target protein, and the interaction of each portion with its target is beneficial to degrade the target protein by placing the target protein near the ubiquitin ligase protein. Exemplary bifunctional compounds can be depicted as:

[0059] (B) PTM-CLM

[0060] (C) PTM—VLM.

[0061] In certain embodiments, the bifunctional compound further comprises a chemical linker ("L"). For example, the bifunctional compound can be depicted as:

[0062] (D) PTM—L—CLM

[0063] (E) PTM-L-VLM,

[0064] wherein PTM is a protein / peptide targeting moiety, L is a chemical linker, CLM is a cerebellum protein E3 ubiquitin ligase binding moiety, and VLM is a VHL binding moiety.

[0065] In certain embodiments, a ULM (eg, CLM or VLM) exhibits activity or an IC of less than about 200 μM. 50 Binds to an E3 ubiquitin ligase (e.g., cerebellum E3 ubiquitin ligase or VHL). 50 It can be determined according to any method known in the art, such as fluorescence polarization analysis.

[0066] In certain additional embodiments, the bifunctional compounds described herein exhibit IC 50 An activity of less than about 100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 mM or less than about 100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 μM or less than about 100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 nM or less than about 100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 pM.

[0067] In certain embodiments, the compounds described herein comprise multiple PTMs (targeting the same or different protein targets), multiple ULMs, one or more ULMs (i.e., moieties that specifically bind to multiple / different E3 ubiquitin ligases, such as VHL and / or cerebellin), or a combination thereof. In any aspect or embodiment described herein, the PTMs and ULMs (e.g., VLMs and / or CLMs) can be coupled directly or via one or more chemical linkers, or a combination thereof. In further embodiments in which the compound has multiple ULMs, the ULMs can be for the same E3 ubiquitin ligase, or each corresponding ULM can specifically bind to a different E3 ubiquitin ligase. In further embodiments in which the compound has multiple PTMs, the PTMs can bind to the same target protein, or each corresponding PTM can specifically bind to a different target protein.

[0068] In certain embodiments where the compound comprises multiple ULMs, the ULMs are identical. In other embodiments where the compound comprises multiple ULMs (e.g., ULMs, ULM's, etc.), at least one PTM is coupled to the ULM directly, via a chemical linker (L), or both. In certain other embodiments, the compound comprising multiple ULMs also comprises multiple PTMs. In other embodiments, the PTMs are identical or, optionally, different. In other embodiments where the PTMs are different, each PTM may bind to the same protein target or specifically bind to different protein targets.

[0069] In certain embodiments, a compound may comprise multiple ULMs and / or multiple ULMs'. In other embodiments where the compound comprises at least two different ULMs, the multiple ULMs and / or multiple ULMs' further comprise at least one PTM coupled to the ULM or ULM' directly or via a chemical linker, or both. In any of the embodiments described herein, a compound comprising at least two different ULMs may also comprise multiple PTMs. In other embodiments, the PTMs are the same or optionally different. In other embodiments where the PTMs are different, each PTM may bind to the same protein target or specifically bind to different protein targets. In other embodiments, the PTM itself is a ULM (or ULM'), such as a VLM, CLM, VLM' and / or CLM'.

[0070] In further embodiments, the present description provides compounds as described herein, including enantiomers, diastereomers, solvates, and polymorphs thereof, including pharmaceutically acceptable salt forms, such as acid and base salt forms.

[0071] The term "independently" is used herein to indicate that independently applied variables vary independently from application to application.

[0072] The term "alkyl" in this context shall mean a straight-chain, branched or cyclic fully saturated hydrocarbon or alkyl group, preferably a C1-C 10 , more preferably C1-C6 or C1-C3 alkyl, it can be optionally substituted.The example of alkyl is especially methyl, ethyl, n-butyl, sec-butyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, isopropyl, 2-methylpropyl, cyclopropyl, cyclopropyl-methyl, cyclobutyl, cyclopentyl, cyclopentylethyl, cyclohexylethyl and cyclohexyl.In certain embodiments, alkyl is blocked with halogen group (At, Br, Cl, F or I).In certain preferred embodiments, compound according to the present disclosure can be used for being covalently bound to dehalogenase.These compounds generally contain the side chain (usually connected by polyethylene glycol group) of alkyl blocking, and the far end of described alkyl has halogen substituent (usually chlorine or bromine), thereby makes the compound containing this type of part be covalently bound to protein.

[0073] The term "alkenyl" refers to a linear, branched or cyclic C2-C 10 (Preferably C2-C6) hydrocarbon group.

[0074] The term "alkynyl" refers to a linear, branched or cyclic C2-C 10 (Preferably C2-C6) hydrocarbon group.

[0075] The term "alkylene" when used herein refers to an optionally substituted -(CH2)n -group (n is generally an integer from 0 to 6). When substituted, the alkylene group is preferably substituted on one or more methylene groups with a C1-C6 alkyl group (including a cyclopropyl or tert-butyl group), and may be substituted with one or more halo groups (preferably 1 to 3 halo groups) or one or two hydroxyl groups, O-(C1 to C6 alkyl) or an amino acid side chain as otherwise disclosed herein. In certain embodiments, the alkylene group may be substituted with a carbamate or alkoxy group (or other group), which is further substituted with a polyethylene glycol chain (a polyethylene glycol chain of 1 to 10, preferably 1 to 6, typically 1 to 4 ethylene glycol units), which is substituted (preferably, but not exclusively, at the distal end of the polyethylene glycol chain); an alkyl chain substituted with a single halo group (preferably a chloro group). In other embodiments, the alkylene (typically methylene) group can be substituted with an amino acid side chain group, such as a side chain group of a natural or unnatural amino acid, for example, alanine, β-alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, proline, serine, threonine, valine, tryptophan, or tyrosine.

[0076] The term "unsubstituted" shall mean substituted only with hydrogen atoms. A carbon atom range including CO means that the carbon is absent and replaced with H. Thus, a carbon atom range of CO-C6 includes 1, 2, 3, 4, 5, and 6 carbon atoms, and for CO, H replaces the carbon.

[0077] The term "substituted" or "optionally substituted" shall independently (i.e., when more than one substituent is present, each substituent is independent of the other substituents) mean one or more substituents (independently up to five substituents, preferably up to three substituents, often 1 or 2 substituents on a moiety in a compound according to the present disclosure, and which may themselves be further substituted) at a carbon (or nitrogen) position anywhere on the molecule within the context, and include hydroxy, thiol, carboxyl, cyano (C≡N), nitro (NO2), halogen (preferably 1, 2 or 3 halogens, especially alkyl, especially methyl such as trifluoromethyl), alkyl (preferably C1-C1-C2), ...1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1 10, more preferably C1-C6), aryl (especially phenyl and substituted phenyl, such as benzyl or benzoyl), alkoxy (preferably C1-C6 alkyl or aryl, including phenyl and substituted phenyl), thioether (C1-C6 alkyl or aryl), acyl (preferably C1-C6 acyl), ester or thioester (preferably C1-C6 alkyl or aryl) including alkylene ester (such that the attachment is on the alkylene, rather than at the ester function, the ester function is preferably substituted with C1-C6 alkyl or aryl), preferably C1-C6 alkyl or aryl, halogen (preferably F or Cl), amine (including five or six membered cyclic alkylene amines, also including C1-C6 C6 alkylamine or C1-C6 dialkylamine, the alkyl group may be substituted with one or two hydroxy groups) or optionally substituted -N(C0-C6 alkyl)C(O)(O-C1-C6 alkyl) group (which may be optionally further substituted with a polyethylene glycol chain, to which an alkyl group containing a single halogen, preferably chlorine, substituent is further bonded), hydrazine, amido, which is preferably substituted with one or two C1-C6 alkyl groups (including carboxamide optionally substituted with one or two C1-C6 alkyl groups), alkanol (preferably C1-C6 alkyl or aryl), or alkanoic acid (preferably C1-C6 alkyl or aryl) as substituents. Substituents according to the present disclosure may include, for example, -SiR1R2R3 groups, wherein R1 and R2 are each as described elsewhere herein, and R3 is H or C1-C6 alkyl, preferably R1, R2, R3 in this context are C1-C3 alkyl (including isopropyl or tert-butyl). Each of the above groups may be directly attached to the substituted moiety, or alternatively, the substituent may be attached via an optionally substituted -(CH2) m - or alternatively optionally substituted -(OCH2) m -、-(OCH2CH2) m -or-(CH2CH2O) m - group (which may be substituted by any one or more of the above substituents) is attached to the substituted moiety (preferably in the case of an aryl or heteroaryl moiety). As identified above, an alkylene group -(CH2) m -or-(CH2) n-Groups or other chains (e.g., ethylene glycol chains) can be substituted anywhere on the chain. Preferred substituents on the alkylene group include halogen or C1-C6 (preferably C1-C3) alkyl, which can be optionally substituted with one or two hydroxyl groups, one or two ether groups (O-C1-C6 groups), up to three halogen groups (preferably F) or the side chains of amino acids as described elsewhere herein and optionally substituted amides (preferably formamides substituted as described above) or carbamate groups (often with one or two C0-C6 alkyl substituents, which can be further substituted). In certain embodiments, the alkylene group (typically a single methylene group) is substituted with one or two optionally substituted C1-C6 alkyl groups, preferably C1-C4 alkyl groups, most typically methyl or O-methyl, or the side chains of amino acids as described elsewhere herein. In the present disclosure, a portion in the molecule can be optionally substituted with up to five substituents, preferably up to three substituents. Most often, in the present disclosure, a substituted portion is substituted with one or two substituents.

[0078] The term "substituted" (each substituent being independent of any other substituent) in the context in which it is used shall also mean C1-C6 alkyl, C1-C6 alkoxy, halogen, amide, formamide, sulfone (including sulfonamide), keto, carboxyl, C1-C6 ester (oxyester or carbonyl ester), C1-C6 keto, carbamate -OC(O)-NR1R2 or -N(R1)-C(O)-O-R1, nitro, cyano and amine (especially including C1-C6 alkylene -NR1R2, mono- or di-C1-C6 alkyl substituted amine, which may be optionally substituted with one or two hydroxy groups). Within the context, unless otherwise stated, each of these groups contains 1 to 6 carbon atoms. In certain embodiments, preferred substituents will include, for example, -NH-, -NHC(O)-, -O-, =O, -(CH2) m - (wherein m and n are in this context 1, 2, 3, 4, 5 or 6), -S-, -S(O)-, SO2- or -NH-C(O)-NH-, -(CH2) n OH, -(CH2) n SH, -(CH2) n COOH, C1-C6 alkyl, -(CH2) n O-(C1-C6 alkyl), -(CH2) n C(O)-(C1-C6 alkyl), -(CH2) n OC(O)-(C1-C6 alkyl), -(CH2) n C(O)O-(C1-C6 alkyl), -(CH2) n NHC(O)-R1, -(CH2) n C(O)-NR1R2, -(OCH2)n OH, -(CH2O) n COOH, C1-C6 alkyl, -(OCH2) n O-(C1-C6 alkyl), -(CH2O) n C(O)-(C1-C6 alkyl), -(OCH2) n NHC(O)-R1, -(CH2O) n C(O)-NR1R2, -S(O)2-R S 、-S(O)-R S (R S is C1-C6 alkyl or -(CH2) m -NR1R2 groups), NO2, CN or halogen (F, Cl, Br, I, preferably F or Cl), depending on the context in which the substituent is used. Within this context, R1 and R2 are each H or C1-C6 alkyl (which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups, preferably fluorine). Within the chemical context of the defined compounds and substituents used, the term "substituted" shall also mean optionally substituted aryl or heteroaryl groups or optionally substituted heterocyclyl groups as described elsewhere herein. As disclosed elsewhere herein, alkylene groups may also be substituted, preferably with optionally substituted C1-C6 alkyl (methyl, ethyl or hydroxymethyl or hydroxyethyl are preferred, thus providing a chiral center), the side chain of an amino acid group as described elsewhere herein, an amide group as described above, or a carbamate group OC(O)-NR1R2 group, wherein R1 and R2 are as described elsewhere herein, but many other groups may also be used as substituents. The various optionally substituted moieties may be substituted with 3 or more substituents, preferably not more than 3 substituents, preferably 1 or 2 substituents. It should be noted that in cases where compounds at a particular position of the molecule require substitution (primarily due to valency) but no substitution is indicated, the substituent is interpreted or understood to be H unless the context of the substitution suggests otherwise.

[0079] In this context, the term "aryl" or "aromatic" refers to a substituted (as otherwise described herein) or unsubstituted monovalent aromatic group having a single ring (e.g., benzene, phenyl, benzyl) or fused rings (e.g., naphthyl, anthracenyl, phenanthrenyl, etc.), and is capable of being bound to the compounds according to the present disclosure at any available stable position on the ring or as otherwise indicated in the presented chemical structure. In this context, other examples of aryl groups may include heterocyclic aromatic ring systems, "heteroaryl" having one or more nitrogen, oxygen, or sulfur atoms in the ring (monocyclic), such as imidazole, furanyl, pyrrole, furanyl, thiophene, thiazole, pyridine, pyrimidine, pyrazine, triazole, oxazole, or fused ring systems such as indole, quinoline, indolizine, azaindolizine, benzofurazane, etc., which may be optionally substituted as described above. Heteroaryl groups that may be mentioned include nitrogen-containing heteroaryl groups such as pyrrole, pyridine, pyridone, pyridazine, pyrimidine, pyrazine, pyrazole, imidazole, triazole, triazine, tetrazole, indole, isoindole, indolizine, azaindolizine, purine, indazole, quinoline, dihydroquinoline, tetrahydroquinoline, isoquinoline, dihydroisoquinoline, tetrahydroisoquinoline, quinolizine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, imidazopyridine, imidazotriazine, pyrazinopyridazine, acridine, phenanthidine, carbazole, carbazoline, pyrimidine, phenanthroline, phenanthene, oxadiazole, benzimidazole, pyrrolopyridine, pyrrolopyrimidine and pyridine pyrrole, pyridoxazine, furopyridine, furopyrimidine, thienopyrimidine and oxazole, all of which may be optionally substituted.

[0080] The term "substituted aryl" refers to an aromatic carbocyclic group comprising at least one aromatic ring or multiple fused rings, at least one of which is aromatic, wherein the ring is substituted with one or more substituents. For example, an aryl group may comprise a substituent selected from: -(CH2) n OH, -(CH2) n -O-(C1-C6)alkyl, -(CH2) n -O-(CH2) n -(C1-C6)alkyl, -(CH2) n -C(O)(C0-C6)alkyl, -(CH2) n -C(O)O(C0-C6)alkyl, -(CH2) n-OC(O)(C0-C6)alkyl, amine, mono- or di-(C1-C6alkyl)amine, wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl or up to three halo (preferably F, Cl) groups, OH, COOH, C1-C6alkyl, preferably CH3, CF3, OMe, OCF3, NO2 or CN groups (each of which may be substituted in the ortho, meta and / or para position, preferably the para position, of the phenyl ring), optionally substituted phenyl (the phenyl group itself is preferably linked to the PTM group, including the ULM group, via a linker group), and / or at least one of F, Cl, OH, COOH, CH3, CF3, OMe, OCF3, NO2 or CN groups (in the ortho, meta and / or para position, preferably the para position, of the phenyl ring), naphthyl (which may be optionally substituted), optionally substituted heteroaryl (preferably optionally substituted isoxazole, including methyl substituted isoxazole), optionally substituted oxazole including methyl substituted oxazole, optionally substituted thiazole including methyl substituted thiazole, optionally substituted isothiazole including methyl substituted isothiazole, optionally substituted pyrrole including methyl substituted pyrrole, optionally substituted imidazole including methylimidazole, optionally substituted benzimidazole or methoxybenzimidazole, optionally substituted oxaimidazole or methyloxaimidazole, optionally substituted diazolyl including methyldiazolyl, optionally substituted triazolyl, optionally substituted pyridinyl including halo- (preferably F) or methyl substituted pyridinyl or oxapyridinyl (wherein the pyridinyl is attached to the phenyl group through an oxygen), optionally substituted furan, optionally substituted benzofuran, optionally substituted dihydrobenzofuran, optionally substituted indole, indolizine or azaindolizine (2, 3 or 4-azaindolizine), optionally substituted quinoline and combinations thereof.

[0081] "Carboxyl" refers to the group --C(O)OR, where R is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl, however, these general substituents have the same meanings as those defined herein.

[0082] The term "heteroaryl" or "hetaryl" may refer to, but is in no way limited to, optionally substituted quinoline (which may be attached to a pharmacophore or substituted on any carbon atom within the quinoline ring), optionally substituted indole (including dihydroindole), optionally substituted indolizine, optionally substituted azaindolizine (2-azaindolizine, 3-azaindolizine or 4-azaindolizine), optionally substituted benzimidazole, benzodiazole, benzofuroxazole, benzothiazolyl ... oxazolidinone, optionally substituted imidazole, optionally substituted isoxazole, optionally substituted oxazole (preferably substituted with methyl), optionally substituted diazole, optionally substituted triazole, tetrazole, optionally substituted benzofuran, optionally substituted thiophene, optionally substituted thiazole (preferably substituted with methyl and / or thiol), optionally substituted isothiazole, optionally substituted triazole (preferably 1,2,3-triazole substituted with methyl, triisopropylsilyl, optionally substituted -(CH2) m -O-C1-C6 alkyl or optionally substituted -(CH2) M -C(O)-O-C1-C6 alkyl), optionally substituted pyridine (2-pyridine, 3-pyridine or 4-pyridine), or a group conforming to the following chemical structure:

[0083]

[0084] in:

[0085] S c It is CHR SS NR URE or O;

[0086] R HET is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halo groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halo groups) or optionally substituted alkynyl -C≡CR a , where R a is H or C1-C6 alkyl (preferably C1-C3 alkyl);

[0087] R SS is H, CN, NO2, halo (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O-(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups), or optionally substituted -C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);

[0088] R UREis H, C1-C6 alkyl (preferably H or C1-C3 alkyl) or -C(O)(C1-C6 alkyl), each of which is optionally substituted with one or two hydroxyl groups or up to three halogen groups (preferably fluoro groups), or an optionally substituted heterocycle, such as piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and

[0089] Y C Is N or CR YC , where R YC is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halo groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halo groups) or optionally substituted alkynyl -C≡CR a , where R a It is H or C1-C6 alkyl (preferably C1-C3 alkyl).

[0090] The terms "aralkyl" and "heteroarylalkyl" refer to groups containing an aryl or heteroaryl group, respectively, and an alkyl and / or heteroalkyl and / or carbocyclic and / or heterocycloalkyl ring system meeting the above definitions.

[0091] As used herein, the term "aralkyl" refers to an aryl group as defined above attached to an alkyl group as defined above. The aralkyl group is attached to the parent moiety via the alkyl group, wherein the alkyl group has one to six carbon atoms. The aryl group in the aralkyl group may be substituted as defined above.

[0092] The term "heterocycle" refers to a ring radical containing at least one heteroatom (e.g., N, O, or S) and can be aromatic (heteroaryl) or non-aromatic. Thus, depending on the context in which it is used, heteroaryl moieties are included under the definition of heterocycle. Exemplary heteroaryl groups are as described above.

[0093] Exemplary heterocycles include: azetidinyl, benzimidazolyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, benzoxazolyl, benzothiazolyl, benzothienyl, dihydroimidazolyl, dihydropyranyl, dihydrofuranyl, dioxanyl, dioxolanyl, ethylene urea, 1,3-dioxolane, 1,3-dioxane, 1,4-dioxane, furanyl, homopiperidinyl, imidazolyl, imidazolinyl, imidazolidinyl, indolinyl, indolyl, isoquinolinyl , isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, naphthyridinyl, oxazolidinyl, oxazolyl, pyridone, 2-pyrrolidone, pyridine, piperazinyl, N-methylpiperazinyl, piperidinyl, phthalimide, succinimide, pyrazinyl, pyrazolinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinolinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydroquinoline, thiazolidinyl, thiazolyl, thienyl, tetrahydrothiophene, oxane, oxetanyl, oxathiolanyl, thiazane and the like.

[0094] The heterocyclic group may be optionally substituted by a member selected from the group consisting of alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocycle, heterocyclooxy, hydroxylamino, alkoxyamino, nitro, -SO-alkyl, alkyl substituted with -SO-, -SOaryl, -SO-heteroaryl, -SO2-alkyl, alkyl substituted with -SO2-, -SO2-aryl, oxo (═O), and -SO2-heteroaryl. Such heterocyclic groups may have a single ring or multiple fused rings. Examples of nitrogen heterocycles and heteroaryl groups include, but are not limited to, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthidine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidinium, imidazoline, piperidine, piperazine, indoline, N-morpholinyl, piperidinyl, tetrahydrofuranyl, and the like, as well as N-alkoxy-nitrogen heterocycles. The term "heterocycle" also includes bicyclic groups in which any one of the heterocycles is fused to a benzene ring or a cyclohexane ring or another heterocycle (e.g., indolyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, etc.).

[0095] The term "cycloalkyl" may refer to, but is in no way limited to, a monovalent group derived from a monocyclic or polycyclic alkyl group or cycloalkane as defined herein, such as a saturated monocyclic hydrocarbon group having three to twenty carbon atoms in the ring, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc. The term "substituted cycloalkyl" may refer to, but is in no way limited to, a monocyclic or polycyclic alkyl group substituted with one or more substituents, such as amino, halogen, alkyl, substituted alkyl, carbonyloxy, carbonylthiol, aryl, nitro, thiol, or sulfonic acid, and these general substituents have the same meanings as the corresponding groups defined in this legend.

[0096] “Heterocycloalkyl” refers to a monocyclic or polycyclic alkyl group wherein at least one ring carbon atom in the cyclic structure is replaced by a heteroatom selected from the group consisting of N, O, S or P. “Substituted heterocycloalkyl” refers to a monocyclic or polycyclic alkyl group wherein at least one ring carbon atom in the cyclic structure is replaced by a heteroatom selected from the group consisting of N, O, S or P and the group contains one or more substituents selected from the group consisting of halogen, alkyl, substituted alkyl, carbonyloxy, carbonylthiol, aryl, nitro, thiol or sulfonic acid, and the meanings of these general substituents are the same as those of the corresponding groups defined in this legend.

[0097] The term "hydrocarbyl" shall mean a compound containing carbon and hydrogen and which may be fully saturated, partially unsaturated or aromatic, and includes aryl, alkyl, alkenyl and alkynyl groups.

[0098] The term "independently" is used herein to indicate that independently applied variables vary independently from application to application.

[0099] The term "lower alkyl" refers to methyl, ethyl or propyl

[0100] The term "lower alkoxy" refers to methoxy, ethoxy or propoxy.

[0101] Exemplary CLM

[0102] New imide compounds

[0103] In one aspect, the present disclosure provides compounds that can be used to bind and / or inhibit cerebellin. In certain embodiments, the compound is selected from the following chemical structures:

[0104]

[0105]

[0106] in:

[0107] W of formula (a) to (f) is independently selected from CH2O, CHR, C=O, SO2, NH, N, optionally substituted cyclopropyl, optionally substituted cyclobutyl and N-alkyl;

[0108] W3 is selected from C or N;

[0109] X of formulae (a) to (f) is independently selected from absent, O, S and CH2;

[0110] Y of formulas (a) to (f) is independently selected from CH2, -C=CR', NH, N-alkyl, N-aryl, N-heteroaryl, N-cycloalkyl, N-heterocyclyl, O and S;

[0111] Z of formulae (a) to (f) is independently selected from absent, O and S or CH2, except that X and Z cannot both be CH2 or absent;

[0112] G and G' of formulae (a) to (f) are independently selected from H, optionally substituted linear or branched alkyl, OH, R'OCOOR, R'OCONRR", CH2-heterocyclyl optionally substituted by R' and benzyl optionally substituted by R';

[0113] Q1-Q4 of formulae (a) to (f) represent carbon C or N substituted by a group independently selected from H, R, N or N-oxide;

[0114] A of formulae (a) to (f) is independently selected from H, optionally substituted linear or branched alkyl, cycloalkyl, Cl and F;

[0115] n' of formulae (a) to (f) represents an integer of 1 to 10 (e.g., 1-4, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10);

[0116] R in formulas (a) to (f) includes, but is not limited to, H, -C(=O)R' (e.g., a carboxyl group), -CONR'R" (e.g., an amide group), -OR' (e.g., OH or OCH3), -NR'R" (e.g., an amine group), -SR', -SO2R', -SO2NR'R", -CR'R"-, -CR'NR'R"-, (-CR'O) n’R", optionally substituted heterocyclyl, optionally substituted aryl (e.g., optionally substituted C5-C7 aryl), optionally substituted alkyl-aryl (e.g., alkyl-aryl comprising at least one of optionally substituted C1-C6 alkyl, optionally substituted C5-C7 aryl, or a combination thereof), optionally substituted heteroaryl), optionally substituted alkyl (e.g., C1-C6 linear or branched alkyl, optionally substituted with one or more halogen, cycloalkyl (e.g., C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted alkoxy (e.g., methoxy, ethoxy, butoxy, propoxy, pentyloxy, or hexyloxy; wherein the alkoxy may be substituted with one or more halogen, alkyl, haloalkyl, fluoroalkyl, cycloalkyl (e.g., C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted (e.g., optionally substituted with one or more halogen, alkyl, haloalkyl, fluoroalkyl, cycloalkyl (e.g., C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted (e.g., optionally substituted with one or more halogen, alkyl, haloalkyl, fluoroalkyl, cycloalkyl (e.g., C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted cycloalkyl, optionally substituted heterocyclyl, -P(O)(OR')R", -P(O)R'R", -OP(O)(OR')R", -OP(O)R'R", -Cl, -F, -Br, -I, -CF3, -CN, -NR'SO2NR'R", -NR 'CONR'R", -CONR'COR", -NR'C(=N-CN)NR'R", -C(=N-CN)NR'R", -NR'C(=N-CN)R", -NR'C(=C-NO2)NR'R ", -SO2NR'COR", -NO2, -CO2R', -C(C=N-OR')R", -CR'=CR'R", -CCR', -S(C=O)(C=N-R')R", -SF5 and -OCF3;

[0117] Each of x, y, and z is independently 0, 1, 2, 3, 4, 5, or 6;

[0118] R' and R" of formula (a) to (f) are independently selected from H, optionally substituted linear or branched alkyl (e.g., methyl or ethyl), optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, -C(=O)R, optionally substituted heterocyclyl;

[0119] n' of formulas (a) to (f) is an integer of 1-10 (e.g., 1-4, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10);

[0120] represents a single bond or a double bond; and

[0121] The bonds of formulae (a) to (f) represent stereospecific ((R) or (S)) or non-stereospecific bonds.

[0122] Exemplary CLM

[0123] In any of the compounds described herein, the CLM comprises a chemical structure selected from:

[0124]

[0125]

[0126] in:

[0127] W of formula (a) to (f) is independently selected from CH2O, CHR, C=O, SO2, NH, N, optionally substituted cyclopropyl, optionally substituted cyclobutyl and N-alkyl;

[0128] W3 is selected from C or N;

[0129] X of formula (a) to (f) is independently selected from O, S and CH2;

[0130] Y of formulas (a) to (f) is independently selected from CH2, -C=CR', NH, N-alkyl, N-aryl, N-heteroaryl, N-cycloalkyl, N-heterocyclyl, O and S;

[0131] Z of formulas (a) to (f) is independently selected from O, S or CH2, except that X and Z cannot both be CH2 or are absent;

[0132] G and G' of formulae (a) to (f) are independently selected from H, optionally substituted linear or branched alkyl, OH, R'OCOOR, R'OCONRR", CH2-heterocyclyl optionally substituted by R' and benzyl optionally substituted by R';

[0133] Q1-Q4 of formulae (a) to (f) represent carbon C or N substituted by a group independently selected from H, R, N or N-oxide;

[0134] A of formulae (a) to (f) is independently selected from H, optionally substituted linear or branched alkyl, cycloalkyl, Cl and F;

[0135] n' of formulae (a) to (f) represents an integer of 1 to 10 (e.g., 1-4, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10);

[0136] R in formulas (a) to (f) includes, but is not limited to, H, -C(=O)R' (e.g., a carboxyl group), -CONR'R" (e.g., an amide group), -OR' (e.g., OH), -NR'R" (e.g., an amine group), -SR', -SO2R', -SO2NR'R", -CR'R"-, -CR'NR'R"-, (-CR'O) n’ R", optionally substituted aryl (e.g., optionally substituted C5-C7 aryl), optionally substituted alkyl-aryl (e.g., alkyl-aryl comprising at least one of optionally substituted C1-C6 alkyl, optionally substituted C5-C7 aryl, or a combination thereof), optionally substituted heteroaryl, optionally substituted linear or branched alkyl (e.g., C1-C6 linear or branched alkyl, optionally substituted with one or more halogen, cycloalkyl (e.g., C3-C6 cycloalkyl) or aryl (e.g., C5-C7 aryl)), optionally substituted alkoxy (e.g., methoxy, ethoxy, butoxy, propoxy, pentyloxy or hexyloxy; wherein the alkoxy may be substituted with one or more halogen, alkyl, haloalkyl, fluoroalkyl, cycloalkyl (e.g., C3-C6 cycloalkyl) or aryl (e.g., C5-C7 aryl)), optionally substituted (e.g., optionally substituted with one or more halogen, alkyl, haloalkyl, fluoroalkyl, cycloalkyl (e.g., C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted (e.g., optionally substituted with one or more halogen, alkyl, haloalkyl, fluoroalkyl, cycloalkyl (e.g., C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted cycloalkyl, optionally substituted heterocyclyl, -P(O)(OR')R", -P(O)R'R", -OP(O)(OR')R", -OP(O)R'R", -Cl, -F, -Br, -I, -CF3, -CN, -NR'SO2NR'R", -NR 'CONR'R", -CONR'COR", -NR'C(=N-CN)NR'R", -C(=N-CN)NR'R", -NR'C(=N-CN)R", -NR'C(=C-NO2)NR'R ", -SO2NR'COR", -NO2, -CO2R', -C(C=N-OR')R", -CR'=CR'R", -CCR', -S(C=O)(C=N-R')R", -SF5 and -OCF3;

[0137] Each of x, y, and z is independently 0, 1, 2, 3, 4, 5, or 6;

[0138] R' and R" of formula (a) to (f) are independently selected from a bond, H, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted heterocycle, -C(=O)R, an optionally substituted heterocyclyl group;

[0139] n' of formulas (a) to (f) is an integer from 1 to 10 (e.g., 1 to 4, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10); and

[0140] The bonds of formulae (a) to (f) represent stereospecific ((R) or (S)) or non-stereospecific bonds.

[0141] In certain embodiments described herein, the CLM or ULM comprises a chemical structure selected from the group consisting of:

[0142]

[0143] Formula (g)

[0144] in:

[0145] W of formula (g) is independently selected from CH2, O, C=O, NH and N-alkyl;

[0146] A of formula (g) is selected from H, methyl or an optionally substituted linear or branched alkyl group;

[0147] n is an integer from 1 to 4;

[0148] R of formula (g) is independently selected from H, O, OH, N, NH, NH2, methyl, optionally substituted linear or branched alkyl (e.g., optionally substituted linear or branched C1-C6 alkyl, C1-C6 alkoxy, -alkyl-aryl (e.g., -alkyl-aryl comprising at least one of C1-C6 alkyl, C4-C7 aryl, or a combination thereof), aryl (e.g., C5-C7 aryl), amine, amide, or carboxyl), wherein one R or W is optionally modified to be covalently linked to a PTM, a chemical linker group (L), ULM, CLM (or CLM'), or a combination thereof; and

[0149] Formula (g) represents a bond that can be stereospecific ((R) or (S)) or non-stereospecific.

[0150] In any aspect or embodiment described herein, R is selected from O, OH, N, NH, NH2, C1-C6 alkyl, C1-C6 alkoxy, -alkyl-aryl (e.g., -alkyl-aryl comprising at least one of C1-C6 alkyl, C4-C7 aryl, or a combination thereof), aryl (e.g., C5-C7 aryl), amine, amide, or carboxyl).

[0151] In any aspect or embodiment described herein, at least one R (R group is selected from O, OH, N, NH2, C1-C6 alkyl, C1-C6 alkoxy, -alkyl-aryl (e.g., -alkyl-aryl comprising at least one of C1-C6 alkyl, C4-C7 aryl, or a combination thereof), aryl (e.g., C5-C7 aryl), amine, amide, or carboxyl) or W is modified to be covalently linked to a PTM, a chemical linking group (L), a ULM, a CLM' (e.g., CLM' is an additional CLM having the same or different structure as the first CLM), or a combination thereof

[0152] In any of the embodiments described herein, W, X, Y, Z, G, G', R, R', R", Q1-Q4, A, and Rn of Formulas (a) to (g) can be independently covalently coupled to a linker and / or a linker to which one or more PTM, ULM, CLM, or CLM' groups are attached.

[0153] In any aspect or embodiment described herein, on the aryl or heteroaryl group of CLM, R n comprises 1 to 4 independently selected functional groups or atoms, such as O, OH, N, C1-C6 alkyl, C1-C6 alkoxy, -alkyl-aryl (e.g., -alkyl-aryl comprising at least one of C1-C6 alkyl, C4-C7 aryl, or a combination thereof), aryl (e.g., C5-C7 aryl), amine, amide, or carboxyl, and optionally, one of which is modified to be covalently linked to a PTM, a chemical linker group (L), ULM, CLM (or CLM'), or a combination thereof.

[0154] More specifically, non-limiting examples of CLMs include those shown below as well as those "hybrid" molecules that arise from a combination of one or more of the different features shown in the molecules below.

[0155]

[0156]

[0157]

[0158]

[0159]

[0160]

[0161]

[0162]

[0163]

[0164]

[0165] In any of the compounds described herein, the CLM comprises a chemical structure selected from:

[0166]

[0167]

[0168]

[0169]

[0170] in:

[0171] W is independently selected from CH2, CHR, C=O, SO2, NH, N, an optionally substituted cyclopropyl group, an optionally substituted cyclobutyl group, and N-alkyl (e.g., CH2, CHR, C=O, SO2, NH, and N-alkyl);

[0172] Q1, Q2, Q3, Q4, Q5 each independently represent a carbon C or N substituted by a group independently selected from R', N or N-oxide;

[0173] R 1 Selected from absent, H, OH, CN, C1-C3 alkyl, C=O;

[0174] R 2 Selected from absent, H, OH, CN, C1-C3 alkyl, CHF2, CF3, CHO, C(=O)NH2;

[0175] R 3 is selected from H, alkyl (e.g., C1-C6 or C1-C3 alkyl), substituted alkyl (e.g., substituted C1-C6 or C1-C3 alkyl), alkoxy (e.g., C1-C6 or C1-C3 alkoxy), substituted alkoxy (e.g., substituted C1-C6 or C1-C3 alkoxy), 3-5 membered cycloalkyl or cycloheteroalkyl;

[0176] R 4 is selected from H, alkyl, substituted alkyl;

[0177] R 5 and R 6 Each is independently H, halogen, C(=O)R', CN, OH, CF3;

[0178] X is C, CH, C═O or N;

[0179] X1 is C=O, N, CH or CH2;

[0180] R' is selected from H, halogen, amine, alkyl (eg C1-C3 alkyl), substituted alkyl (eg C1-C3 alkyl), alkoxy (eg C1-C3 alkoxy), substituted alkoxy (eg C1-C3 alkoxy), NR 2 R 3 、C(=O)OR 2 、C(=O)R 2 , optionally substituted phenyl;

[0181] n is 0-4;

[0182] is a single bond or a double bond; and

[0183] The CLM is covalently linked to a PTM, a chemical linker group (L), a ULM, a CLM (or CLM'), or a combination thereof.

[0184] In any aspect or embodiment described herein, CLM or CLM' is cleaved via an R group (e.g., R 1 、R 2 、R 3 、R 4 or R'), W, X, or a Q group (eg, Q1, Q2, Q3, Q4, or Q5) is covalently linked to a PTM, a chemical linker group (L), ULM, CLM, CLM', or a combination thereof.

[0185] In any of the embodiments described herein, CLM or CLM' is cleaved via W, X, R, R 1 、R 2 、R 3 、R 4 、R 5 , R', Q1, Q2, Q3, Q4 and Q5 are covalently linked to a PTM, a chemical linker group (L), ULM, CLM, CLM' or a combination thereof.

[0186] In any of the embodiments described herein, W, X, R 1 、R 2 、R 3 、R 4 , R', Q1, Q2, Q3, Q4 and Q5 can be independently covalently coupled to a linker and / or a linker attached to one or more PTM, ULM, ULM', CLM or CLM' groups.

[0187] More specifically, non-limiting examples of CLMs include those shown below, as well as "hybrid" molecules or compounds that arise from combining one or more of the different features of the following compounds:

[0188]

[0189]

[0190]

[0191] in:

[0192] W is independently selected from CH2, CHR, C=O, SO2, NH and N-alkyl;

[0193] R 1 Selected from absent, H, CH, CN, C1-C3 alkyl;

[0194] R 2 is H or C1-C3 alkyl;

[0195] R 3 is selected from H, alkyl, substituted alkyl, alkoxy, substituted alkoxy;

[0196] R 4 is methyl or ethyl;

[0197] R 5 is H or halogen;

[0198] R 6 is H or halogen;

[0199] The R of CLM is H;

[0200] R' is H or the point of attachment of a PTM, PTM', a chemical linker group (L), a ULM, a CLM, or a CLM',

[0201] Q1 and Q2 are each independently C or N substituted with a group independently selected from H or C1-C3 alkyl;

[0202] is a single bond or a double bond; and

[0203] Rn includes a functional group or an atom.

[0204] In any of the embodiments described herein, W, R 1 、R 2 , Q1, Q2, Q3, Q4 and Rn can be independently covalently coupled to a linker and / or a linker attached to one or more PTM, ULM, ULM', CLM or CLM' groups.

[0205] In any of the embodiments described herein, R 1 、R 2 , Q1, Q2, Q3, Q4 and Rn can be independently covalently coupled to a linker and / or a linker attached to one or more PTM, ULM, ULM', CLM or CLM' groups.

[0206] In any of the embodiments described herein, Q1, Q2, Q3, Q4, and Rn can be independently covalently coupled to a linker and / or a linker attached to one or more PTM, ULM, ULM', CLM, or CLM' groups.

[0207] In any aspect or embodiment described herein, R n Modified to be covalently attached to a linker group (L), a PTM, a ULM, a second CLM having the same chemical structure as the CLM, a CLM', a second linker, or any multiple or combination thereof.

[0208] In any aspect or embodiment described herein, the CLM is selected from:

[0209]

[0210]

[0211] Where R' is a halogen, and R 1 As described in any aspect or embodiment described herein.

[0212] In some cases, a "CLM" can be an imide bound to a cerebellin E3 ligase. These imide and linker attachment points can be, but are not limited to, the following structures:

[0213]

[0214] Exemplary VLM

[0215] In certain embodiments of the compounds as described herein, the ULM is a VLM and comprises a chemical structure selected from ULM-a:

[0216]

[0217] in:

[0218] The dashed line indicates the attachment of at least one PTM, another ULM or VLM or CLM (i.e., ULM' or VLM' or CLM'), or a chemical linker moiety coupling at least one PTM, ULM' or VLM' or CLM' to the other end of the linker;

[0219] Formula ULM-a X 1 、X 2 Each independently selected from a bond, O, NR Y3 , CR Y3 R Y4 , C=O, C=S, SO and SO2;

[0220] R of formula ULM-aY3 、R Y4 Each independently selected from H, a linear or branched C optionally substituted by one or more halogens 1-6 Alkyl, optionally substituted C 1-6 Alkoxy (eg, optionally with 0-3 R P group substitution);

[0221] R of formula ULM-a P is 0, 1, 2 or 3 groups, each independently selected from H, halogen, -OH, C 1-3 Alkyl, C=O;

[0222] W of ULM-a 3 is selected from optionally substituted T, optionally substituted -TN(R 1a R 1b) X 3 , optionally substituted -TN(R 1a R 1b ), optionally substituted -T-aryl, optionally substituted -T-heteroaryl, optionally substituted -T-diheteroaryl, optionally substituted -T-heterocyclyl, optionally substituted -T-diheterocyclyl, optionally substituted -NR 1 -T-aryl, optionally substituted-NR 1 -T-heteroaryl or optionally substituted-NR 1 -T-heterocyclyl;

[0223] Formula ULM-a X 3 C=O、R 1 、R 1a 、R 1b ;

[0224] R 1 、R 1a 、R 1b Each is independently selected from H, a linear or branched C1-C6 alkyl group optionally substituted with one or more halo or -OH groups, R Y3 C=O、R Y3 C=S、R Y3 SO, R Y3 SO2、N(R Y3 R Y4 )C=O、N(R Y3 R Y4 )C=S、N(R Y3 R Y4 )SO and N(R Y3 R Y4 )SO2;

[0225] T of formula ULM-a is selected from optionally substituted alkyl, -(CH2)n -group, optionally substituted, linear or branched-(CH2) n -OC 1-6 alkyl or optionally substituted -(CH2) n -O-heterocyclyl, wherein each of the methylene groups is optionally substituted by one or two groups selected from halogen, methyl, optionally substituted alkoxy, linear or branched C1-C6 alkyl optionally substituted by one or more halogens, C(O)NR 1 R 1a or NR 1 R 1a Substituents, or R 1 and R 1a connected to form an optionally substituted heterocyclic group, or an -OH group or an optionally substituted amino acid side chain;

[0226] W of ULM-a 4 is optionally substituted -NR1-T-aryl, wherein the aryl may be optionally substituted with an optionally substituted 5-6 membered heteroaryl or an optionally substituted aryl, an optionally substituted -NR1-T-heteroaryl or an optionally substituted -NR1-T-heterocyclyl, wherein -NR1 is covalently bonded to X 2 , and R1 is H or CH3, preferably H; and

[0227] n is 0 to 6, typically 0, 1, 2 or 3, preferably 0 or 1.

[0228] In any of the embodiments described herein, T is selected from optionally substituted alkyl, -(CH2) n - group, wherein each of the methylene groups is optionally substituted by one or two groups selected from halogen, methyl, optionally substituted alkoxy, linear or branched C1-C6 alkyl optionally substituted by one or more halogens, C(O)NR 1 R 1a or NR 1 R 1a Substituents, or R 1 and R 1a are connected to form an optionally substituted heterocycle, or an -OH group or an optionally substituted amino acid side chain; and n is 0 to 6, typically 0, 1, 2 or 3, preferably 0 or 1.

[0229] In certain embodiments, W of Formula ULM-a 4 for Where: W 5 is optionally substituted (e.g., W 5 is optionally substituted phenyl, optionally substituted naphthyl or optionally substituted 5-10 membered heteroaryl) (e.g., W 5optionally substituted with one or more [e.g., 1, 2, 3, 4, or 5] halo, CN, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, hydroxy, or optionally substituted haloalkoxy), and R 14a 、R 14b, are each independently selected from H, haloalkyl (e.g., fluoroalkyl), optionally substituted alkyl, optionally substituted alkoxy, optionally substituted hydroxyalkyl, optionally substituted alkylamine, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR 26 、CONR 27a R 27b 、NHCOR 26 or NHCH3COR 26 ; and R 14a and R 14b The other one is H; or R 14a 、R 14b Together with the carbon atoms to which they are attached, they form an optionally substituted 3- to 5-membered cycloalkyl, heterocycloalkyl, spirocycloalkyl, or spiroheterocyclyl, wherein the spiroheterocyclyl is not an epoxide or an aziridine.

[0230] In any embodiment, W of Formula ULM-b 5 is selected from optionally substituted phenyl, optionally substituted naphthyl or optionally substituted 5-10 membered heteroaryl (e.g., W 5 optionally substituted with one or more [such as 1, 2, 3, 4 or 5] halo, CN, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, hydroxy or optionally substituted haloalkoxy),

[0231] R of formula ULM-a 15 Selected from H, halogen, CN, OH, NO2, NR 14a R 14b , OR 14a 、CONR 14a R 14b NR 14a COR 14b 、SO2NR 14a R 14b NR 14a SO2R 14b , optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy; optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted cycloheteroalkyl;

[0232] In another embodiment, W used in the present disclosure 4Substituents also specifically include (and are not limited to the specific compounds disclosed) W 4 Substituents, which are found in the identified compounds disclosed herein. These W 4 Each of the substituents may be combined with any number of W also disclosed herein. 3 Substituents are used in combination.

[0233] In certain additional embodiments, ULM-a is optionally replaced by 0-3 R P Each R P are independently H, halo, -OH, C1-3 alkyl, or C=O.

[0234] In any of the embodiments described herein, W of Formula ULM-a 3 、W 4 Can be independently covalently coupled to a linker to which one or more PTM groups are attached.

[0235] and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM'), or a chemical linker moiety that couples at least one PTM or ULM', or both, to the ULM.

[0236] In certain embodiments, the ULM is VHL and is represented by the following structure:

[0237]

[0238] in:

[0239] W of ULM-b 3 is selected from optionally substituted aryl, optionally substituted heteroaryl or

[0240] R9 and R of formula ULM-b 10 are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl or haloalkyl, or R9, R 10 and the carbon atom to which they are attached form an optionally substituted cycloalkyl group;

[0241] R of formula ULM-b 11 is selected from optionally substituted heterocycle, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted aryl,

[0242] R of formula ULM-b 12 is selected from H or optionally substituted alkyl;

[0243] R of formula ULM-b 13is selected from H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl or optionally substituted aralkyl;

[0244] R of formula ULM-b 14a 、R 14b are each independently selected from H, haloalkyl (e.g., fluoroalkyl), optionally substituted alkyl, optionally substituted alkoxy, aminomethyl, alkylaminomethyl, alkoxymethyl, optionally substituted hydroxyalkyl, optionally substituted alkylamine, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, CONR 27a R 27b 、CH2NHCOR 26 or (CH2)N(CH3)COR 26 ; and R 14a and R 14b The other one is H; or R 14a 、R 14b together with the carbon atom to which they are attached, form an optionally substituted 3- to 6-membered cycloalkyl, heterocycloalkyl, spirocycloalkyl, or spiroheterocyclyl, wherein the spiroheterocyclyl is not an epoxide or an aziridine;

[0245] W of ULM-b 5 is selected from optionally substituted phenyl or optionally substituted 5-10 membered heteroaryl (e.g., W 5 optionally substituted with one or more [such as 1, 2, 3, 4 or 5] halo, CN, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, hydroxy or optionally substituted haloalkoxy),

[0246] R of formula ULM-b 15 Selected from H, halogen, CN, OH, NO2, NR 14a R 14b , OR 14a 、CONR 14a R 14b NR 14a COR 14b 、SO2NR 14a R 14b NR 14a SO2R 14b , optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloheteroalkyl;

[0247] Each R of the formula ULM-b16 independently selected from CN, halo, optionally substituted alkyl, optionally substituted haloalkyl, hydroxy, or optionally substituted haloalkoxy;

[0248] o of formula ULM-b is 0, 1, 2, 3 or 4;

[0249] R of formula ULM-b 18 are independently selected from H, halogen, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy, or a linker; and

[0250] p of formula ULM-b is 0, 1, 2, 3, or 4, and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM'), or a chemical linker moiety coupling at least one PTM or ULM', or both, to the ULM.

[0251] In any aspect or embodiment described herein, R of Formula ULM-b 15 Selected from H, halogen, CN, OH, NO2, NR 27a R 27b , OR 27a 、CONR 27a R 27b NR 27a COR 27b 、SO2NR 27a R 27b NR 27a SO2R 27b , optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocyclyl, wherein each R 26 are independently selected from H, optionally substituted alkyl or NR 27a R 27b ; and each R 27a and R 27b are independently H, optionally substituted alkyl, or R 27a and R 27b Together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic group.

[0252] In certain embodiments, R of Formula ULM-b 15 yes where R 17 is H, halogen, optionally substituted C 3-6 Cycloalkyl, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl and C 1-6 haloalkyl; and Xa is S or O.

[0253] In certain embodiments, R of Formula ULM-b 17 Selected from methyl, ethyl, isopropyl and cyclopropyl.

[0254] In certain additional embodiments, R of Formula ULM-b 15 Selected from:

[0255]

[0256]

[0257] In certain embodiments, R of Formula ULM-b 11 Selected from:

[0258]

[0259] In certain embodiments, R of Formula ULM-b 14a and R 14b are each independently selected from H, optionally substituted haloalkyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted hydroxyalkyl, optionally substituted alkylamine, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, CH2OR 30 、CH2NHR 30 、CH2NCH3R 30 、CONR 27a R 27b 、CH2CONR 27a R 27b 、CH2NHCOR 26 or CH2NCH3COR 26 ; and R 14a and R 14b The other one is H; or R 14a 、R 14b Together with the carbon atoms to which they are attached, they form an optionally substituted 3- to 6-membered cycloalkyl, heterocycloalkyl, spirocycloalkyl, or spiroheterocyclyl, wherein the spiroheterocyclyl is not an epoxide or an aziridine; wherein the spirocycloalkyl or spiroheterocycloalkyl is itself optionally substituted with an alkyl, haloalkyl, or -COR 33 Substituted, where R 33 is an alkyl group or a haloalkyl group,

[0260] where R 30 R is selected from H, alkyl, alkynylalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl or heteroarylalkyl, which is further optionally substituted; 26 and R 27 As mentioned above.

[0261] In certain embodiments, R of Formula ULM-b 15 Selected from H, halogen, CN, OH, NO2, NR 27a R 27b , OR 27a 、CONR 27a R 27b NR 27a COR 27b 、SO2NR 27a R 27b NR 27a SO2R 27b , optionally substituted alkyl, optionally substituted haloalkyl (e.g., optionally substituted fluoroalkyl), optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocyclyl, wherein the optional substitution of aryl, heteroaryl, cycloalkyl and heterocyclyl includes CH2OR 30 、CH2NHR 30 、CH2NCH3R 30 、CONR 27a R 27b 、CH2CONR 27a R 27b 、CH2NHCOR 26 、CH2NCH3COR 26 or where R 26 、R 27 、R 30 and R 14 aAs described above.

[0262] In certain embodiments, R of Formula ULM-b 14a 、R 14b are each independently selected from H, optionally substituted haloalkyl, optionally substituted alkyl, CH2OR 30 、CH2NHR 30 、CH2NCH3R 30 、CONR 27a R 27b 、CH2CONR 27a R 27b 、CH2NHCOR 26 or CH2NCH3COR 26 ; and R 14a and R 14b The other one is H; or R 14a 、R 14bTogether with the carbon atoms to which they are attached, they form an optionally substituted 3- to 6-membered spirocycloalkyl or spiroheterocyclyl, wherein the spiroheterocyclyl is not an epoxide or an aziridine; wherein the spirocycloalkyl or spiroheterocycloalkyl itself is optionally substituted with an alkyl, haloalkyl or -COR 33 Substituted, where R 33 is an alkyl group or a halogenated alkyl group, wherein R 30 is selected from H, alkyl, alkynylalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl or heteroarylalkyl, which is further optionally substituted;

[0263] R of formula ULM-b 15 Selected from H, halogen, CN, OH, NO2, NR 27a R 27b , OR 27a 、CONR 27a R 27b NR 27a COR 27b 、SO2NR 27a R 27b NR 27a SO2R 27b , optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocyclyl, wherein the aryl, heteroaryl, cycloalkyl and heterocyclyl optionally substituted include CH2OR 30 、CH2NHR 30 、CH2NCH3R 30 、CONR 27a R 27b 、CH2CONR 27a R 27b 、CH2NHCOR 26 、CH2NCH3COR 26 or where R 26 、R 27 、R 30 and R 14 aAs described above.

[0264] In certain embodiments, the ULM has a chemical structure selected from the group consisting of:

[0265]

[0266] in:

[0267] R1 of formula ULM-c, ULM-d and ULM-e is H, ethyl, isopropyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl or haloalkyl;

[0268] R of formula ULM-c, ULM-d and ULM-e 14a is H, haloalkyl, optionally substituted alkyl, methyl, fluoromethyl, hydroxymethyl, ethyl, isopropyl or cyclopropyl;

[0269] R of formula ULM-c, ULM-d and ULM-e 15 is selected from H, halogen, CN, OH, NO2, optionally substituted heteroaryl, optionally substituted aryl; optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted cycloalkyl or optionally substituted cycloheteroalkyl;

[0270] X of formula ULM-c, ULM-d and ULM-e is C, CH2 or C=O;

[0271] R3 of formula ULM-c, ULM-d and ULM-e is absent or is an optionally substituted 5- or 6-membered heteroaryl; and

[0272] The dashed lines indicate the site of attachment of at least one PTM, another ULM (ULM'), or a chemical linker moiety that couples at least one PTM or ULM', or both, to the ULM.

[0273] In certain embodiments, a ULM comprises a group according to the following chemical structure:

[0274]

[0275] in:

[0276] R of ULM-f 14a is H, haloalkyl, optionally substituted alkyl, methyl, fluoromethyl, hydroxymethyl, ethyl, isopropyl or cyclopropyl;

[0277] R9 of formula ULM-f is H;

[0278] R of ULM-f 10 is H, ethyl, isopropyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

[0279] R of ULM-f 11 yes

[0280] or optionally substituted heteroaryl;

[0281] p of the formula ULM-f is 0, 1, 2, 3 or 4;

[0282] Each R of the formula ULM-f 18 is independently halogen, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy, or a linker;

[0283] R of ULM-f 12 It is H, C=O;

[0284] R of ULM-f 13 is H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl or optionally substituted aralkyl,

[0285] R of ULM-f 15 is selected from H, halogen, Cl, CN, OH, NO2, optionally substituted haloalkyl, optionally substituted heteroaryl, optionally substituted aryl,

[0286] and

[0287] The dashed line in formula ULM-f indicates the site of attachment of at least one PTM, another ULM (ULM'), or a chemical linker moiety that couples at least one PTM or ULM', or both, to the ULM.

[0288] In certain embodiments, the ULM is selected from the following structures:

[0289]

[0290] where n is 0 or 1.

[0291] In certain embodiments, the ULM is selected from the following structures:

[0292]

[0293]

[0294]

[0295] wherein the phenyl rings in ULM-a1 to ULM-a15, ULM-b1 to ULM-b12, ULM-c1 to ULM-c15, and ULM-d1 to ULM-d9 are optionally substituted with fluorine, lower alkyl, and alkoxy groups, and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM'), or a chemical linker moiety that couples at least one PTM or ULM', or both, to ULM-a.

[0296] In one embodiment, the phenyl rings in ULM-a1 to ULM-a15, ULM-b1 to ULM-b12, ULM-c1 to ULM-c15, and ULM-d1 to ULM-d9 can be functionalized as esters so that they become part of a prodrug.

[0297] In certain embodiments, the hydroxyl group on the pyrrolidine ring of ULM-a1 through ULM-a15, ULM-b1 through ULM-b12, ULM-c1 through ULM-c15, and ULM-d1 through ULM-d9, respectively, comprises an ester-linked prodrug moiety.

[0298] In any aspect or embodiment described herein, ULM and ULM', if present, are each independently a group according to the following chemical structure:

[0299]

[0300] or a pharmaceutically acceptable salt thereof, wherein:

[0301] ULM-g R 1’ is an optionally substituted C1-C6 alkyl, an optionally substituted -(CH2) n OH, optionally substituted -(CH2) n SH, optionally substituted (CH2) n -O-(C1-C6)alkyl, optionally substituted (CH2) n -WCOCW-(C0-C6)alkyl containing an epoxide moiety WCOCW, wherein each W is independently H or C1-C3 alkyl, optionally substituted -(CH2) n COOH, optionally substituted -(CH2) n C(O)-(C1-C6 alkyl), optionally substituted-(CH2) n NHC(O)-R″, optionally substituted-(CH2) n C(O)-NR", optionally substituted -(CH2) n OC(O)-N(R″)2, -(CH2O) n H, optionally substituted -(CH2) nOC(O)-(C1-C6 alkyl), optionally substituted-(CH2) n C(O)-O-(C1-C6 alkyl), optionally substituted-(CH2O) n COOH, optionally substituted -(OCH2) n O-(C1-C6 alkyl), optionally substituted-(CH2O) n C(O)-(C1-C6 alkyl), optionally substituted-(OCH2) n NHC(O)-R1, optionally substituted -(CH2O) n C(O)-N(R”)2, -(CH2CH2O) n H, optionally substituted -(CH2CH2O) n COOH, optionally substituted -(OCH2CH2) n O-(C1-C6 alkyl), optionally substituted-(CH2CH2O) n C(O)-(C1-C6 alkyl), optionally substituted-(OCH2CH2) n NHC(O)-R', optionally substituted -(CH2CH2O) n C(O)-N(R″)2, optionally substituted-SO2R S , optionally substituted S(O)R S , NO2, CN or halogen (F, Cl, Br, I, preferably F or Cl);

[0302] Each R" of ULM-g is independently H or C1-C6 alkyl which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups (preferably fluorine);

[0303] ULM-g R S is C1-C6 alkyl, optionally substituted aryl, heteroaryl or heterocyclic group or -(CH2) m N(R")2 group;

[0304] X and X' of ULM-g are each independently C=O, C=S, -S(O), S(O)2, (preferably X and X' are both C=O);

[0305] ULM-g R 2’ is optionally substituted -(CH2) n -(C=O) u (NR”) v (SO2) w alkyl, optionally substituted -(CH2) n -(C=O) u (NR”) v (SO2)w NR 1N R 2N group, optionally substituted -(CH2) n -(C=O) u (NR”) v (SO2) w -aryl, optionally substituted -(CH2) n -(C=O) u (NR”) v (SO2) w -heteroaryl, optionally substituted-(CH2) n -(C=O) v NR”(SO2) w -heterocycle, optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -alkyl, optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -NR 1N R 2N , optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -NR”C(O)R 1N , optionally substituted -NR"-(CH2) n -(C=O) u (NR”) v (SO2) w -aryl, optionally substituted -NR"-(CH2) n -(C=O) u (NR”) v (SO2) w -heteroaryl or optionally substituted -NR"-(CH2) n -(C=O) v NR”(SO2) w -heterocycle, optionally substituted -X R2’ -alkyl; optionally substituted -X R2 '-aryl; optionally substituted-X R2 '-heteroaryl; optionally substituted-X R2 '-heterocyclyl; optional substituent;

[0306] ULM-g R 3’is optionally substituted alkyl, optionally substituted -(CH2) n -(O) u (NR1) v (SO2) w -alkyl, optionally substituted-(CH2) n -C(O) u (NR”) v (SO2) w -NR 1N R 2N , optionally substituted -(CH2) n -C(O) u (NR”) v (SO2) w -NR”C(O)R 1N , optionally substituted -(CH2) n -C(O) u (NR”) v (SO2) w -C(O)N(R")2, optionally substituted -(CH2) n -C(O) u (NR”) v (SO2) w -aryl, optionally substituted -(CH2) n -C(O) u (NR”) v (SO2) w -heteroaryl, optionally substituted-(CH2) n -C(O) u (NR”) v (SO2) w -heterocycle, optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -alkyl, optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -NR 1N R 2N , optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -NR”C(O)R 1N , optionally substituted -NR"-(CH2) n -C(O) u(NR”) v (SO2) w -aryl, optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -heteroaryl, optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -heterocyclic, optionally substituted -O-(CH2)n-(C=O) u (NR”) v (SO2) w -alkyl, optionally substituted-O-(CH2)n-(C=O) u (NR”) v (SO2) w -NR 1N R 2N , optionally substituted -O-(CH2)n-(C=O) u (NR”) v (SO2) w -NR1C(O)R 1N , optionally substituted -O-(CH2)n-(C=O) u (NR”) v (SO2) w -aryl, optionally substituted -O-(CH2) n -(C=O) u (NR”) v (SO2) w -heteroaryl or optionally substituted -O-(CH2) n -(C=O) u (NR”) v (SO2) w -heterocyclyl; -(CH2) n -(V) n’ -(CH2) n -(V) n’ -alkyl, optionally substituted-(CH2) n -(V) n’ -(CH2) n -(V) n’ -aryl, optionally substituted -(CH2) n -(V) n '-(CH2) n -(V) n’ -heteroaryl, optionally substituted-(CH2) n-(V) n’ -(CH2) n -(V) n’ -heterocyclyl, optionally substituted-(CH2) n -N(R 1’ )(C=O) m’ -(V) n’ -alkyl, optionally substituted-(CH2) n -N(R 1’ )(C=O) m’ -(V) n’ -aryl, optionally substituted -(CH2) n -N(R 1’ )(C=O) m’ -(V) n’ -heteroaryl, optionally substituted-(CH2) n -N(R 1’ )(C=O) m’ -(V) n’ -heterocyclyl, optionally substituted -X R3’ -alkyl; optionally substituted -X R3 '-aryl; optionally substituted-X R3 '-heteroaryl; optionally substituted-X R3 '-heterocyclyl; optional substituent;

[0307] ULM-g R 1N and R 2N are each independently H, C1-C6 alkyl optionally substituted with one or two hydroxyl groups and up to three halogen groups, or optionally substituted -(CH2) n -aryl, -(CH2) n -heteroaryl or -(CH2) n -heterocyclic group;

[0308] V in ULM-g is O, S, or NR”;

[0309] ULM-g R 1’ Each independently is H or C1-C3 alkyl;

[0310] ULM-gX R2’ and X R3’ each independently optionally substituted -CH2) n -、-CH2) n -CH(X v )=CH(X v )-(cis or trans), -CH2) n -CH≡CH-, -(CH2CH2O) n - or C3-C6 cycloalkyl, wherein Xv is H, halogen or optionally substituted C1-C3 alkyl;

[0311] Each m of ULM-g is independently 0, 1, 2, 3, 4, 5, 6;

[0312] Each m' of ULM-g is independently 0 or 1;

[0313] Each n of ULM-g is independently 0, 1, 2, 3, 4, 5, 6;

[0314] Each n' of ULM-g is independently 0 or 1;

[0315] Each u of ULM-g is independently 0 or 1;

[0316] Each v of ULM-g is independently 0 or 1;

[0317] Each w of ULM-g is independently 0 or 1; and

[0318] When the PTM is not ULM', R of ULM-g 1’ 、R 2’ 、R 3’ Any one or more of X, X and X' is optionally modified to be covalently bound to the PTM group through a linker group, or when the PTM is ULM', R of each of ULM and ULM' 1’ 、R 2’ 、R 3’ Any one or more of X, X and X' are optionally modified to be covalently bound to each other directly or through a linker group, or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.

[0319] In any aspect or embodiment described herein, ULM and ULM', if present, are each independently a group according to the following chemical structure:

[0320]

[0321] in:

[0322] ULM-h R 1’ ,R 2’ and R 3 Each of ' is the same as above, and X is a C=O, C=S, -S(O) ... group or a S(O) 2 group, more preferably a C=O group, and

[0323] When the PTM is not ULM', the R of ULM-h 1’ 、R 2’ and R 3’Any one or more of is optionally modified to incorporate a linker group that further covalently binds to the PTM group, or when the PTM is ULM', R of each of ULM and ULM' 1’ 、R 2’ 、R 3’ Any one or more of are optionally modified to be covalently bound to each other directly or through a linker group, or

[0324] or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.

[0325] In any aspect or embodiment described herein, the ULM and any ULM' present are each independently according to the chemical structure:

[0326]

[0327] in:

[0328] When the PTM is not ULM', R of ULM-I 1’ 、R 2’ and R 3’ Any one or more of is optionally modified to incorporate a linker group that further covalently binds to the PTM group, or when the PTM is ULM', R of each of ULM and ULM' 1’ 、R 2’ 、R 3’ Any one or more of are optionally modified to be covalently bound to each other directly or through a linker group, or

[0329] or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.

[0330] In a further preferred aspect of the present disclosure, R of ULM-g to ULM-i 1’ Preferably, it is hydroxy or a group that can be metabolized to a hydroxy or carboxyl group, so that the compound represents a prodrug form of the active compound. 1’ Groups include, for example, -(CH2) n OH, (CH2) n -O-(C1-C6)alkyl, -(CH2) n COOH, -(CH2O) n H, optionally substituted -(CH2) n OC(O)-(C1-C6 alkyl) or optionally substituted-(CH2) n C(O)-O-(C1-C6 alkyl), wherein n is 0 or 1. 1’When it is or contains a carboxylic acid group, the hydroxyl or amine group, hydroxyl group, carboxylic acid group or amine group (each of which may be optionally substituted) may be further chemically modified to provide a covalent linker group to which the PTM group (including the ULM) is bonded;

[0331] When present, X and X' of ULM-g and ULM-h are preferably C=O, C=S, -S(O) groups or S(O)2 groups, more preferably C=O groups;

[0332] R from ULM-g to ULM-i 2’ Preferably, it is an optionally substituted -NR"-T-aryl group (e.g., optionally substituted NH-T-aryl or optionally substituted N(CH3)-T-aryl), an optionally substituted -NR"-T-heteroaryl group (e.g., optionally substituted NH-T-heteroaryl or optionally substituted N(CH3)-T-heteroaryl) or an optionally substituted -NR"-T-heterocyclyl group (e.g., optionally substituted NH-T-heterocyclyl or optionally substituted N(CH3)-T-heterocyclyl), wherein R" is H or CH3, preferably H and T are optionally substituted -(CH2) n - group, wherein each of the methylene groups may be optionally substituted by one or two substituents, preferably selected from halogen, an amino acid side chain as described elsewhere herein, or a C1-C3 alkyl group, preferably one or two methyl groups, which may be optionally substituted; and n is 0 to 6, typically 0, 1, 2 or 3, preferably 0 or 1. Alternatively, T may also be -(CH2O) n - group, -(OCH2) n -group, -(CH2CH2O) n - group, -(OCH2CH2) n - groups, all of which are optionally substituted.

[0333] R from ULM-g to ULM-i 2’Preferred aryl groups include optionally substituted phenyl or naphthyl, preferably phenyl, wherein the phenyl or naphthyl is linked to the PTM (including the ULM' group) via a linker group and / or is optionally substituted by halogen (preferably F or Cl), amine, mono- or dialkylamine (preferably dimethylamine), F, Cl, OH, COOH, C1-C6 alkyl, preferably CH3, CF3, OMe, OCF3, NO2 or CN groups (each of which may be substituted in the ortho, meta and / or para positions of the phenyl ring). , preferably para), optionally substituted phenyl (phenyl itself optionally linked to the PTM group, including ULM', via a linker group), and / or optionally substituted with at least one of F, Cl, OH, COOH, CH3, CF3, OMe, OCF3, NO2 or CN groups (in the ortho, meta and / or para position of the phenyl ring, preferably para), optionally substituted naphthyl, optionally substituted heteroaryl, preferably optionally substituted isoxazole (including isoxazole substituted with methyl), optionally substituted optionally substituted oxazole (including oxazole substituted with methyl), optionally substituted thiazole (including thiazole substituted with methyl), optionally substituted isothiazole (including isothiazole substituted with methyl), optionally substituted pyrrole (including pyrrole substituted with methyl), optionally substituted imidazole (including methylimidazole), optionally substituted benzimidazole or methoxybenzimidazole, optionally substituted oxaimidazole or methyloxaimidazole, optionally substituted diazole group (including methyldiazole group), optionally substituted triazole group (including substituted with methyl), an optionally substituted pyridine group (including a pyridine group or an oxapyridine group substituted with a halo (preferably F) or methyl group, wherein the pyridine group is attached to the phenyl group through an oxygen), an optionally substituted furan, an optionally substituted benzofuran, an optionally substituted dihydrobenzofuran, an optionally substituted indole, indolizine or azaindolizine (2-azaindolizine, 3-azaindolizine or 4-azaindolizine), an optionally substituted quinoline, an optionally substituted group according to the following chemical structure:

[0334]

[0335] in:

[0336] S for ULM-g to ULM-i c It is CHR SS NR URE or O;

[0337] R from ULM-g to ULM-i HETis H, CN, NO2, halogen (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halogen groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halogen groups) or optionally substituted alkynyl -C≡CR a , where R a is H or C1-C6 alkyl (preferably C1-C3 alkyl);

[0338] R from ULM-g to ULM-i SS is H, CN, NO2, halogen (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halogen groups), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups), or optionally substituted -C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups);

[0339] R from ULM-g to ULM-i URE is H, C1-C6 alkyl (preferably H or C1-C3 alkyl) or -C(O)(C1-C6 alkyl), each of which is optionally substituted by one or two hydroxyl groups or up to three halogen groups, preferably fluoro groups, or optionally substituted phenyl, optionally substituted heteroaryl, or optionally substituted heterocyclyl, preferably for example piperidine, morpholine, pyrrolidine, tetrahydrofuran);

[0340] R from ULM-g to ULM-i PRO is H, optionally substituted C1-C6 alkyl or optionally substituted aryl (phenyl or naphthyl), a heteroaryl or heterocyclyl selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oxamidazole, pyrrole, pyrrolidine, furan, dihydrofuran, tetrahydrofuran, thiophene, dihydrothiophene, tetrahydrothiophene, pyridine, piperidine, piperazine, morpholine, quinoline (each preferably substituted by C1-C3 alkyl, preferably methyl or halo, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;

[0341] R from ULM-g to ULM-i PRO1 and R PRO2 are each independently H, optionally substituted C1-C3 alkyl, or together form a keto group; and

[0342] Each n of ULM-g to ULM-i is independently 0, 1, 2, 3, 4, 5 or 6 (preferably 0 or 1), or an optionally substituted heterocyclic group, preferably tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine or morpholine (when substituted, each of said groups is preferably substituted with methyl or halogen (F, Br, Cl), each of which may be optionally linked to a PTM group (including a ULM' group) via a linker group).

[0343] In certain preferred aspects, ULM-g to ULM-i yes

[0344] Group,

[0345] Among them, R PRO and n are the same as above.

[0346] About R of ULM-g to ULM-i 2’ Preferred heteroaryl groups include optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), optionally substituted indole, optionally substituted indolizine, optionally substituted azaindolizine, optionally substituted benzofuran, including optionally substituted benzofuran, optionally substituted isoxazole, optionally substituted thiazole, optionally substituted isothiazole, optionally substituted thiophene, optionally substituted pyridine (2-, 3- or 4-pyridine), optionally substituted imidazole, optionally substituted pyrrole, optionally substituted diazole, optionally substituted triazole, tetrazole, optionally substituted oxamidazole, or a group according to the following chemical structure:

[0347]

[0348] in:

[0349] S for ULM-g to ULM-i c It is CHR SS NR URE or O;

[0350] R from ULM-g to ULM-i HET is H, CN, NO2, halogen (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halogen groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halogen groups) or optionally substituted alkynyl -C≡CR a , where R of ULM-g to ULM-i a is H or C1-C6 alkyl (preferably C1-C3 alkyl);

[0351] R from ULM-g to ULM-i SS is H, CN, NO2, halogen (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halogen groups), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups), or optionally substituted -C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups);

[0352] R from ULM-g to ULM-i URE is H, C1-C6 alkyl (preferably H or C1-C3 alkyl) or -C(O)(C1-C6 alkyl), each of which is optionally substituted by one or two hydroxyl groups or up to three halogen groups, preferably fluoro groups, or an optionally substituted heterocycle, such as piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and

[0353] Y for ULM-g to ULM-i C Is N or CR YC , where R YC is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halo groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halo groups) or optionally substituted alkynyl -C≡CR a , where R a is H or C1-C6 alkyl (preferably C1-C3 alkyl), each of which may be optionally linked to a PTM group (including a ULM' group) via a linker group.

[0354] R from ULM-g to ULM-i 2’ Preferred heterocyclic groups include tetrahydrofuran, tetrahydrothiophene, tetrahydroquinoline, piperidine, piperazine, pyrrolidine, morpholine, oxane or thiazane, each of which may be optionally substituted, or a group according to the following chemical structure:

[0355]

[0356] Preferably, Group,

[0357] in:

[0358] R from ULM-g to ULM-i PRO is H, optionally substituted C1-C6 alkyl, or optionally substituted aryl, heteroaryl or heterocyclyl;

[0359] R from ULM-g to ULM-i PRO1 and R PRO2 are each independently H, optionally substituted C1-C3 alkyl or together form a keto group, and

[0360] Each n of ULM-g to ULM-i is independently 0, 1, 2, 3, 4, 5 or 6 (typically 0 or 1), each of which may be optionally linked to a PTM group (including a ULM' group) via a linker group.

[0361] Preferred R for ULM-g to ULM-i 2’ Substituents also specifically include (and are not limited to the specific compounds disclosed) R 2’ Substituents found in the identified compounds disclosed herein (including specific compounds disclosed in this specification and the accompanying drawings). These R 2 Each of the substituents may be combined with any number of R 3 'Substituents are used in combination.

[0362] R from ULM-g to ULM-i 3’ Preferably, it is optionally substituted -T-aryl, optionally substituted -T-heteroaryl, optionally substituted -T-heterocycle, optionally substituted -NR"-T-aryl (e.g., optionally substituted NH-T-aryl, optionally substituted N(CH3)-T-aryl, or optionally substituted N(C1-C3 alkyl)-T-aryl), optionally substituted -NR"-T-heteroaryl (e.g., optionally substituted NH-T-heteroaryl, optionally substituted N(CH3)-T-heteroaryl, or optionally substituted N(C1-C3 alkyl)-T-heteroaryl), or optionally substituted -NR 1 -T-heterocyclyl (e.g., optionally substituted NH-T-heterocyclyl, optionally substituted N(CH3)-T-heterocyclyl, or optionally substituted N(C1-C3 alkyl)-T-heterocyclyl), wherein R" is H or C1-C3 alkyl, preferably H or CH3, and T is optionally substituted -(CH2) n - group, wherein each of the methylene groups may be optionally substituted by one or two substituents, preferably selected from halogen, C1-C3 alkyl or an amino acid side chain as described elsewhere herein, preferably methyl, which may be optionally substituted; and n is 0 to 6, typically 0, 1, 2 or 3, preferably 0 or 1. Alternatively, T may also be -(CH2O) n - group, -(OCH2) n -group, -(CH2CH2O) n - group, -(OCH2CH2) n- groups, each of which is optionally substituted.

[0363] R from ULM-g to ULM-i 3’ Preferred aryl groups include optionally substituted phenyl or naphthyl, preferably phenyl, wherein the phenyl or naphthyl is optionally linked to the PTM group (including the ULM' group) via a linker group and / or is optionally substituted by halogen (preferably F or Cl), amine, mono- or di-alkylamine (preferably dimethylamine), amide (preferably -(CH2) m -NR"C(O)R" group, where m is the same as above), halo (usually F or Cl), OH, CH3, CF3, OMe, OCF3, NO2, CN or S(O)2R S Group (R S is C1-C6 alkyl, optionally substituted aryl, heteroaryl or heterocyclic group or -(CH2) m N (R ") 2 group, each of which can be substituted in the ortho position, meta position and / or para position of the phenyl ring, preferably the para position), or aryl (preferably phenyl), heteroaryl or heterocyclic group. Preferably, the substituted phenyl group is an optionally substituted phenyl group (i.e., the substituted phenyl group itself is preferably substituted with at least one of F, Cl, OH, SH, COOH, CH3, CF3, OMe, OCF3, NO2, CN or a linker group to which a PTM group (including a ULM' group) is attached, wherein the substitution occurs in the ortho position, meta position and / or para position of the phenyl ring, preferably the para position), which may be optionally substituted include naphthyl as described above, optionally substituted heteroaryl (preferably optionally substituted isoxazole including methyl substituted isoxazole, optionally substituted oxazole including methyl substituted oxazole, optionally substituted The thiazole includes methyl substituted thiazole, the optionally substituted pyrrole includes methyl substituted pyrrole, the optionally substituted imidazole includes methylimidazole, benzylimidazole or methoxybenzylimidazole, oxyimidazole (oximidazole) or methoxyimidazole (methyloximidazole), the optionally substituted diazolyl includes methyldiazolyl, the optionally substituted triazolyl includes methyl substituted triazolyl, the pyridyl includes halogen- (preferably F) or methyl substituted pyridyl or oxapyridyl (wherein the pyridine group is linked to the phenyl group through oxygen) or an optionally substituted heterocycle (tetrahydrofuran, tetrahydrothiophene, pyrrolidine, piperidine, morpholine, piperazine, tetrahydroquinoline, oxane or thiazane. Each aryl, heteroaryl or heterocyclic group may be optionally linked to the PTM group (including the ULM' group) through a linker group.

[0364] R from ULM-g to ULM-i 3’Preferred heteroaryl groups include optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), optionally substituted indole (including dihydroindole), optionally substituted indolizine, optionally substituted azaindolizine (2, 3 or 4-azaindolizine), optionally substituted benzimidazole, benzodiazole, benzofuran, optionally substituted imidazole, optionally substituted isoxazole, optionally substituted oxazole (preferably substituted with methyl), optionally substituted diazole, optionally substituted triazole, tetrazole, optionally substituted benzofuran, optionally substituted thiophene, optionally substituted thiazole (preferably substituted with methyl and / or thiol), optionally substituted isothiazole, optionally substituted triazole (preferably substituted with methyl, triisopropylsilyl, optionally substituted -(CH2) m -O-C1-C6 alkyl or optionally substituted -(CH2) m -C(O)-O-C1-C6 alkyl-substituted 1,2,3-triazole), optionally substituted pyridine (2-pyridine, 3-pyridine or 4-pyridine) or a group according to the following chemical structure:

[0365]

[0366] in:

[0367] S for ULM-g to ULM-i c It is CHR SS NR URE or O;

[0368] R from ULM-g to ULM-i HET is H, CN, NO2, halogen (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halogen groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halogen groups) or optionally substituted alkynyl -C≡CR a , where R a is H or C1-C6 alkyl (preferably C1-C3 alkyl);

[0369] R from ULM-g to ULM-i SS is H, CN, NO2, halogen (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halogen groups), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups), or optionally substituted -C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups);

[0370] R from ULM-g to ULM-iURE is H, C1-C6 alkyl (preferably H or C1-C3 alkyl) or -C(O)(C1-C6 alkyl), each of which is optionally substituted by one or two hydroxyl groups or up to three halogen groups, preferably fluoro groups, or optionally substituted heterocyclic groups, such as piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and

[0371] Y for ULM-g to ULM-i C Is N or CR YC , where R YC is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halo groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halo groups) or optionally substituted alkynyl -C≡CR a , where R a is H or C1-C6 alkyl (preferably C1-C3 alkyl), and each of the heteroaryl groups may be optionally linked to a PTM group (including a ULM' group) via a linker group.

[0372] R from ULM-g to ULM-i 3’ Preferred heterocyclic groups include tetrahydroquinoline, piperidine, piperazine, pyrrolidine, morpholine, tetrahydrofuran, tetrahydrothiophene, oxane and thiazane, each of which may be optionally substituted, or a group according to the following chemical structure:

[0373] Preferably, Group,

[0374] in:

[0375] R from ULM-g to ULM-i PRO is H, optionally substituted C1-C6 alkyl or optionally substituted aryl (phenyl or naphthyl), a heteroaryl or heterocyclyl selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oxamidazole, pyrrole, pyrrolidine, furan, dihydrofuran, tetrahydrofuran, thiophene, dihydrothiophene, tetrahydrothiophene, pyridine, piperidine, piperazine, morpholine, quinoline (each preferably substituted by C1-C3 alkyl, preferably methyl or halo, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;

[0376] R from ULM-g to ULM-i PRO1 and R PRO2 are each independently H, optionally substituted C1-C3 alkyl or together form a keto group, and

[0377] Each n in ULM-g to ULM-i is 0, 1, 2, 3, 4, 5 or 6 (preferably 0 or 1), wherein each of the heterocyclic groups may be optionally linked to a PTM group (including a ULM' group) via a linker group.

[0378] Preferred R for ULM-g to ULM-i 3’ Substituents also specifically include (and are not limited to the specific compounds disclosed) R 3’ Substituents found in the identified compounds disclosed herein (including specific compounds disclosed in this specification and the accompanying drawings). These R 3’ Each of the substituents may be combined with any number of R 2’ Substituents are used in combination.

[0379] In certain alternative preferred embodiments, R of ULM-g to ULM-i 2 ' is optionally substituted -NR1-X R2 '-alkyl, -NR1-X R2 '-aryl; optionally substituted-NR1-X R2 '-HET, optionally substituted-NR1-X R2 '-aryl-HET or optionally substituted-NR1-X R2 '-HET-heteroaryl,

[0380] in:

[0381] R1 of ULM-g to ULM-i is H or C1-C3 alkyl (preferably H);

[0382] X for ULM-g to ULM-i R2’ is optionally substituted -CH2) n -、-CH2) n -CH(X v )=CH(X v )-(cis or trans), -(CH2) n -CH≡CH-, -(CH2CH2O) n - or C3-C6 cycloalkyl; and

[0383] X for ULM-g to ULM-i v is H, halogen or C1-C3 alkyl optionally substituted by one or two hydroxyl groups or up to three halogen groups;

[0384] The alkyl groups of ULM-g to ULM-i are optionally substituted C1-C 10 an alkyl (preferably a C1-C6 alkyl) group (in certain preferred embodiments, the alkyl group is terminated with a halogen group (typically Cl or Br));

[0385] Aryl of ULM-g to ULM-i is optionally substituted phenyl or naphthyl (preferably phenyl); and

[0386] HET of ULM-g to ULM-i is optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oxaimidazole, pyrrole, pyrrolidine, furan, dihydrofuran, tetrahydrofuran, thiophene, dihydrothiophene, tetrahydrothiophene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline (when substituted, each preferably substituted by C1-C3 alkyl, preferably methyl or halo, preferably F or Cl) or a group according to the following chemical structure:

[0387]

[0388] S for ULM-g to ULM-i c It is CHR SS NR URE or O;

[0389] R from ULM-g to ULM-i HET is H, CN, NO2, halogen (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halogen groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halogen groups) or optionally substituted alkynyl -C≡CR a , where R a is H or C1-C6 alkyl (preferably C1-C3 alkyl);

[0390] R from ULM-g to ULM-i SS is H, CN, NO2, halogen (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halogen groups), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups), or optionally substituted -C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups);

[0391] R from ULM-g to ULM-i URE is H, C1-C6 alkyl (preferably H or C1-C3 alkyl) or -C(O)(C1-C6 alkyl), each of which is optionally substituted by one or two hydroxyl groups or up to three halogen groups, preferably fluoro groups, or an optionally substituted heterocyclic group, such as piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted;

[0392] Y for ULM-g to ULM-iC Is N or CR YC , where R YC is H, OH, CN, NO2, halogen (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halogen groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halogen groups) or optionally substituted alkynyl -C≡CR a , where R a is H or C1-C6 alkyl (preferably C1-C3 alkyl);

[0393] R from ULM-g to ULM-i PRO is H, optionally substituted C1-C6 alkyl or optionally substituted aryl (phenyl or naphthyl), a heteroaryl or heterocyclyl selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oxamidazole, pyrrole, pyrrolidine, furan, dihydrofuran, tetrahydrofuran, thiophene, dihydrothiophene, tetrahydrothiophene, pyridine, piperidine, piperazine, morpholine, quinoline (each preferably substituted by C1-C3 alkyl, preferably methyl or halo, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;

[0394] R from ULM-g to ULM-i PRO1 and R PRO2 are each independently H, optionally substituted C1-C3 alkyl or together form a keto group, and

[0395] Each n of ULM-g to ULM-i is independently 0, 1, 2, 3, 4, 5 or 6 (preferably 0 or 1).

[0396] Each of these groups may optionally be linked to a PTM group (including a ULM' group) via a linker group.

[0397] In certain alternative preferred embodiments of the present disclosure, R of ULM-g to ULM-i 3 ' is optionally substituted -(CH2) n -(V) n’ -(CH2) n -(V) n’ -R S3’ group, optionally substituted -(CH2) n -N(R 1’ )(C=O) m’ -(V) n’ -R S3’ group, optionally substituted -X R3 '-alkyl, optionally substituted-X R3 '-aryl; optionally substituted-XR3 '-HET group, optionally substituted -X R3 '-aryl-HET group or an optionally substituted -X R3 '-HET-aryl,

[0398] in:

[0399] R S3’ is an optionally substituted alkyl group (C1-C 10 , preferably C1-C6 alkyl), optionally substituted aryl or HET group;

[0400] R 1’ is H or C1-C3 alkyl (preferably H);

[0401] V is O, S, or NR 1’ ;

[0402] X R3’ Yes - (CH2) n -、-(CH2CH2O) n -、-CH2) n -CH(X v )=CH(X v )-(cis or trans), -CH2) n -CH≡CH- or C3-C6 cycloalkyl, all of which are optionally substituted;

[0403] X v is H, halogen or C1-C3 alkyl optionally substituted by one or two hydroxyl groups or up to three halogen groups;

[0404] Alkyl is an optionally substituted C1-C 10 an alkyl (preferably a C1-C6 alkyl) group (in certain preferred embodiments, the alkyl group is terminated with a halogen group (typically Cl or Br));

[0405] Aryl is optionally substituted phenyl or naphthyl (preferably phenyl); and

[0406] HET is optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oxaimidazole, pyrrole, pyrrolidine, furan, dihydrofuran, tetrahydrofuran, thiophene, dihydrothiophene, tetrahydrothiophene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline (when substituted, each preferably by C1-C3 alkyl, preferably methyl or halo, preferably F or Cl) or a group according to the following chemical structure:

[0407]

[0408] S for ULM-g to ULM-i c It is CHRSS NR URE or O;

[0409] R from ULM-g to ULM-i HET is H, CN, NO2, halogen (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halogen groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halogen groups) or optionally substituted alkynyl -C≡CR a , where R a is H or C1-C6 alkyl (preferably C1-C3 alkyl);

[0410] R from ULM-g to ULM-i SS is H, CN, NO2, halogen (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halogen groups), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups), or optionally substituted -C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups);

[0411] R from ULM-g to ULM-i URE is H, C1-C6 alkyl (preferably H or C1-C3 alkyl) or -C(O)(C0-C6 alkyl), each of which is optionally substituted by one or two hydroxyl groups or up to three halogen groups, preferably fluoro groups, or optionally substituted heterocyclic groups, such as piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted;

[0412] Y for ULM-g to ULM-i C Is N or CR YC , where R YC is H, OH, CN, NO2, halogen (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halogen groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halogen groups) or optionally substituted alkynyl -C≡CR a , where R a is H or C1-C6 alkyl (preferably C1-C3 alkyl);

[0413] R from ULM-g to ULM-i PROis H, optionally substituted C1-C6 alkyl or optionally substituted aryl (phenyl or naphthyl), a heteroaryl or heterocyclyl selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oxamidazole, pyrrole, pyrrolidine, furan, dihydrofuran, tetrahydrofuran, thiophene, dihydrothiophene, tetrahydrothiophene, pyridine, piperidine, piperazine, morpholine, quinoline (each preferably substituted by C1-C3 alkyl, preferably methyl or halo, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;

[0414] R from ULM-g to ULM-i PRO1 and R PRO2 are each independently H, optionally substituted C1-C3 alkyl, or together form a keto group;

[0415] Each n of ULM-g to ULM-i is independently 0, 1, 2, 3, 4, 5 or 6 (preferably 0 or 1);

[0416] Each m' of ULM-g to ULM-i is 0 or 1; and

[0417] Each n' of ULM-g to ULM-i is 0 or 1;

[0418] Each of the compounds is preferably linked to a PTM group (including a ULM' group) via a linker group, preferably on an alkyl, aryl or Het group.

[0419] In an alternative embodiment, R of ULM-g to ULM-i 3 'Yes-(CH2) n -aryl, -(CH2CH2O) n -aryl, -(CH2) n -HET or -(CH2CH2O) n -HET,

[0420] in:

[0421] The aryl group of ULM-g to ULM-i is a phenyl group optionally substituted with one or two substituents, wherein the substituents are preferably selected from (CH2) n OH, C1-C6 alkyl which itself is further optionally substituted by CN, halogen (up to three halogen groups), OH, -(CH2) n O(C1-C6)alkyl, amine, mono- or di-(C1-C6alkyl)amine, wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl groups or up to three halogen (preferably F, Cl) groups, or

[0422] The aryl groups of ULM-g to ULM-i are replaced by -(CH2) n OH, -(CH2) n-O-(C1-C6)alkyl, -(CH2) n -O-(CH2) n -(C1-C6)alkyl, -(CH2) n -C(O)(C0-C6)alkyl, -(CH2) n -C(O)O(C0-C6)alkyl, -(CH2) n -OC(O)(C0-C6)alkyl, amine, mono- or di-(C1-C6alkyl)amine, wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl groups or up to three halogen (preferably F, Cl) groups, CN, NO2, optionally substituted -(CH2) n -(V) m’ -CH2) n -(V) m’ -(C1-C6)alkyl, -(V) m’ -(CH2CH2O) n -R PEG Group substituted, where V is O, S or NR 1’ , R 1’ is H or C1-C3 alkyl (preferably H), and R PEG is H or optionally substituted (including optionally substituted by carboxyl) C1-C6 alkyl, or

[0423] The aryl groups of ULM-g to ULM-i are optionally substituted with heterocycles, including heteroaryls selected from oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oxaimidazole, pyrrole, pyrrolidine, furan, dihydrofuran, tetrahydrofuran, thiophene, dihydrothiophene, tetrahydrothiophene, pyridine, piperidine, piperazine, morpholine, quinoline, benzofuran, indole, indolizine, azaindolizine (when substituted, each preferably substituted with C1-C3 alkyl, preferably methyl or halo, preferably F or Cl), or a group according to the following chemical structure:

[0424]

[0425] S for ULM-g to ULM-i c It is CHR SS NR URE or O;

[0426] R from ULM-g to ULM-i HET is H, CN, NO2, halogen (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halogen groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halogen groups) or optionally substituted alkynyl -C≡CR a , where Ra is H or C1-C6 alkyl (preferably C1-C3 alkyl);

[0427] R from ULM-g to ULM-i SS is H, CN, NO2, halogen (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halogen groups), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups), or optionally substituted -C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups);

[0428] R from ULM-g to ULM-i URE is H, C1-C6 alkyl (preferably H or C1-C3 alkyl) or -C(O)(C0-C6 alkyl), each of which is optionally substituted by one or two hydroxyl groups or up to three halogen groups, preferably fluoro groups, or an optionally substituted heterocycle, such as piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted;

[0429] Y for ULM-g to ULM-i C Is N or CR YC , where R YC is H, OH, CN, NO2, halogen (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halogen groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halogen groups) or optionally substituted alkynyl -C≡CR a , where R a is H or C1-C6 alkyl (preferably C1-C3 alkyl);

[0430] R from ULM-g to ULM-i PRO is H, optionally substituted C1-C6 alkyl or optionally substituted aryl (phenyl or naphthyl), a heteroaryl or heterocyclyl selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oxamidazole, pyrrole, pyrrolidine, furan, dihydrofuran, tetrahydrofuran, thiophene, dihydrothiophene, tetrahydrothiophene, pyridine, piperidine, piperazine, morpholine, quinoline (each preferably substituted by C1-C3 alkyl, preferably methyl or halo, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;

[0431] R from ULM-g to ULM-i PRO1 and R PRO2 are each independently H, optionally substituted C1-C3 alkyl, or together form a keto group;

[0432] HET of ULM-g to ULM-i is preferably oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oxaimidazole, pyrrole, pyrrolidine, furan, dihydrofuran, tetrahydrofuran, thiophene, dihydrothiophene, tetrahydrothiophene, pyridine, piperidine, piperazine, morpholine, quinoline (each preferably substituted with C1-C3 alkyl, preferably methyl or halo, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine, or a group according to the following chemical structure:

[0433]

[0434] S for ULM-g to ULM-i c It is CHR SS NR URE or O;

[0435] R from ULM-g to ULM-i HET is H, CN, NO2, halogen (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halogen groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halogen groups) or optionally substituted alkynyl -C≡CR a , where R a is H or C1-C6 alkyl (preferably C1-C3 alkyl);

[0436] R from ULM-g to ULM-i SS is H, CN, NO2, halogen (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halogen groups), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups), or optionally substituted -C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halogen groups);

[0437] R from ULM-g to ULM-i URE is H, C1-C6 alkyl (preferably H or C1-C3 alkyl) or -C(O)(C0-C6 alkyl), each of which is optionally substituted by one or two hydroxyl groups or up to three halogen groups, preferably fluoro groups, or optionally substituted heterocyclic groups, such as piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted;

[0438] Y for ULM-g to ULM-i C Is N or CR YC , where R YCis H, OH, CN, NO2, halogen (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted by one or two hydroxyl groups or up to three halogen groups (e.g. CF3)), optionally substituted O(C1-C6 alkyl) (preferably substituted by one or two hydroxyl groups or up to three halogen groups) or optionally substituted alkynyl -C≡CR a , where R a is H or C1-C6 alkyl (preferably C1-C3 alkyl);

[0439] R from ULM-g to ULM-i PRO is H, optionally substituted C1-C6 alkyl, or optionally substituted aryl, heteroaryl or heterocyclyl;

[0440] R from ULM-g to ULM-i PRO1 and R PRO2 are each independently H, optionally substituted C1-C3 alkyl, or together form a keto group;

[0441] Each m' of ULM-g to ULM-i is independently 0 or 1; and

[0442] Each n of ULM-g to ULM-i is independently 0, 1, 2, 3, 4, 5 or 6 (preferably 0 or 1),

[0443] Each of the compounds is preferably linked to a PTM group (including a ULM' group) on the alkyl or HET group, optionally via a linker group.

[0444] In further embodiments, preferred compounds include compounds according to the following chemical structure:

[0445]

[0446] in:

[0447] ULM-i R 1’ is OH or a group that metabolizes or undergoes OH in the patient;

[0448] ULM-i R 2 ' is -NH-CH2-aryl-HET (preferably a phenyl group directly linked to a methyl-substituted thiazole);

[0449] ULM-i R 3’ Yes-CHR CR3’ -NH-C(O)-R 3P1 Group or -CHR CR3’ -R 3P2 group;

[0450] ULM-i R CR3’is C1-C4 alkyl, preferably methyl, isopropyl or tert-butyl;

[0451] ULM-i R 3P1 is a C1-C3 alkyl group (preferably methyl), an optionally substituted oxetane group (preferably methyl substituted, -(CH2) n OCH3 group, wherein n is 1 or 2 (preferably 2), or groups (the ethyl ether group is preferably substituted on the phenyl portion), morpholino groups (attached to the carbonyl group at the 2- or 3-position;

[0452] ULM-i R 3P2 yes group;

[0453] The aryl group of ULM-i is phenyl;

[0454] HET of ULM-i is an optionally substituted thiazole or isothiazole; and

[0455] ULM-i R HET is H or a halogen group (preferably H);

[0456] or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof, wherein each of said compounds is optionally linked to a PTM group (including a ULM' group) via a linker group.

[0457] In certain aspects, the bifunctional compound comprises a ubiquitin E3 ligase binding moiety (ULM), wherein the ULM is a group according to the following chemical structure:

[0458]

[0459] in:

[0460] each R5 and R6 of ULM-j is independently OH, SH or an optionally substituted alkyl group, or R5, R6 and the carbon atom to which they are attached form a carbonyl group;

[0461] R7 of ULM-j is H or optionally substituted alkyl;

[0462] E of ULM-j is a bond, C=O, or C=S;

[0463] G of ULM-j is a bond, optionally substituted alkyl, -COOH, or C=J;

[0464] The J of ULM-j is O or N-R8;

[0465] R8 of ULM-j is H, CN, optionally substituted alkyl or optionally substituted alkoxy;

[0466] M of ULM-j is an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted heterocyclic group or

[0467] Each R9 and R of ULM-j 10 are independently H; optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted thioalkyl, disulfide-linked ULM, optionally substituted heteroaryl or haloalkyl; or R9, R 10 and the carbon atom to which they are attached form an optionally substituted cycloalkyl group;

[0468] ULM-j R 11 is an optionally substituted heterocyclic group, an optionally substituted alkoxy group, an optionally substituted heteroaryl group, an optionally substituted aryl group or

[0469] ULM-j R 12 is H or optionally substituted alkyl;

[0470] ULM-j R 13 is H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl or optionally substituted aralkyl; optionally substituted (oxoalkyl)carbamate,

[0471] Each R of ULM-j 14 is independently H, haloalkyl, optionally substituted cycloalkyl, optionally substituted alkyl, or optionally substituted heterocyclyl;

[0472] ULM-j R 15 is H, CN, optionally substituted heteroaryl, haloalkyl, optionally substituted aryl, optionally substituted alkoxy or optionally substituted heterocyclyl;

[0473] Each R of ULM-j 16 is independently halo, optionally substituted alkyl, optionally substituted haloalkyl, CN, or optionally substituted haloalkoxy;

[0474] Each R of ULM-j 25 are independently H or optionally substituted alkyl; or two R 25 The groups may be taken together to form oxo or optionally substituted cycloalkyl;

[0475] ULM-j R 23 is H or OH;

[0476] Z1, Z2, Z3 and Z4 of ULM-j are independently C or N; and

[0477] o of ULM-j is 0, 1, 2, 3 or 4, or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.

[0478] In certain embodiments, wherein G of ULM-j is C=J, J is O, R7 is H, each R 14 is H, and o is 0.

[0479] In certain embodiments, wherein G of ULM-j is C=J, J is O, R7 is H, each R 14 It's H, R 15 is optionally substituted heteroaryl, and o is 0. In other cases, E is C=O and M is

[0480] In certain embodiments, wherein E of ULM-j is C=O, R 11 is an optionally substituted heterocyclic group or And M is

[0481] In certain embodiments, wherein E of ULM-j is C=O and M is And R 11 yes Each R 18 is independently halo, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, or haloalkoxy; and p is 0, 1, 2, 3, or 4.

[0482] In certain embodiments, ULM and any ULM' present are each independently a group according to the following chemical structure:

[0483]

[0484] in:

[0485] The G of ULM-k is C=J, and J is O;

[0486] R7 of ULM-k is H;

[0487] Each R of ULM-k 14 It is H;

[0488] The o of ULM-k is 0;

[0489] R of ULM-k 15 yes and

[0490] R of ULM-k 17 is H, halogen, optionally substituted cycloalkyl, optionally substituted alkyl, optionally substituted alkenyl and haloalkyl.

[0491] In other cases, the R of ULM-k 17 is an alkyl group (eg, methyl) or a cycloalkyl group (eg, cyclopropyl).

[0492] In other embodiments, ULM and any ULM' present are each independently a group according to the following chemical structure:

[0493]

[0494] in:

[0495] The G of ULM-k is C=J, and J is O;

[0496] R7 of ULM-k is H;

[0497] Each R of ULM-k 14 It is H;

[0498] ULM-k has o = 0; and

[0499] R of ULM-k 15 Selected from:

[0500]

[0501] The R of ULM-k 30 is H or optionally substituted alkyl.

[0502] In other embodiments, ULM and any ULM' present are each independently a group according to the following chemical structure:

[0503]

[0504] in:

[0505] The E of ULM-k is C=O;

[0506] The M of ULM-k is and

[0507] R of ULM-k 11 Selected from:

[0508]

[0509] In yet other embodiments, the compound has the chemical structure,

[0510] Wherein E of ULM-k is C=O;

[0511] R of ULM-k 11 yes and

[0512] The M of ULM-k is

[0513] ULM-k's q is 1 or 2;

[0514] R of ULM-k 20 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or

[0515] R of ULM-k 21 is H or optionally substituted alkyl; and

[0516] R of ULM-k 22 is H, optionally substituted alkyl, optionally substituted alkoxy or haloalkyl.

[0517] In any of the embodiments described herein, R of ULM-j or ULM-k 11 Selected from:

[0518]

[0519]

[0520]

[0521] In certain embodiments, R of ULM-j or ULM-k 11 Selected from:

[0522]

[0523]

[0524] In certain embodiments, the ULM (or ULM' where present) is a group according to the following chemical structure:

[0525] in:

[0526] X of ULM-l is O or S;

[0527] Y of ULM-1 is H, methyl or ethyl;

[0528] ULM-1 R 17 is H, methyl, ethyl, hydroxymethyl or cyclopropyl;

[0529] M of ULM-1 is an optionally substituted aryl group, an optionally substituted heteroaryl group,

[0530] R9 of ULM-l is H;

[0531] ULM-1 R 10 is H, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted hydroxyalkyl, optionally substituted thioalkyl, or cycloalkyl;

[0532] R11 of ULM-1 is an optionally substituted heteroaromatic, an optionally substituted heterocyclic, an optionally substituted aryl or

[0533] ULM-1 R 12 is H or optionally substituted alkyl; and

[0534] ULM-1 R 13 is H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl or optionally substituted aralkyl; optionally substituted (oxoalkyl)carbamate.

[0535] In some embodiments, ULM and any ULM' present are each independently a group according to the following chemical structure:

[0536]

[0537] in:

[0538] Y of ULM-m is H, methyl or ethyl;

[0539] R9 of ULM-m is H;

[0540] R 10 is isopropyl, tert-butyl, sec-butyl, cyclopentyl or cyclohexyl;

[0541] ULM-m R 11 is an optionally substituted amide, an optionally substituted isoindolinone, an optionally substituted isoxazole, or an optionally substituted heterocycle.

[0542] In other preferred embodiments of the present disclosure, ULM and ULM', if present, are each independently a group according to the following chemical structure:

[0543]

[0544] in:

[0545] ULM-nR 17 is methyl, ethyl or cyclopropyl; and

[0546] ULM-n R9, R 10 and R 11 As defined above. In other cases, R9 is H; and

[0547] ULM-nR 10 is H, alkyl or cycloalkyl (preferably isopropyl, tert-butyl, sec-butyl, cyclopentyl or cyclohexyl).

[0548] In other preferred embodiments of the present disclosure, ULM and ULM', if present, are each independently a group according to the following chemical structure:

[0549]

[0550] or a pharmaceutically acceptable salt thereof, wherein:

[0551] R1 is H, optionally substituted alkyl or optionally substituted cycloalkyl;

[0552] R3 is an optionally substituted 5-6 membered heteroaryl;

[0553] W 5 is optionally substituted phenyl, optionally substituted naphthyl or optionally substituted pyridyl;

[0554] R 14a and R 14b wherein one of them is H, optionally substituted alkyl, optionally substituted haloalkyl (e.g., fluoroalkyl), optionally substituted alkoxy, optionally substituted hydroxyalkyl, optionally substituted alkylamine, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR 26 、CONR 27a R 27b 、NHCOR 26 or NHCH3COR 26 ; and R 14a and R 14b The other one is H; or R 14a 、R 14b together with the carbon atom to which they are attached, form an optionally substituted 3- to 6-membered cycloalkyl, heterocycloalkyl, spirocycloalkyl, or spiroheterocyclyl, wherein the spiroheterocyclyl is not an epoxide or an aziridine;

[0555] R 15 is CN, optionally substituted fluoroalkyl, Optionally substituted (For example, where R 28a is halo, optionally substituted alkyl or fluoroalkyl) or

[0556] Each R 16 independently selected from halo, CN, optionally substituted alkyl, optionally substituted haloalkyl, hydroxy, or haloalkoxy;

[0557] Each R 26 are independently H, optionally substituted alkyl or NR 27a R 27b ;

[0558] Each R 27a and R 27b is independently H, optionally substituted alkyl, or R 27a and R 27b Together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic group;

[0559] R 28 is H, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heteroalkyl, optionally substituted alkylamine, optionally substituted hydroxyalkyl, amine, optionally substituted alkynyl, or optionally substituted cycloalkyl; and

[0560] o is 0, 1, or 2.

[0561] In any aspect or embodiment described herein, the ULM has the formula:

[0562]

[0563] in:

[0564] X 4 、X 5 and X 6 are each selected from CH and N, not more than 2 of which are N;

[0565] R 1 is a C1-6 alkyl group;

[0566] R 14a and R 14b wherein one of them is H, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyalkyl, optionally substituted alkylamine, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR 26 、CONR 27a R 27b 、NHCOR 26 or NHCH3COR 26 ; and R 14a and R 14b The other one is H; or R14a and R 14b together with the carbon atom to which they are attached, form an optionally substituted 3- to 5-membered cycloalkyl, heterocycloalkyl, spirocycloalkyl, or spiroheterocyclyl, wherein the spiroheterocyclyl is not an epoxide or an aziridine;

[0567] R 27a and R 27b are each independently H or C 1-6 alkyl;

[0568] q is 1, 2, 3, or 4;

[0569] R 15 yes or CN;

[0570] R 28 It is H, methyl, CH2N(Me)2, CH2OH, CH2O(C 1-4 alkyl), CH2NHC(O)C 1-4 Alkyl, NH2,

[0571] R 28C is H, methyl, fluoro or chloro; and

[0572] R 16 It is H, C 1-4 Alkyl, fluorine, chlorine, CN or C 1-4 Alkoxy.

[0573] In any aspect or embodiment described herein, R 14a and R 14b Selected from: H, C 1-4 Alkyl, C 1-4 Cycloalkyl, C 1-4 Halogenated alkyl, C 1-4 Hydroxyalkyl, C 1-4 Alkyloxyalkyl, C 1-4 Alkyl-NR 27a R 27b and CONR 27a R 27b .

[0574] In any aspect or embodiment described herein, R 14a and R 14b At least one of them is H (e.g., R 14a and R 14b Both are H).

[0575] In any aspect or embodiment described herein, R 14a and R 14bAt least one of them is optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyalkyl, optionally substituted alkylamine, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR 26 、CONR 27a R 27b 、NHCOR 26 or NHCH3COR 26 Alternatively, in any aspect or embodiment described herein, R 14a and R 14b wherein one of them is optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyalkyl, optionally substituted alkylamine, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR 26 、CONR 27a R 27b 、NHCOR 26 or NHCH3COR 26 ; and R 14a and R 14b The other one is H.

[0576] In any aspect or embodiment described herein, R 14a and R 14b Together with the carbon atoms to which they are attached, they form where R 23 Selected from H, C 1-4 Alkyl, -C(O)C 1-4 alkyl.

[0577] In other preferred embodiments of the present disclosure, ULM and ULM', if present, are each independently a group according to the following chemical structure:

[0578]

[0579] or a pharmaceutically acceptable salt thereof, wherein:

[0580] X is CH or N; and

[0581] R1, R3, R of ULM-q and ULM-r 14a 、R 14b and R 15 Same as defined for ULM-o and ULM-p.

[0582] In any aspect or embodiment described herein, R1 is C 1-6 alkyl.

[0583] In any aspect or embodiment described herein, R 14a and R 14b One of them is H, C 1-6 Alkyl, C 1-6 Haloalkyl, optionally substituted C 1-4 Alkylamine, C 1-6 Alkoxy, (CH2) q C 1-6 Alkoxy, (CH2) q C 1-6 Alkoxy-C3-C7 heterocycloalkyl, (CH2) q OH, (CH2) q NR 27a R 27b 、(CH2) q NHCOC 1-6 Alkyl, C 3-6 Cycloalkyl or NR 27a R 27b ; R 26 Each independently is H, C 1-6 Alkyl or NR 27a R 27b ; R 27a and R 27b are each independently H or C 1-6 alkyl; and q is 1, 2, 3 or 4.

[0584] In any aspect or embodiment described herein, R 14a and R 14b One of them is H, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, optionally substituted C 1-4 Alkylamine, (CH2) q C 1-6 Alkoxy, (CH2) q C 1-6 Alkoxy-C3-C7 heterocycloalkyl, (CH2) q OH, (CH2) q NR 27a R 27b 、(CH2) q NHCOC 1-6 Alkyl, C 3-6 Cycloalkyl or NR 27a R 27b ; R 26 Each independently is H, C 1-4 Alkyl or NR 27a R 27b ; R 27a and R 27bare each independently H or C 1-4 alkyl; and q is 1 or 2.

[0585] In any aspect or embodiment described herein, R 28 It is C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, (CH2) q OC 1-6 Alkyl, (CH2) q OH, (CH2) q NR 27a R 27b 、(CH2) q NHCOC 1-6 Alkyl or

[0586] R 29 It is H, C 1-6 Alkyl, NR 27a R 27b or q NHCOC 1-6 alkyl; and

[0587] where q is 1 or 2.

[0588] In any aspect or embodiment described herein, R 3 In any aspect or embodiment described herein, X is CH.

[0589] In any aspect or embodiment described herein, the ULM is according to the formula:

[0590]

[0591] or a pharmaceutically acceptable salt thereof,

[0592] in:

[0593] R1, R 14a and R 14b As mentioned in this article;

[0594] X is CH or N;

[0595] R 30 is H, F or Cl;

[0596] R 16 It is H, C 1-4 Alkyl, fluorine, chlorine, CN or C 1-4 alkoxy; and

[0597] R28 It is H, methyl, CH2N(Me)2, CH2OH, CH2O(C 1-4 alkyl), CH2NHC(O)C 1-4 Alkyl, NH2,

[0598] In any aspect or embodiment described herein, the ULM is according to the formula:

[0599]

[0600] or a pharmaceutically acceptable salt thereof,

[0601] in:

[0602] R1, R 14a 、R 14b each as described herein; and

[0603] R 30 It is H, F or Cl.

[0604] In any aspect or embodiment described herein, the ULM as described herein (or ULM' as present) can be a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof. In addition, in any aspect or embodiment described herein, the ULM as described herein (or ULM' as present) can be directly coupled to the PTM via a bond or chemical linker.

[0605] In certain aspects of the present disclosure, the ULM moiety is selected from:

[0606]

[0607]

[0608]

[0609]

[0610]

[0611]

[0612]

[0613]

[0614]

[0615]

[0616]

[0617]

[0618]

[0619]

[0620]

[0621]

[0622]

[0623]

[0624]

[0625]

[0626]

[0627]

[0628] Wherein the VLM can be linked to the PTM via a linker as described herein at any suitable position, including, for example, an aryl, heteroaryl, phenyl or phenyl group of an indole group, optionally via any suitable functional group, such as an amine, ester, ether, alkyl or alkoxy group.

[0629] In any aspect or embodiment described herein, the ULM is selected from:

[0630]

[0631]

[0632]

[0633]

[0634] in:

[0635] Q1, Q3, Q4 and Q5 are independently nitrogen atoms or atoms having hydrogen, halogen, OH or C 1-3 the carbon atom of an alkoxy group;

[0636] ULM Indicates the point of attachment to the linker group or PTM. And

[0637] N* is the nitrogen atom shared with the chemical linker group or PTM.

[0638] Exemplary linkers

[0639] In certain embodiments, the compounds as described herein comprise one or more PTMs chemically linked or coupled to one or more ULMs (e.g., at least one of a CLM, a VLM, or a combination thereof) via a chemical linker (L). In certain embodiments, the linker group L is a structural unit comprising one or more covalently linked units (e.g., -A L 1…(A L ) q -or-(A L ) q -) group, where A L 1 is a group coupled to PTM, and (A L ) q is the group coupled to the ULM.

[0640] In any aspect or embodiment described herein, the linker (L) connection or coupling of the ULM (e.g., VLM or CLM) is a stable L-ULM connection. For example, in any aspect or embodiment described herein, when the linker (L) and the ULM are connected via a heteroatom, any subsequent heteroatom (if present) is separated by at least one single carbon atom (e.g., -CH2-), such as from an acetal or amino group. For another example, in any aspect or embodiment described herein, when the linker (L) and the ULM are connected via a heteroatom, the heteroatom is not part of an ester.

[0641] In any aspect or embodiment described herein, the linker group L is a bond or is of the formula -(A L ) q -represented chemical linker group, wherein A is a chemical moiety and q is an integer from 1 to 100 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 , 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 or 80), and wherein L is covalently bound to the PTM and the ULM and provides sufficient binding of the PTM to the protein target and the ULM to the E3 ubiquitin ligase, thereby resulting in ubiquitination of the target protein.

[0642] In any aspect or embodiment described herein, the linker group L is -(A L ) q-,in:

[0643] (A l ) Q is a group attached to at least one of a ULM (e.g., CLM or VLM), a PTM moiety, or a combination thereof;

[0644] The linker q is an integer greater than or equal to 1;

[0645] Each A L are independently selected from a bond, CR L1 R L2 、O、S、SO、SO2、NR L3 、SO2NR L3 ,SONR L3 、CONR L3 NR L3 CONR L4 NR L3 SO2NR L4 , CO, CR L1 =CR L2 、C≡C、SiR L1 R L2 、P(O)R L1 、P(O)OR L1 NR L3 C(=NCN)NR L4 NR L3 C(=NCN),NR L3 C(=CNO2)NR L4 , 0-6 R's can be selected L1 and / or R L2 C 3-11 Cycloalkyl, optionally substituted by 0-9 R L1 and / or R L2 C 5-13 Spirocycloalkyl, optionally substituted by 0-6 R L1 and / or R L2 C 3-11 Heterocyclic group, optionally substituted by 0-8 R L1 and / or R L2 C 5-13 Spiroheterocyclic group, optionally substituted by 0-6 R L1 and / or R L2 substituted aryl, optionally substituted with 0-6 R L1 and / or R L2 A heteroaryl group substituted with a group, wherein R L1 or R L2 Each independently is optionally linked to other groups to form an optionally 0-4 R L5substituted cycloalkyl and / or heterocyclyl moieties; and

[0646] R L1 、R L2 、R L3 、R L4 and R L5 are independently H, halogen, C 1-8 Alkyl, OC 1-8 Alkyl, SC 1-8 Alkyl, NHC 1-8 Alkyl, N(C 1-8 Alkyl)2, C 3-11 Cycloalkyl, aryl, heteroaryl, C 3-11 Heterocyclic group, OC 1-8 Cycloalkyl, SC 1-8 Cycloalkyl, NHC 1-8 Cycloalkyl, N(C 1-8 Cycloalkyl)2, N(C 1-8 Cycloalkyl)(C 1-8 alkyl), OH, NH2, SH, SO2C 1-8 Alkyl, P(O)(OC 1-8 Alkyl)(C 1-8 alkyl), P(O)(OC 1-8 Alkyl)2, CC-C 1-8 Alkyl, CCH, CH=CH(C 1-8 alkyl), C(C 1-8 alkyl)=CH(C 1-8 alkyl)C(C 1-8 alkyl)=C(C 1-8 alkyl)2、Si(OH)3、Si(C 1-8 Alkyl)3, Si(OH)(C 1-8 Alkyl)2, COC 1-8 Alkyl, CO2H, halogen, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NHC 1-8 Alkyl, SO2N(C 1-8 Alkyl)2, SONHC 1-8 Alkyl, SON(C 1-8 Alkyl)2, CONHC 1-8 Alkyl, CON(C 1-8 Alkyl)2, N(C 1-8 alkyl)CONH(C 1-8 alkyl), N(C 1-8 alkyl)CON(C 1-8 alkyl)2、NHCONH(C 1-8 Alkyl), NHCON(C 1-8 alkyl)2、NHCONH2、N(C1-8 alkyl)SO2NH(C 1-8 alkyl), N(C 1-8 alkyl)SO2N(C 1-8 Alkyl)2, NH SO2NH(C 1-8 alkyl), NH SO2N(C 1-8 Alkyl)2, NH SO2NH2.

[0647] In any aspect or embodiment described herein, q of the linker is an integer greater than or equal to 0. In certain embodiments, q is an integer greater than or equal to 1.

[0648] In any aspect or embodiment described herein, for example, when q of the linker is greater than 2, (A L ) q Yes to A L 1 and (A L ) q A group wherein unit A L The PTM was coupled to the ULM.

[0649] In any aspect or embodiment described herein, for example, when q of the linker is 2, (A L ) q To connect to A L 1 and ULM groups.

[0650] In any aspect or embodiment described herein, for example, when q of the linker is 1, the structure of the linker group L is -A L 1-, and A L 1 is a group connected to the ULM moiety and the PTM moiety.

[0651] In any aspect or embodiment described herein, unit A of linker (L) L Contains a group represented by a general structure selected from the following:

[0652] -NR(CH2) n -(lower alkyl)-, -NR(CH2) n -(lower alkoxy)-, -NR(CH2) n -(lower alkoxy)-OCH2-, -NR(CH2) n -(lower alkoxy)-(lower alkyl)-OCH2-, -NR(CH2) n -(cycloalkyl)-(lower alkyl)-OCH2-, -NR(CH2) n -(Heterocycloalkyl)-, -NR(CH2CH2O) n -(lower alkyl)-O-CH2-, -NR(CH2CH2O) n-(Heterocycloalkyl)-O-CH2-, -NR(CH2CH2O) n -Aryl-O-CH2-, -NR(CH2CH2O) n -(heteroaryl)-O-CH2-, -NR(CH2CH2O) n -(cycloalkyl)-O-(heteroaryl)-O-CH2-, -NR(CH2CH2O) n -(cycloalkyl)-O-aryl-O-CH2-, -NR(CH2CH2O) n -(lower alkyl)-NH-aryl-O-CH2-, -NR(CH2CH2O) n -(lower alkyl)-O-aryl-CH2, -NR(CH2CH2O) n -cycloalkyl-O-aryl-, -NR(CH2CH2O) n -cycloalkyl-O-(heteroaryl)l-, -NR(CH2CH2) n -(cycloalkyl)-O-(heterocyclyl)-CH2, -NR(CH2CH2) n -(heterocyclyl)-(heterocyclyl)-CH2, -N(R1R2)-(heterocyclyl)-CH2; wherein

[0653] n of the linker can be 0 to 10;

[0654] The R of the linker can be H, lower alkyl;

[0655] R1 and R2 of the linker may form a ring via the attached N.

[0656] In any aspect or embodiment described herein, the linker (L) comprises an optionally substituted C1-C 50 Alkyl (e.g., C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 、C 11 、C 12 、C 13 、C 14 、C 15 、C 16 、C 17 、C 18 、C 19 、C 20 、C 21 、C 22 、C 23 、C 24 、C 25 、C 26 、C 27 、C 28 、C 29 、C 30 、C31 、C 32 、C 33 、C 34 、C 35 、C 36 、C 37 、C 38 、C 39 、C 40 、C 41 、C 42 、C 43 、C 44 、C 45 、C 46 、C 47 、C 48 、C 49 or C 50 alkyl), wherein each carbon is optionally substituted with: (1) a heteroatom selected from N, S, P, or Si atoms with an appropriate number of hydrogen atoms, substituents, or both to complete the valence, (2) an optionally substituted cycloalkyl or bicyclic cycloalkyl, (3) an optionally substituted heterocycloalkyl or bicyclic heterocycloalkyl, (4) an optionally substituted aryl or bicyclic aryl, or (5) an optionally substituted heteroaryl or bicyclic heteroaryl. In any aspect or embodiment described herein, the linker (L) does not have heteroatom-heteroatom linkages (e.g., no heteroatoms are covalent linkers or adjacently positioned).

[0657] In any aspect or embodiment described herein, the linker (L) comprises an optionally substituted C1-C 50 Alkyl (e.g. C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 、C 11 、C 12 、C 13 、C 14 、C 15 、C 16 、C 17 、C 18 、C 19 、C 20 、C 21 、C 22 、C 23 、C 24 、C 25 、C 26 、C 27 、C 28 、C 29 、C 30 、C 31 、C 32 、C 33 、C 34 、C 35 、C 36、C 37 、C 38 、C 39 、C 40 、C 41 、C 42 、C 43 、C 44 、C 45 、C 46 、C 47 、C 48 、C 49 or C 50 alkyl), wherein:

[0658] Each carbon is optionally substituted with the following groups: CR L1 R L2 、O、S、SO、SO2、NR L3 、SO2NR L3 ,SONR L3 、CONR L3 NR L3 CONR L4 NR L3 SO2NR L4 , CO, CR L1 =CR L2 、C≡C、SiR L1 R L2 、P(O)R L1 、P(O)OR L1 NR L3 C(=NCN)NR L4 NR L3 C(=NCN),NR L3 C(=CNO2)NR L4 , 0-6 R's can be selected L1 and / or R L2 C 3-11 Cycloalkyl, optionally substituted by 0-9 R L1 and / or R L2 C 5-13 Spirocycloalkyl, optionally substituted by 0-6 R L1 and / or R L2 C 3-11 Heterocyclic group, optionally substituted by 0-8 R L1 and / or R L2 C 5-13 Spiroheterocycloalkyl, optionally substituted by 0-6 R L1 and / or R L2 substituted aryl, optionally substituted with 0-6 R L1 and / or R L2 A heteroaryl group substituted with a group, wherein R L1or R L2 Each independently is optionally linked to other groups to form an optionally 0-4 R L5 substituted cycloalkyl and / or heterocyclyl moieties; and

[0659] R L1 、R L2 、R L3 、R L4 and R L5 are independently H, halogen, C 1-8 Alkyl, OC 1-8 Alkyl, SC 1-8 Alkyl, NHC 1-8 Alkyl, N(C 1-8 Alkyl)2, C 3-11 Cycloalkyl, aryl, heteroaryl, C 3-11 Heterocyclic group, OC 1-8 Cycloalkyl, SC 1-8 Cycloalkyl, NHC 1-8 Cycloalkyl, N(C 1-8 Cycloalkyl)2, N(C 1-8 Cycloalkyl)(C 1-8 alkyl), OH, NH2, SH, SO2C 1-8 Alkyl, P(O)(OC 1-8 Alkyl)(C 1-8 alkyl), P(O)(OC 1-8 Alkyl)2, CC-C 1-8 Alkyl, CCH, CH=CH(C 1-8 alkyl), C(C 1-8 alkyl)=CH(C 1-8 alkyl)C(C 1-8 alkyl)=C(C 1-8 alkyl)2、Si(OH)3、Si(C 1-8 Alkyl)3, Si(OH)(C 1-8 Alkyl)2, COC 1-8 Alkyl, CO2H, halogen, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NHC 1-8 Alkyl, SO2N(C 1-8 Alkyl)2, SONHC 1-8 Alkyl, SON(C 1-8 Alkyl)2, CONHC 1-8 Alkyl, CON(C 1-8 Alkyl)2, N(C 1-8 alkyl)CONH(C 1-8 alkyl), N(C 1-8 alkyl)CON(C 1-8 alkyl)2、NHCONH(C1-8 alkyl), NHCON(C 1-8 alkyl)2、NHCONH2、N(C 1-8 alkyl)SO2NH(C 1-8 alkyl), N(C 1-8 alkyl)SO2N(C 1-8 Alkyl)2, NH SO2NH(C 1-8 alkyl), NH SO2N(C 1-8 In any aspect or embodiment described herein, the linker (L) has no heteroatom-heteroatom bonding (eg, no heteroatoms are covalently linked or adjacently positioned).

[0660] In any aspect or embodiment described herein, the linker (L) comprises from about 1 to about 50 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50) optionally substituted alkylene glycol units, wherein a carbon or oxygen may be substituted with a heteroatom selected from N, S, P, or Si atoms, with an appropriate number of hydrogen atoms to complete the valence. For example, in any aspect or embodiment described herein, the linker (L) has a chemical structure selected from:

[0661]

[0662]

[0663] wherein the carbon or oxygen may be replaced by a heteroatom selected from N, S, P or Si atoms, with an appropriate number of hydrogens to complete the valence, and m, n, o, p, q, r and s are independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20.

[0664] In any aspect or embodiment described herein, unit A of linker (L) L Contains a group represented by a general structure selected from the following:

[0665]

[0666]

[0667] in:

[0668] each independently is a 3-7 membered cycloalkyl or heterocycloalkyl group (e.g., a 4-6 membered cycloalkyl or heterocycloalkyl group), wherein overlapping circles indicate a spirocycle;

[0669] each m, n, o, and p is independently 0, 1, 2, 3, 4, 5, or 6; and

[0670] Indicates the attachment point to the PTM or ULM.

[0671] In any aspect or embodiment described herein, unit A of linker (L) L Contains a group represented by a general structure selected from the following:

[0672]

[0673]

[0674]

[0675]

[0676]

[0677] in:

[0678] N* is a nitrogen atom covalently attached to or shared with the ULM or PTM;

[0679] Indicates the point of attachment to the PTM or ULM; and

[0680] Each of m, n, o, p, q and r is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0681] In any aspect or embodiment described herein, unit A of linker (L) l Selected from:

[0682]

[0683]

[0684]

[0685]

[0686]

[0687]

[0688]

[0689]

[0690]

[0691]

[0692]

[0693]

[0694]

[0695]

[0696]

[0697] wherein N* is a nitrogen atom covalently attached to or shared with a ULM or PTM, and Indicates the attachment point to the ULM or PTM.

[0698] In any aspect or embodiment described herein, unit A of linker (L) L Contains a group represented by a general structure selected from the following:

[0699] -N(R)-(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -OCH2-,

[0700] -O-(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -OCH2-,

[0701] -O-(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -O-,

[0702] -N(R)-(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -O-,

[0703] -(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -O-,

[0704] -(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -OCH2-,

[0705]

[0706]

[0707] in

[0708] m, n, o, p, q, and r of the linker are independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;

[0709] When the number is zero, there is no NO or OO key

[0710] R of the linker is H, methyl and ethyl;

[0711] The X of the linker is H and F

[0712]

[0713] The m of the linker can be 2, 3, 4, 5

[0714]

[0715]

[0716]

[0717]

[0718]

[0719]

[0720]

[0721]

[0722]

[0723] wherein each n and m of the linker can independently be 0, 1, 2, 3, 4, 5, or 6. In any aspect or embodiment described herein, unit A of the linker (L) L Selected from:

[0724]

[0725]

[0726]

[0727] wherein each n and m is independently selected from 0, 1, 2, 3, 4, 5 or 6.

[0728] In any aspect or embodiment described herein, unit A of linker (L) L Selected from:

[0729]

[0730]

[0731]

[0732]

[0733]

[0734]

[0735]

[0736]

[0737]

[0738]

[0739]

[0740]

[0741]

[0742]

[0743]

[0744]

[0745]

[0746]

[0747]

[0748]

[0749]

[0750]

[0751]

[0752]

[0753]

[0754]

[0755]

[0756]

[0757]

[0758]

[0759] wherein each of m, n, o, p, q, r, and s is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0760] In any aspect or embodiment described herein, unit A of linker (L) L Selected from:

[0761]

[0762]

[0763]

[0764]

[0765]

[0766]

[0767]

[0768]

[0769]

[0770]

[0771]

[0772]

[0773]

[0774]

[0775]

[0776] In any aspect or embodiment described herein, the Linker unit of Linker (L) comprises a group represented by a structure selected from:

[0777] -O-(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -O(CH2) s -O(CH2) t -、

[0778] -O-(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -O(CH2) s -O-,

[0779] -(CH2) m -O(CH2) n-O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -O(CH2) s -O(CH2) t -、

[0780] -CH=CH(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -O(CH2) s -O(CH2) t -

[0781] -O(CH2) n NCH3(=O)(CH2) m -;

[0782]

[0783]

[0784]

[0785]

[0786] wherein m, n, o, p, q, r, s and t are each independently selected from the integers 0, 1, 2, 3 and 4.

[0787] In any aspect or embodiment described herein, the linker (L) is selected from:

[0788]

[0789] In any aspect or embodiment described herein, the linker (L) comprises a structure selected from, but not limited to, the structures shown below, wherein the dashed line indicates the point of attachment to the PTM or ULM moiety:

[0790]

[0791] in:

[0792] W L1 and W L2 Each independently does not exist, is a 4-8 membered ring having 0-4 heteroatoms, optionally replaced by R Q Replace, each R Qare independently H, halogen, OH, CN, CF3, optionally substituted linear or branched C1-C6 alkyl, optionally substituted linear or branched C1-C6 alkoxy, or 2 R Q The groups, together with the atoms to which they are attached, form a 4-8 membered ring system containing 0-4 heteroatoms;

[0793] Y L1 Each is independently a bond, an optionally substituted linear or branched C1-C6 alkyl group, and optionally one or more C atoms are replaced by O; or an optionally substituted linear or branched C1-C6 alkoxy group;

[0794] n is 0-10; and

[0795] Indicates the point of attachment to the PTM or ULM portion.

[0796] In any aspect or embodiment described herein, the linker (L) comprises a structure selected from, but not limited to, the structures shown below, wherein the dashed line indicates the point of attachment to the PTM or ULM moiety:

[0797]

[0798] in:

[0799] W L1 and W L2 Each independently does not exist and is an aryl, heteroaryl, ring, heterocycle, C 1-6 Alkyl and optionally one or more C atoms are replaced by O, C 1-6 Olefins and optionally one or more C atoms are replaced by O, C 1-6 Alkyne and optionally one or more C atoms are replaced by O, bicyclic, biaryl, biheteroaryl or biheterocyclic, each optionally replaced by R Q Replace, each R Q are independently H, halogen, OH, CN, CF3, hydroxyl, nitro, C≡CH, C 2-6 Alkenyl, C 2-6 Alkynyl, optionally substituted straight chain or branched C1-C6 alkyl, optionally substituted straight chain or branched C1-C6 alkoxy, optionally substituted OC 1-3 Alkyl (e.g., optionally substituted with 1 or more -F), OH, NH2, NR Y1 R Y2 , CN, or 2 R Q The groups, together with the atoms to which they are attached, form a 4-8 membered ring system containing 0-4 heteroatoms;

[0800] Y L1 Each independently is a bond, NR YL1, O, S, NR YL2 , CR YL1 R YL2 , C=O, C=S, SO, SO2, optionally substituted linear or branched C1-C6 alkyl and optionally one or more C atoms are replaced by O; optionally substituted linear or branched C1-C6 alkoxy;

[0801] Q L is a 3-6 membered alicyclic or aromatic ring having 0-4 heteroatoms, optionally bridged, optionally surrounded by 0-6 R Q Replace, each R Q are independently H, optionally substituted linear or branched C 1-6 Alkyl (eg, optionally substituted with one or more halo or C 1-6 alkoxy substituted), or 2 R Q The groups, together with the atoms to which they are attached, form a 3-8 membered ring system containing 0-2 heteroatoms;

[0802] R YL1 、R YL2 are each independently H, OH, an optionally substituted linear or branched C 1-6 Alkyl (e.g., optionally substituted with one or more halo, C 1-6 alkoxy substituted), or R 1 、R 2 Together with the atoms to which they are attached, they form a 3-8 membered ring system containing 0-2 heteroatoms;

[0803] n is 0-10; and

[0804] Indicates the point of attachment to the PTM or ULM portion.

[0805] In any aspect or embodiment described herein, the linker group is an optionally substituted (poly)ethylene glycol having from 1 to about 100 ethylene glycol units (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 7, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, etc. ethylene glycol units), about 1 to about 50 ethylene glycol units, about 1 to about 25 ethylene glycol units, about 1 to 10 ethylene glycol units, about 1 to about 8 ethylene glycol units and 1 to 6 ethylene glycol units, about 2 to 4 ethylene glycol units; or an optionally substituted alkyl group interspersed with optionally substituted O, N, S, P or Si atoms. In certain embodiments, the linker is substituted with an aryl, phenyl, benzyl, alkyl, alkylene or heterocyclyl group. In certain embodiments, the linker can be asymmetric or symmetric.

[0806] In any aspect or embodiment described herein, the linker group can be any suitable moiety described herein. In one embodiment, the linker is a substituted or unsubstituted polyethylene glycol group ranging in size from about 1 to about 12 ethylene glycol units, 1 to about 10 ethylene glycol units, about 2 to about 6 ethylene glycol units, about 2 to 5 ethylene glycol units, about 2 to 4 ethylene glycol units.

[0807] In any aspect or embodiment described herein, the present disclosure relates to a compound comprising a PTM group as described above that is bound to a target protein or polypeptide (e.g., BCL6), the PTM group being ubiquitinated by a ubiquitin ligase and being chemically linked directly or through a linker moiety L to a ULM group, or the PTM is alternatively a ULM' group, which is also a ubiquitin ligase binding moiety that can be the same or different from the ULM group as described above and is directly linked to the ULM group or through a linker moiety; and L is a linker moiety as described above that can be present or absent and that chemically (covalently) links the ULM to the PTM; or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, or polymorph thereof.

[0808] In any aspect or embodiment described herein, the linker group L is a group comprising one or more covalently linked structural units independently selected from:

[0809]

[0810] X is selected from O, N, S, S(O) and SO2; n is an integer from 1 to 5; R L1is hydrogen or an alkyl group, is a monocyclic or bicyclic aryl or heteroaryl group optionally substituted by 1 to 3 substituents selected from alkyl, halogen, haloalkyl, hydroxy, alkoxy or cyano; is a monocyclic or bicyclic cycloalkyl or heterocyclic group optionally substituted by 1-3 substituents selected from alkyl, halogen, haloalkyl, hydroxyl, alkoxy or cyano; and the phenyl ring fragment may be optionally substituted by 1, 2 or 3 substituents selected from alkyl, halogen, haloalkyl, hydroxyl, alkoxy and cyano. In one embodiment, the linker group L comprises up to 10 covalently linked structural units, as described above.

[0811] Although the ULM group and the PTM group can be covalently linked to the linker group through any group that is suitable and stable for the linker chemistry, in preferred aspects of the present disclosure, the linker is independently covalently bound to the ULM group and the PTM group, preferably through an amide, ester, thioester, keto, carbamate (urethane), carbon, or ether, each of which can be inserted anywhere on the ULM group and the PTM group to maximize binding of the ULM group on the ubiquitin ligase to the PTM group on the target protein to be degraded. (Note that in certain aspects where the PTM group is a ULM group, the target protein for degradation can be the ubiquitin ligase itself). In certain preferred aspects, the linker can be attached to an optionally substituted alkyl, alkylene, alkenyl or alkynyl, aryl, or heterocyclic group on the ULM and / or PTM group.

[0812] Exemplary PTMs

[0813] In a preferred aspect of the present disclosure, the PTM group is a group that binds to a target protein. The targets of the PTM group are of various types and are selected from proteins expressed in cells so that at least a portion of the sequence is present in the cell and can bind to the PTM group. The term "protein" includes oligopeptides and polypeptide sequences of sufficient length so that they can bind to the PTM group according to the present disclosure. As described elsewhere herein, any protein in a eukaryotic system or microbial system (including viruses, bacteria or fungi) is a target for ubiquitination mediated by a compound according to the present disclosure. Preferably, the target protein is a eukaryotic protein.

[0814] PTM groups according to the present disclosure include, for example, any portion of the following non-limiting examples that specifically bind to a protein (binds to a target protein) and include small molecule target protein portions: Hsp90 inhibitors, kinase inhibitors, BCL6 inhibitors, HDM2 and MDM2 inhibitors, compounds targeting human BET bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, nuclear hormone receptor compounds, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR), etc. The compositions described below illustrate some members of the small molecule target protein binding portion. Such small molecule target protein binding portions also include pharmaceutically acceptable salts, enantiomers, solvates, and polymorphs of these compositions, as well as other small molecules that can target the protein of interest. These binding portions are preferably connected to the ubiquitin ligase binding portion via a linker so as to present the target protein (to which the protein target portion binds) in the vicinity of the ubiquitin ligase for ubiquitination and degradation.

[0815] Any protein that can bind to a protein target portion or PTM group and act or degrade by a ubiquitin ligase is a target protein according to the present disclosure. Typically, target proteins can include, for example, structural proteins, receptors, enzymes, cell surface proteins, proteins associated with cellular integration functions (including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catabolism), antioxidant activity, proteolysis, biosynthesis), proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transduction activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, response to stimulation Proteins of interest include proteins involved in transport, including protein transport activity, nuclear transport, ion transporter activity, channel transporter activity, carrier activity, permease activity, secretion activity, electron transporter activity, pathogenesis, chaperone regulatory protein activity, nucleic acid binding activity, transcriptional regulatory protein activity, extracellular organization and biogenesis activity, translational regulatory protein activity. Proteins of interest can include proteins from eukaryotes and prokaryotes, including humans as targets for drug therapy, other animals including domesticated animals, microorganisms and plants for use as targets for the determination of antibiotics and other antimicrobial agents, and even viruses, among many others.

[0816] The present disclosure can be used to treat a wide variety of disease states and / or conditions, including any disease state and / or condition in which a protein is dysregulated and in which a patient would benefit from the degradation and / or inhibition of the protein.

[0817] On the other hand, this specification provides therapeutic compositions, which include an effective amount of a compound as described herein or a salt form thereof, and a pharmaceutically acceptable carrier, additive or excipient, and optionally another bioactive agent. The therapeutic composition regulates protein degradation in a patient or subject (e.g., an animal, such as a human), and can be used to treat or improve a disease state or condition regulated by degraded protein. In certain embodiments, the therapeutic composition as described herein can be used to achieve degradation of a protein of interest to treat or improve a disease, such as cancer. In certain other embodiments, the disease is lymphoma, B cell non-Hodgkin's lymphoma, large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma, intravascular large B cell lymphoma, B cell leukemia, acute B cell lymphocytic leukemia, chronic myeloid leukemia, non-small cell lung cancer.

[0818] In an alternative aspect, the present disclosure relates to a method for treating a disease state in a subject in need thereof or ameliorating the symptoms of a disease or condition by degrading a protein or polypeptide used to modulate the disease state or condition, the method comprising administering to the patient or subject an effective amount, e.g., a therapeutically effective amount, of at least one compound as described above, optionally in combination with a pharmaceutically acceptable carrier, additive, or excipient and optionally an additional bioactive agent, wherein the composition is effective to treat or ameliorate the disease or condition or its symptoms in the subject. The methods according to the present disclosure can be used to treat a variety of disease states or conditions, including cancer, by administering an effective amount of at least one compound described herein. The disease state or condition can be a disease caused by a microbial agent or other exogenous agent (e.g., a virus, bacteria, fungus, protozoa, or other microorganism), or can be a disease state caused by overexpression of a protein, which results in the disease state and / or condition.

[0819] In another aspect, the present description provides methods of identifying the effects of degradation of a protein of interest in a biological system using compounds according to the present disclosure.

[0820] The term "target protein" is used to describe a protein or polypeptide that is a target for binding to a compound according to the present disclosure and for degradation by a ubiquitin ligase as described below. Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates, and polymorphs of these compositions, as well as other small molecules that can target a protein of interest. These binding moieties are linked to at least one ULM group (e.g., VLM and / or CLM) via at least one linker group L.

[0821] Target proteins that can be bound to a protein target portion and degraded by the ligase to which the ubiquitin ligase binding portion is bound include any protein or peptide, including fragments thereof, analogs thereof, and / or homologs thereof. Target proteins include proteins and peptides having any biological function or activity, including structural, regulatory, hormonal, enzymatic, genetic, immune, contractile, storage, transport, and signal transduction. More specifically, a variety of drug targets for human therapy represent protein targets to which a protein target portion can be bound and incorporated into the compounds according to the present disclosure.These include proteins that can be used to restore function in a variety of polygenic diseases, including, for example, B7.1 and B7, TINFR1m, TNFR2, NADPH oxidase, BclIBax and other partners in the apoptotic pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDE I, PDEII, PDEIII, squalene cyclase inhibitor, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclooxygenase 1, cyclooxygenase 2, 5HT receptor, dopamine receptor, G protein (i.e., Gq), histamine receptor, 5-lipoxygenase, tryptase-like serine protease, thymidylate synthase, purine nucleoside phosphorylase, trypanosomal GAPDH, glycogen phosphorylase, carbonic anhydrase, chemokine receptors, JAW STAT, RXR and the like, HIV 1 protease, HIV 1 integrase, influenza neuraminidase, hepatitis B reverse transcriptase, sodium channel, multidrug resistance (MDR), protein P-glycoprotein (and MRP), tyrosine kinase, CD23, CD124, tyrosine kinase p56 lck, CD4, CD5, IL-2 receptor, BCL6, IL-1 receptor, TNF-αR, ICAM1, Cat+ channel, VCAM, VLA-4 integrin, selectins, CD40 / CD40L, newokinin and receptor, inosine monophosphate dehydrogenase, p38 MAP kinase, RaslRaflMEWERK pathway, interleukin-1 converting enzyme, caspase, HCV, NS3 protease, HCV NS3 RNA helicase, glycinamide ribonucleotide formyltransferase, rhinovirus 3C protease, herpes simplex virus-1 (HSV-I), protease, cytomegalovirus (CMV) protease, poly (ADP-ribose) polymerase, cyclin-dependent kinase, vascular endothelial growth factor, oxytocin receptor, microsomal transporter inhibitor, bile acid transport inhibitor, 5α-reductase inhibitor, angiotensin 11, glycine receptor, norepinephrine reuptake receptor, endothelin receptor, neurotransmitter Peptide Y and receptors, estrogen receptor, androgen receptor, adenosine receptor, adenosine kinase and AMP deaminase, purinergic receptor (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7), farnesyl transferase, geranyl transferase, TrkA receptor of NGF, beta-amyloid protein, tyrosine kinase Flk-IIKDR, vitronectin receptor, integrin receptor, Her-21neu, telomerase inhibition, cytosolic phospholipase A2 and EGF receptor tyrosine kinase. Additional protein targets include, for example, ecdysone 20-monooxygenase, GABA-gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel and chloride channel. Additional target proteins include acetyl-CoA carboxylase, adenylate succinate synthetase, protoporphyrinogen oxidase and enolpyruvylshikimate phosphate synthase.

[0822] These protein targets can be used in screens to identify compound moieties that bind to the protein, and by incorporating such moieties into compounds according to the disclosure, the activity level of the protein can be altered to achieve a therapeutic end result.

[0823] The term "protein targeting moiety" or PTM is used to describe a small molecule that binds to a target protein or other protein or polypeptide of interest and places / presents the protein or polypeptide in the vicinity of a ubiquitin ligase so that degradation of the protein or polypeptide by the ubiquitin ligase can occur. The compositions described below illustrate some members of the small molecule target protein. Exemplary protein targeting moieties according to the present disclosure include RAF inhibitors, haloalkyl halogenase inhibitors, Hsp90 inhibitors, kinase inhibitors, BCL6 inhibitors, MDM2 inhibitors, compounds targeting human BET bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR).

[0824] The compositions described herein exemplify some members of these types of small molecule target protein binding moieties. Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates, and polymorphs of these compositions, as well as other small molecules that can target proteins of interest. The references cited below are incorporated herein by reference in their entirety.

[0825] In any aspect or embodiment described herein, the PTM is a small molecule that binds to BCL6. For example, in any aspect or embodiment described herein, the PTM is represented by the chemical structure PTMI, PTMII, PTMIII, or PTMIV:

[0826]

[0827] in:

[0828] Each R PTM1are independently: H; halogen (e.g., Cl or F); -CN; -OH; -NO2; -NH2; optionally substituted straight or branched alkyl (e.g., optionally substituted straight or branched C1-C6 alkyl or optionally substituted straight or branched C1-C4 alkyl or C1-C8 alkyl optionally substituted with OH or isopropyl); O-optionally substituted straight or branched C1-C4 alkyl; optionally substituted C1-C4 alkynyl; optionally substituted C1-C4 alkynyl hydrocarbon; optionally substituted straight or branched hydroxyalkyl (e.g., optionally substituted straight or branched C1-C7 hydroxyalkyl); optionally substituted alkylcycloalkyl (e.g., including optionally substituted C1-C6 alkyl, optionally substituted C3-C10 cycloalkyl; or both); optionally substituted alkyl-aryl (e.g., including optionally substituted straight or branched C1-C6 alkyl, optionally substituted 5-10 membered heteroaryl, or both); optionally substituted alkyl-heteroaryl alkyl (e.g., including optionally substituted straight or branched C1-C6 alkyl, optionally substituted 5-10 membered heteroaryl, or both); optionally substituted alkyl-heteroaryl (e.g., including C1-C6 alkyl, optionally substituted 5- or 6-membered heteroaryl, optionally substituted with C1-C4 alkyl; heteroaryl selected from oxazol-4-yl, 1,3,4-triazol-2-yl and imidazol-1-yl; or a combination thereof); optionally substituted -NH-alkyl-heteroaryl (e.g., including C1-C6 alkyl, optionally substituted 5- or 6-membered heteroaryl, optionally substituted with C1-C4 alkyl; heteroaryl selected from oxazol-4-yl, 1,3,4-triazol-2-yl and imidazol-1-yl; or a combination thereof); optionally substituted -NH-alkyl-heteroaryl (e.g., optionally substituted straight or branched C1-C5 alkyl, optionally substituted 5-8 membered heteroaryl, optionally substituted C1-C4 alkyl, N-CH2-pyrazol-4-yl, or a combination thereof); optionally substituted alkoxy (e.g., optionally substituted straight or branched C1-C6 alkyl or -OCH3); optionally substituted O-heterocyclyl (e.g., including optionally substituted 3-12 or 4-7 membered heterocyclyl; optionally substituted heterocycloalkyl; optionally substituted C 3-12 monocyclic or bicyclic heterocycloalkyl; optionally substituted with at least one OH, C1-C5 alkyl (e.g., methyl), =O, NH2, or a combination thereof; or a combination thereof); optionally substituted S-heterocyclyl (e.g., including optionally substituted 4-7 membered heterocyclyl; optionally substituted heterocycloalkyl; optionally substituted with at least one C1-C4 alkyl (e.g., methyl), =O, or a combination thereof; or a combination thereof); optionally substituted (e.g., optionally substituted with linear or branched C1-C4 alkyl; -(CH2) u CO(CH2) v CH3, -COCH3 or -CH2CH2COCH3, wherein each u and v is independently selected from 1, 2, 3, 4 or 5);

[0829] Optionally substituted (e.g., optionally substituted with linear or branched C1-C4 alkyl; -O(CH2) uCO(CH2) v CH3, -O(CH2) u CH((CH2) x CH3)(CH2) w CO(CH2) v CH3, -O-CH2COCH3, -O-CH2COCH2CH3, -O-CH(CH 3) COCH3, -OCH2COCH3 or -OCH2(CH3)COCH3, wherein each u, v, w and x are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -(CH2) u CO(CH2) v NR PTM1a R PTM2a 、-CONR PTM1a R PTM2a 、-CH2CONR PTM1a R PTM2a 、-CH2CH2CONR PTM1a R PTM2a , -CONHCH3 or -CH2CONHCH3, wherein each u and v are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with linear or branched C1-C4 alkyl; -O(CH2) u CO(CH2) v NR PTM1a R PTM2a 、-O(CH2) u CH((CH2) x CH3)(CH2) w CO(CH2) v NR PTM1a R PTM2a 、-O-CH(CH3)CONR PTM1a R PTM2a 、-O-CH2CONR PTM1a R PTM2a or -OCH2C(O)NHOCH3, wherein each u, v, w and x are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -(CH2) u CHCH(CH2) w CO(CH2) v NR PTM1a R PTM2a or -CHCHCONR PTM1a R PTM2a, wherein each u, v and w are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -NH-(CH2) u CO(CH2) v NR PTM1a R PTM2a or -NH-CH2CONR PTM1a R PTM2a , wherein each u and v is independently selected from 1, 2, 3, 4 or 5); fluoroalkoxy (e.g., mono-, di- and / or trifluoroalkoxy); optionally substituted monocyclic or bicyclic cycloalkyl (e.g., optionally substituted 3-12 membered cycloalkyl; optionally substituted with at least one of OH, =O, linear or branched C1-C6 alkyl (e.g., methyl, ethyl or butyl) or NH2; or a combination thereof); optionally substituted hydroxycycloalkyl; optionally substituted aryl (e.g., optionally substituted C5-C10 aryl, any optionally substituted 5-7 membered aryl; optionally substituted with at least one halogen or C1-C3 alkyl (e.g., methyl or ethyl); or a combination thereof), optionally substituted heteroaryl (e.g., optionally substituted 5-10 membered heteroaryl, optionally substituted 5-7 membered heteroaryl; optionally substituted 5 membered heteroaryl; optionally substituted with at least one halogen or C1-C3 alkyl (e.g., methyl or ethyl); or a combination thereof), which is optionally connected to Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14, Q15, Q16, Q17, Q18, Q19, Q20, Q210, Q220, Q23, Q24, Q25, Q26, Q27, Q28, Q29, Q30, Q31, Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41, Q42, Q43, Q44, Q45, Q46, Q47, Q48, Q49, Q50, Q51, Q52, Q53, Q54, Q55, Q56, Q57, Q58, Q59, Q60, Q61, Q72, Q73, Q74, Q89, Q61, Q75 10 , Q 11 , Q 12 , Q 13 , Q 14 or Q 15 (e.g., optionally via an optionally substituted -(CH2) u O(CH2) v O(CH2) x - or a combination thereof and optionally connected to Q 16 at least one of ); an optionally substituted monocyclic or bicyclic heterocyclyl (e.g., an optionally substituted 3-12 membered heterocyclyl; a C3-C12 monocyclic or bicyclic heterocycloalkyl, an azetidin-1-yl, a pyrrolidin-1-yl, a piperidin-1-yl, a piperazin-1-yl or a morpholin-4-yl or a homopiperazin-1-yl, each optionally substituted with OH, a straight or branched C1-C5 alkyl (methyl, ethyl or butyl) or NH2), which is optionally linked to Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14, Q15, Q16, Q17, Q18, Q19, Q20, Q210, Q22, Q23, Q24, Q25, Q26, Q27, Q28, Q29, Q30, Q31, Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41, Q42, Q43, Q44, Q45, Q46, Q47, Q48, Q49, Q50, Q51, Q52, Q53, Q54, Q56, Q57, Q58, Q59, Q60, Q61, Q71, Q72, Q8 10 , Q 11 , Q 12 , Q 13 , Q 14 or Q 15 (e.g., optionally via an optionally substituted -(CH2) uO(CH2) v O(CH2) x - or both and optionally connected to Q 16 at least one of );

[0830] Each t1 is independently selected from 1, 2, 3, 4 or 5;

[0831] Each t2 is independently selected from 0, 1, 2, 3, 4 or 5;

[0832] Each R PTM1a and R PTM2a are independently H, optionally substituted C1-C4 alkyl (e.g., CH3 or CH2CH 3) , optionally substituted C1-C4 alkoxy (eg, -OCH2 or -CH2CH3), CH2OCH3 or R PTM1a and R PTM2a Joined together to form a 3-10 membered ring;

[0833] Q6, Q7, Q8, Q9, Q 10 , Q 11 , Q 12 , Q 13 , Q 14 and Q 15 are each independently N, O or C, each optionally replaced by one or more independently selected R PTM1 (e.g., 1, 2, or 3 independently selected R PTM1 , depending on valence) substitution;

[0834] Q 16 for CH;

[0835] X is O, S or CH2;

[0836] is a single bond or a double bond;

[0837] n is an integer from 0 to 10; and

[0838] PTM The point of attachment to the linker group or ULM is indicated.

[0839] In any aspect or embodiment described herein, at least one R of PTMI, PTMII, PTMIII, PTMIV PMT1 or other PTM structures described herein are modified to covalently link to a linker group (L) or ULM. In any aspect or embodiment described herein, the Q6-Q 15At least one of the or other PTM structures described herein is modified to covalently link to a chemical linker group (L) or ULM.

[0840] In any aspect or embodiment described herein, X of the PTM (eg, the associated position of PTMI, PTMII, PTMIII, PTMIV, or other PTM structures described herein) is O.

[0841] In any aspect or embodiment described herein, the PTM is selected from:

[0842]

[0843]

[0844]

[0845] Among them, PTM Indicates the point of attachment to the linker group (L) or ULM. In any aspect or embodiment described herein, the PTM is selected from:

[0846]

[0847]

[0848]

[0849]

[0850]

[0851] Among them, PTM The point of attachment to the linker group (L) or ULM is indicated.

[0852] In any aspect or embodiment described herein, at least one R PTM1 Selected from

[0853] In any aspect or embodiment described herein, the PTM has the following chemical structure:

[0854]

[0855]

[0856]

[0857]

[0858]

[0859]

[0860]

[0861]

[0862]

[0863] in:

[0864] R PTM5 is H, optionally substituted straight or branched chain alkyl (e.g., optionally substituted straight or branched chain C1-C6 alkyl or isopropyl or C1-C4 alkyl-NH(C1-C3 alkyl) or C1-C4 alkyl-N(C1-C3 alkyl)2), optionally substituted -alkyl-aryl (e.g., optionally substituted C1-C6 alkyl, optionally substituted C5-C10 aryl, or both), optionally substituted -alkyl-heteroaryl (e.g., optionally substituted C1-C6 alkyl, optionally substituted C5-C10 hetero ... aryl, or both), optionally substituted aryl (e.g., optionally substituted C5-C10 aryl), optionally substituted heteroaryl (e.g., optionally substituted C5-C10 heteroaryl), optionally substituted cycloalkyl (e.g., optionally substituted C3-C10 cycloalkyl), optionally substituted -alkyl-cycloalkyl (e.g., optionally substituted C1-C6 alkyl, optionally substituted C3-C10 cycloalkyl, or both), optionally substituted heterocyclyl (e.g., optionally substituted C3-C10 heterocyclyl);

[0865] Q6 is N, CH, C(NO2) or C(CN);

[0866] Q7 and Q 14 are each independently N or CH;

[0867] X PTM1 H or F;

[0868] X PTM2 is H, Cl, F or CN;

[0869] Q8 and Q9 One of is a single bond, a double bond or absent, when Q8 is absent;

[0870] When Q8 does not exist, Does not exist and Q 10 does not exist;

[0871] When Q8 and Q9 are connected via a single button:

[0872] Q8 is CH2, O, CH(RPTM3 )、N(R PTM3 ) or N(CH3); and

[0873] Q9 is CH2, O, CH(R PTM3 )、N(R PTM3 )、N(CH 3) , N(CH2CH2CONHCH3) or N(CH2CH2COCH3);

[0874] When Q8 and Q9 are connected by a double bond:

[0875] Q8 is CH, C(R PTM3 ),N(R PTM3 ), N or optionally substituted C(NH-alkyl-heteroaryl) (such as optionally substituted C1-C5 alkyl, optionally substituted 5-7 membered heteroaryl, or both);

[0876] Q9 is CH, C(R PTM3 ), N or N(R PTM3 );and

[0877] R PTM3 is: -OH; optionally substituted linear or branched alkyl, optionally substituted alkoxy (eg, optionally substituted with linear or branched C1-C4 alkyl or -OCH3); optionally substituted (e.g., optionally substituted with linear or branched C1-C4 alkyl; -(CH2) u CO(CH2) v CH3, -COCH3 or -CH2CH2COCH3, wherein each u and v is independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with linear or branched C1-C4 alkyl; -O(CH2) u CO(CH2) v CH3, -O(CH2) u CH((CH2) x CH3)(CH2) w CO(CH2) v CH3, -O-CH2COCH3, -O-CH2COCH2CH3, -O-CH(CH 3) COCH3, -OCH2COCH3 or -OCH2(CH3)COCH3, wherein each u, v, w and x are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -(CH2) u CO(CH2) v NR PTM1a RPTM2a 、-CONR PTM1a R PTM2a 、-CH2CONR PTM1a R PTM2a 、-CH2CH2CONR PTM1a R PTM2a , -CONHCH3 or -CH2CONHCH3, wherein each u and v are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with linear or branched C1-C4 alkyl; -O(CH2) u CO(CH2) v NR PTM1a R PTM2a 、-O(CH2) u CH((CH2) x CH3)(CH2) w CO(CH2) v NR PTM1a R PTM2a 、-O-CH(CH3)CONR PTM1a R PTM2a 、-O-CH2CONR PTM1a R PTM2a or -OCH2C(O)NHOCH3, wherein each u, v, w and x are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -(CH2) u CHCH(CH2) w CO(CH2) v NR PTM1a R PTM2a or -CHCHCONR PTM1a R PTM2a , wherein each u, v and w are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -NH-(CH2) u CO(CH2) v NR PTM1a R PTM2a or -NH-CH2CONR PTM1a R PTM2a , wherein each u and v is independently selected from 1, 2, 3, 4 or 5); optionally substituted -alkyl-heteroaryl (e.g., optionally substituted with C1-C4 alkyl; -(CH2) t2- optionally substituted 5- or 6-membered heteroaryl; the heteroaryl being selected from oxazol-4-yl, 1,3,4-triazol-2-yl and imidazol-1-yl; and combinations thereof); optionally substituted -NH-alkyl-heteroaryl (e.g., optionally substituted with C1-C4 alkyl or a combination thereof, -NH-(CH2) t2 -(CH2)-(C1-C4)-alkyl, optionally substituted 5- or 6-membered heteroaryl, N-CH2-pyrazol-4-yl); optionally substituted alkyl-cycloalkyl or alkyl-heterocycloalkyl (e.g., optionally substituted C1-C4 alkyl, -(CH2)-(C1-C4)-alkyl, t2 - optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl); optionally substituted -NH-alkyl-cycloalkyl or -NH-alkyl-heterocycloalkyl (e.g., optionally substituted with C1-C4 alkyl, -NH-(CH2) t2 - optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl); optionally substituted -O-cycloalkyl or -O-heterocycloalkyl (e.g., optionally substituted 3-5 membered cycloalkyl or heterocycloalkyl; -O-(oxetane-3-yl)); optionally substituted -O-alkyl-cycloalkyl or -O-alkyl-heterocycloalkyl (e.g., O-(CH2) t2 - optionally substituted 3-5 membered cycloalkyl or heterocycloalkyl; optionally substituted with at least one of ═O, OH and C1-C4 alkyl); optionally substituted S-heterocyclyl (e.g., including optionally substituted 4-7 membered heterocyclyl; optionally substituted heterocycloalkyl; optionally substituted with at least one C1-C4 alkyl (e.g., methyl), ═O or a combination thereof; or a combination thereof);

[0878] Each R PTM1a and R PTM2a are independently H, optionally substituted C1-C4 alkyl (e.g., CH3 or CH2CH 3) , optionally substituted C1-C4 alkoxy (eg, -OCH2 or -CH2CH3), CH2OCH3 or R PTM1a and R PTM2a Joined together to form a 3-10 membered ring;

[0879] Each t1 is independently selected from 1, 2, 3, 4 or 5; and

[0880] Each t2 is independently selected from 0, 1, 2, 3, 4 or 5;

[0881] Q 10 Not present or CH2;

[0882] Q 11 CH2, CHR PMT3 or NR PMT4 ;

[0883] R PTM4is a linear or branched C1-C8 alkyl group optionally substituted by OH;

[0884] R PMT2 is H, OH, CN, optionally substituted straight or branched C1-C4 alkyl, optionally substituted -NH2 (e.g., -N(C1-C3 alkyl) or -NH(C1-C3 alkyl)), O-optionally substituted straight or branched C1-C4 alkyl, optionally substituted C1-C4 alkynyl, optionally substituted C1-C4 alkyne, optionally substituted monocyclic or bicyclic C3-C12 heterocyclyl (e.g., optionally substituted C3-C12 monocyclic or bicyclic heterocycloalkyl, such as C3-C12 monocyclic or bicyclic heterocycloalkyl, azetidin-1-yl, azetidin-1-yl-3-ol, pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl or morpholin-4-yl, homopiperazin-1-yl, each of which is optionally substituted with one or more of OH, linear or branched C1-C5 alkyl or NH2) or optionally substituted -OC 3-12 Monocyclic or bicyclic heterocyclic groups (eg, optionally substituted -OC 3-12 Monocyclic or bicyclic heterocycloalkyl, such as -OC 3-12 a monocyclic or bicyclic heterocycloalkyl group, which is optionally substituted with at least one OH, a linear or branched C1-C5 alkyl group, or NH2) or an optionally substituted C3-C12 membered ring (e.g., an optionally substituted C3-C12 non-aryl membered ring, which is optionally substituted with one or more of OH, a linear or branched C1-C5 alkyl group, or NH2), wherein when R PTM2 When it is a ring structure, it is optionally connected via R PTM2 C or N of the ring is covalently linked to Q 16 ;and

[0885] PTM The point of attachment to the linker group (L) or ULM is indicated.

[0886] In any aspect or embodiment described herein, R of PTMI, PTMII, PTMIII, PTMIV PTM1 、R PTM2 、Q6、Q7、Q8、Q9、Q 10 、X PTM1 、X PTM2 At least one (e.g., 1, 2, or 3), or associated positions of other PTM structures described herein, is directly or indirectly connected to a ULM or a chemical linker group (L).

[0887] In any aspect or embodiment described herein, R of a PTM described herein (e.g., PTMI, PTMII, PTMIII, PTMIV, and derivatives thereof)PTM2 Or the corresponding position may be substituted by one or more groups selected from the following: OH, linear or branched C1-C5 alkyl or NH2.

[0888] In any aspect or embodiment described herein, R of any PTM described herein (e.g., PTMI, PTMII, PTMIII, PTMIV, and derivatives thereof) PTM5 or the corresponding positions are: H, optionally substituted straight or branched alkyl (e.g., optionally substituted straight or branched C1-C6 alkyl or C1-C4 alkyl-NH(C1-C3 alkyl) or C1-C4 alkyl-N(C1-C3 alkyl)2), optionally substituted -alkyl-aryl (e.g., optionally substituted C1-C6 alkyl, optionally substituted C5-C10 aryl, or both), optionally substituted -alkyl-heteroaryl (e.g., optionally substituted C1-C6 alkyl, optionally substituted C5-C10 C-C10 cycloalkyl), optionally substituted -alkyl-cycloalkyl (e.g., optionally substituted C1-C6 alkyl, optionally substituted C3-C10 cycloalkyl, or both), optionally substituted heterocyclyl (e.g., optionally substituted C3-C10 heterocyclyl).

[0889] In any aspect or embodiment described herein, R of a PTM described herein (e.g., PTMI, PTMII, PTMIII, PTMIV, and derivatives thereof) PTM5 or the corresponding position is selected from H, methyl, CFH2, CF2H, ethyl, propyl, isopropyl, cyclopropyl, butyl, pentyl, hexyl, -CH2CH2OCH3, -CH2CH(CH3)2, -CH2CHN(CH3)2, -CH2-cyclopropyl, -CH2-CH2-cyclopropyl,

[0890] In any aspect or embodiment described herein, X of any PTM described herein (e.g., PTMI, PTMII, PTMIII, PTMIV, and derivatives thereof) PTM1 Or the corresponding position is H or F.

[0891] In any aspect or embodiment described herein, X of any PTM described herein (e.g., PTMI, PTMII, PTMIII, PTMIV, and derivatives thereof) PTM2 Or the corresponding position is H, Cl, F or CN.

[0892] In any aspect or embodiment described herein, R of any PTM described herein (e.g., PTMI, PTMII, PTMIII, PTMIV, and derivatives thereof) PTM2 Or the corresponding position is selected from: H, OH, ethyl, NH2, -N(CH3)2, in represents a bond that can be stereospecific ((R) or (S)) or non-stereospecific;

[0893] In any aspect or embodiment described herein, R of any PTM described herein (e.g., PTMI, PTMII, PTMIII, PTMIV, and derivatives thereof) PTM3 Or the corresponding position is: OH; optionally substituted straight chain or branched alkyl, optionally substituted alkoxy (for example, optionally substituted with straight chain or branched C1-C4 alkyl or -OCH3); optionally substituted (e.g., optionally substituted with linear or branched C1-C4 alkyl; -(CH2) u CO(CH2) v CH3, -COCH3 or -CH2CH2COCH3, wherein each u and v is independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with linear or branched C1-C4 alkyl; -O(CH2) u CO(CH2) v CH3, -O(CH2) u CH((CH2) x CH3)(CH2) w CO(CH2) v CH3, -O-CH2COCH3, -O-CH2COCH2CH3, -O-CH(CH 3) COCH3, -OCH2COCH3 or -OCH2(CH3)COCH3, wherein each u, v, w and x are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -(CH2) u CO(CH2) v NR PTM1a R PTM2a 、-CONR PTM1a R PTM2a 、-CH2CONR PTM1a R PTM2a 、-CH2CH2CONR PTM1a R PTM2a, -CONHCH3 or -CH2CONHCH3, wherein each u and v are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with linear or branched C1-C4 alkyl; -O(CH2) u CO(CH2) v NR PTM1a R PTM2a 、-O(CH2) u CH((CH2) x CH3)(CH2) w CO(CH2) v NR PTM1a R PTM2a 、-O-CH(CH3)CONR PTM1a R PTM2a 、-O-CH2CONR PTM1a R PTM2a or -OCH2C(O)NHOCH3, wherein each u, v, w and x are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -(CH2) u CHCH(CH2) w CO(CH2) v NR PTM1a R PTM2a or -CHCHCONR PTM1a R PTM2a , wherein each u, v and w are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -NH-(CH2) u CO(CH2) v NR PTM1a R PTM2a or -NH-CH2CONR PTM1a R PTM2a , wherein each u and v is independently selected from 1, 2, 3, 4 or 5); optionally substituted -alkyl-heteroaryl (e.g., optionally substituted with C1-C4 alkyl; -(CH2) t2 - optionally substituted 5- or 6-membered heteroaryl; the heteroaryl being selected from oxazol-4-yl, 1,3,4-triazol-2-yl and imidazol-1-yl; and combinations thereof); optionally substituted -NH-alkyl-heteroaryl (e.g., optionally substituted with C1-C4 alkyl or a combination thereof, -NH-(CH2) t2 -(CH2)-(C1-C4)-alkyl, optionally substituted 5- or 6-membered heteroaryl, N-CH2-pyrazol-4-yl); optionally substituted alkyl-cycloalkyl or alkyl-heterocycloalkyl (e.g., optionally substituted C1-C4 alkyl, -(CH2)-(C1-C4)-alkyl,t2 - optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl); optionally substituted -NH-alkyl-cycloalkyl or -NH-alkyl-heterocycloalkyl (e.g., optionally substituted with C1-C4 alkyl, -NH-(CH2) t2 - optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl); optionally substituted -O-cycloalkyl or -O-heterocycloalkyl (e.g., optionally substituted 3-5 membered cycloalkyl or heterocycloalkyl; -O-(oxetane-3-yl)); optionally substituted -O-alkyl-cycloalkyl or -O-alkyl-heterocycloalkyl (e.g., O-(CH2) t2 -optionally substituted 3-5 membered cycloalkyl or heterocycloalkyl; optionally substituted with at least one of =O, OH and C1-C4 alkyl); optionally substituted S-heterocyclyl (for example, including optionally substituted 4-7 membered heterocyclyl; optionally substituted heterocycloalkyl; optionally substituted with at least one C1-C4 alkyl (e.g., methyl), =O or a combination thereof; or a combination thereof).

[0894] In any aspect or embodiment described herein, R of any PTM described herein (e.g., PTMI, PTMII, PTMIII, PTMIV, and derivatives thereof) PTM3 Or the corresponding position is selected from: (For example, ), in: represents a bond that can be stereospecific ((R) or (S)) or non-stereospecific; and X PTM3 Selected from CH2, O and S.

[0895] In any aspect or embodiment described herein, R of any PTM described herein (e.g., PTMI, PTMII, PTMIII, PTMIV, and derivatives thereof) PTM4 Or the corresponding position is a straight or branched C1-C8 alkyl group optionally substituted by OH.

[0896] In any aspect or embodiment described herein, R of any PTM described herein (e.g., PTMI, PTMII, PTMIII, PTMIV, and derivatives thereof) PMT2or H, OH, CN, optionally substituted straight or branched C1-C4 alkyl, optionally substituted -NH2 (e.g., -N(C1-C3 alkyl) or -NH(C1-C3 alkyl) or -N(CH3)2), O-optionally substituted straight or branched C1-C4 alkyl, optionally substituted C1-C4 alkynyl, optionally substituted C1-C4 alkyne, optionally substituted monocyclic or bicyclic C3-C12 heterocyclyl (e.g., optionally substituted C3-C12 monocyclic or bicyclic heterocycloalkyl, such as C3-C12 monocyclic or bicyclic heterocycloalkyl, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl or morpholin-4-yl or homopiperazin-1-yl, each of which is optionally substituted with one or more of OH, straight or branched C1-C5 alkyl or NH2) or optionally substituted -OC 3-12 Monocyclic or bicyclic heterocyclic groups (eg, optionally substituted -OC 3-12 Monocyclic or bicyclic heterocycloalkyl, such as -OC 3-12 a monocyclic or bicyclic heterocycloalkyl group, which is optionally substituted with at least one OH, a linear or branched C1-C5 alkyl group, or NH2) or an optionally substituted C3-C12 membered ring (e.g., an optionally substituted C3-C12 non-aryl membered ring, which is optionally substituted with one or more of OH, a linear or branched C1-C5 alkyl group, or NH2), wherein when R PTM2 When it is a ring structure, it is optionally connected via R PTM2 C or N of the ring is covalently linked to Q 16 ;

[0897] In any aspect or embodiment described herein, the PTM is represented by a chemical structure selected from the group consisting of:

[0898]

[0899]

[0900]

[0901]

[0902]

[0903]

[0904]

[0905]

[0906]

[0907]

[0908]

[0909]

[0910]

[0911]

[0912]

[0913]

[0914]

[0915]

[0916]

[0917]

[0918]

[0919]

[0920] in represents a bond that can be stereospecific ((R) or (S)) or non-stereospecific.

[0921] In any aspect or embodiment described herein, the PTM is selected from:

[0922]

[0923]

[0924]

[0925]

[0926]

[0927]

[0928]

[0929]

[0930]

[0931]

[0932]

[0933] wherein the PTM indicates the point of attachment to the linker group (L) or the ULM; and represents a bond that can be stereospecific ((R) or (S)) or non-stereospecific.

[0934] In any aspect or embodiment described herein, the PTM is selected from:

[0935]

[0936]

[0937]

[0938]

[0939]

[0940]

[0941]

[0942]

[0943]

[0944]

[0945]

[0946]

[0947]

[0948]

[0949]

[0950]

[0951]

[0952]

[0953]

[0954]

[0955]

[0956]

[0957]

[0958]

[0959]

[0960]

[0961]

[0962]

[0963]

[0964]

[0965]

[0966]

[0967]

[0968]

[0969] Among them, PTM indicates the point of attachment to the linker group (L) or ULM, and represents a bond that can be stereospecific ((R) or (S)) or non-stereospecific.

[0970] In any aspect or embodiment described herein, the PTM is selected from:

[0971]

[0972]

[0973]

[0974]

[0975]

[0976]

[0977]

[0978]

[0979]

[0980]

[0981]

[0982]

[0983]

[0984]

[0985]

[0986]

[0987]

[0988]

[0989]

[0990]

[0991]

[0992]

[0993]

[0994] Among them, PTM indicates the point of attachment to the linker group (L) or ULM, and represents a bond that can be stereospecific ((R) or (S)) or non-stereospecific.

[0995] Therapeutic compositions

[0996] Pharmaceutical compositions comprising an effective amount of at least one bifunctional compound as described herein in combination with one or more compounds described elsewhere herein, in combination with a pharmaceutically effective amount of a carrier, additive, or excipient represent further aspects of the present disclosure.

[0997] Where applicable, the present disclosure includes compositions comprising pharmaceutically acceptable salts, particularly acid or base addition salts of the compounds described herein. Acids used to prepare pharmaceutically acceptable acid addition salts of the above-mentioned base compounds that can be used according to this aspect are those that form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, sucrose, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoic acid)] salts, and the like.

[0998] Pharmaceutically acceptable base addition salts can also be used to prepare pharmaceutically acceptable salt forms of compounds or derivatives according to the present disclosure. Chemical bases that are acidic in nature and can be used as reagents for preparing pharmaceutically acceptable basic salts of compounds herein are those that form non-toxic basic salts with such compounds. Such non-toxic basic salts include, but are not limited to, those derived from such pharmaceutically acceptable cations, such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium, zinc, and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), as well as other basic salts of lower alkanolammonium and pharmaceutically acceptable organic amines, and the like.

[0999] Compounds as described herein can be administered orally, parenterally or topically in single doses or divided doses according to the present disclosure. The scope of administration of the active compound can be from continuous (intravenous drip) to oral administration several times a day (e.g., QID), and can include oral, topical, parenteral, intramuscular, intravenous, subcutaneous, transdermal (which can include a penetration enhancer), buccal, sublingual and suppository administration, and other administration routes. Enteric-coated oral tablets can also be used to enhance the bioavailability of compounds from oral administration routes. The most effective dosage form depends on the pharmacokinetics of the selected specific agent and the severity of the disease in the patient. It is also possible to use a spray, mist or aerosol according to the present disclosure for intranasal, intratracheal or pulmonary administration. Therefore, the present disclosure also relates to pharmaceutical compositions, which include an effective amount of a compound as described herein, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient. Compounds according to the present disclosure can be administered in an immediate release, intermediate release or sustained or controlled release form. Sustained or controlled release forms are preferably administered orally, but may also be administered as suppositories and transdermal or other topical forms. Intramuscular injection of liposomes may also be used to control or sustain the release of the compound at the injection site.

[1000] The compositions as described herein can be formulated in a conventional manner using one or more pharmaceutically acceptable carriers and can also be administered in controlled release formulations. Pharmaceutically acceptable carriers that can be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as prolamin sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol, and lanolin.

[1001] The compositions described herein can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally, or intravenously.

[1002] Sterile injectable forms of the compositions described herein may be aqueous or oily suspensions. These suspensions can be formulated using suitable dispersants or wetting agents and suspending agents according to techniques known in the art. Sterile injectable preparations may also be sterile injectable solutions or suspensions in a nontoxic, parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally used as solvents or suspending media. For this purpose, any bland, fixed oil may be used, including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives, may be used to prepare injectables, as may natural pharmaceutically acceptable oils, such as olive oil or castor oil, particularly in their polyoxyethylated forms. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as Ph. Helvetic acid or similar alcohols.

[1003] The pharmaceutical compositions described herein can be orally administered in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions, or solutions. In the case of tablets for oral use, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also typically added. For oral administration in capsule form, useful diluents include lactose and dry corn starch. When an aqueous suspension is desired for oral use, the active ingredient is mixed with an emulsifier and a suspending agent. Certain sweeteners, flavorings, or coloring agents may also be added, if desired.

[1004] Alternatively, the pharmaceutical compositions as described herein can be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycol.

[1005] The pharmaceutical compositions described herein can also be administered topically. Suitable topical formulations are readily prepared for each of these regions or organs. Topical administration to the lower intestinal tract can be achieved with a rectal suppository formulation (see above) or with a suitable enema formulation. Topically acceptable transdermal patches can also be used.

[1006] For topical application, the pharmaceutical composition can be formulated into a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of the present disclosure include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax, and water. In certain preferred aspects of the present disclosure, the compound can be applied to a stent that is to be surgically implanted in a patient in order to inhibit or reduce the likelihood of the stent becoming blocked in the patient.

[1007] Alternatively, the pharmaceutical composition can be formulated into a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.

[1008] For ophthalmic use, the pharmaceutical composition can be formulated as a micronized suspension in isotonic, pH-adjusted sterile saline, or preferably, as a solution in isotonic, pH-adjusted sterile saline, with or without a preservative such as benzalkonium chloride. Alternatively, for ophthalmic use, the pharmaceutical composition can be formulated as an ointment such as petrolatum.

[1009] The pharmaceutical compositions described herein can also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and can be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.

[1010] The amount of compound in a pharmaceutical composition as described herein that can be combined with a carrier material to prepare a single dosage form will vary depending on the host and disease being treated, the particular mode of administration, etc. Preferably, the composition should be formulated to contain from about 0.05 mg to about 750 mg or more, more preferably from about 1 mg to about 600 mg, even more preferably from about 10 mg to about 500 mg of the active ingredient, either alone or in combination with at least one other compound according to the present disclosure.

[1011] It will also be understood that the specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the activity of the specific compound employed, age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination, as well as the judgment of the treating physician and the severity of the specific disease or condition being treated.

[1012] A patient or subject in need of treatment with a compound according to the methods described herein can be treated by administering to the patient (subject) an effective amount of a compound according to the present disclosure, including a pharmaceutically acceptable salt, solvate, or polymorph thereof, optionally in a pharmaceutically acceptable carrier or diluent, alone or in combination with other known therapeutic agents as identified elsewhere herein.

[1013] The compounds may be administered by any appropriate route, for example orally, parenterally, intravenously, intradermally, subcutaneously or topically, including transdermally, in liquid, cream, gel or solid form or by aerosol form.

[1014] The active compound is included in a pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to the patient a therapeutically effective amount for the desired indication without causing severe toxic effects in the treated patient. Preferred dosages of the active compound for all conditions mentioned herein are in the range of about 10 ng / kg to 300 mg / kg, preferably 0.1 to 100 mg / kg / day, more typically 0.5 to about 25 mg / kg of recipient / patient body weight / day. Typical topical dosages range from 0.01-5% by weight in a suitable carrier.

[1015] The compound is conveniently administered in any suitable unit dosage form, including but not limited to unit dosage forms containing less than 1 mg, 1 mg to 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosage form. An oral dose of about 25-250 mg is generally convenient.

[1016] The active ingredient is preferably administered to achieve a peak plasma concentration of the active compound of about 0.00001-30 mM, preferably about 0.1-30 μM. This can be achieved, for example, by intravenous injection of a solution or formulation of the active ingredient, optionally in saline or an aqueous medium, or as a bolus injection of the active ingredient. Oral administration is also suitable for generating effective plasma concentrations of the active agent.

[1017] The concentration of the active compound in the pharmaceutical composition will depend on the absorption, distribution, inactivation and excretion rate of the drug, as well as other factors known to those skilled in the art. It should be noted that the dosage value will also change with the severity of the condition to be alleviated. It should also be understood that for any particular subject, specific dosage regimens should be adjusted over time based on individual needs and the professional judgment of the individual who administers or oversees the administration of the composition, and the concentration ranges described herein are only exemplary and are not intended to limit the scope or practice of the claimed composition. The active ingredient can be administered at once, or can be divided into many smaller doses, administered at different time intervals.

[1018] Oral compositions will typically contain an inert diluent or edible carrier. They can be encapsulated in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound or its prodrug derivative can be mixed with an excipient and used in the form of tablets, lozenges or capsules. Pharmaceutically compatible binders and / or adjuvant materials may be included as part of the composition.

[1019] Tablets, pills, capsules, lozenges, and the like may contain any of the following ingredients or compounds of a similar nature: binders such as microcrystalline cellulose, tragacanth, or gelatin; excipients such as starch or lactose; dispersants such as alginic acid, Primogel, or corn starch; lubricants such as magnesium stearate or Sterotes; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavorings such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the types mentioned above, a liquid carrier such as a fatty oil. Additionally, the dosage unit form may contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.

[1020] The active compound or its pharmaceutically acceptable salt can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum, etc. A syrup may contain, in addition to the active compound, sucrose as a sweetening agent and certain preservatives, dyes and colorings, and flavors.

[1021] The active compound or its pharmaceutically acceptable salt may also be mixed with other active materials that do not impair the desired effect, or with materials that supplement the desired effect, such as anticancer agents, particularly as described herein. In certain preferred aspects of the present disclosure, one or more compounds according to the present disclosure are co-administered with another biologically active agent, such as an anticancer agent or a wound healing agent, including an antibiotic, as described elsewhere herein.

[1022] Solutions or suspensions for parenteral, intradermal, subcutaneous or topical administration may contain the following components: a sterile diluent such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerol, propylene glycol or other synthetic solvents; an antibacterial agent such as benzyl alcohol or methyl paraben; an antioxidant such as ascorbic acid or sodium bisulfite; a chelating agent such as ethylenediaminetetraacetic acid; a buffer such as acetate, citrate or phosphate and an agent for adjusting tonicity such as sodium chloride or glucose. Parenteral preparations can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[1023] If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).

[1024] In one embodiment, the active compound is prepared with a carrier that protects the compound from rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such formulations will be apparent to those skilled in the art.

[1025] Liposomal suspensions can also be pharmaceutically acceptable carriers. These can be prepared according to methods well known to persons skilled in the art, for example, as described in U.S. Patent number 4,522,811 (which is incorporated herein by reference in its entirety). For example, liposome preparations can be prepared by dissolving suitable lipids (such as stearoylphosphatidylethanolamine, stearoylphosphatidylcholine, arachidonic acid phosphatidylcholine and cholesterol) in an organic solvent, then evaporating the organic solvent, leaving a thin film of dry lipids on the surface of the container. The aqueous solution of the active compound is then introduced into the container. The container is then rotated by hand to release lipid material and disperse lipid aggregates from the side of the container, thereby forming a liposomal suspension.

[1026] Treatment

[1027] In another aspect, the present disclosure provides therapeutic compositions comprising an effective amount of a compound as described herein or a salt thereof and a pharmaceutically acceptable carrier. The therapeutic compositions regulate protein degradation in a patient or subject (e.g., an animal, such as a human) and can be used to treat or ameliorate a disease state or condition mediated by degraded protein.

[1028] As used herein, the terms "treat," "treating," and "treatment" and the like refer to any action that provides a benefit to a patient to whom the compounds herein can be administered, including the treatment of any disease state or condition modulated by a protein to which the compounds herein bind. Disease states or conditions that can be treated using the compounds according to the present disclosure are described above, including cancer.

[1029] This specification provides a therapeutic composition as described herein for achieving degradation of a target protein to treat or improve a disease, such as cancer. In certain other embodiments, the disease is multiple myeloma. Therefore, on the other hand, this specification provides a method for ubiquitination / degradation of a target protein in a cell. In certain embodiments, the method includes administering a bifunctional compound as described herein, the bifunctional compound comprising, for example, a ULM and a PTM preferably connected by a linker moiety as described herein, wherein the ULM is coupled to the PTM and wherein the ULM recognizes ubiquitin pathway proteins (e.g., ubiquitin ligases, such as E3 ubiquitin ligases, including cerebellin and / or VHL) and the PTM recognizes the target protein, so that when the target protein is positioned adjacent to the ubiquitin ligase, degradation of the target protein will occur, thereby achieving inhibition of the degradation / target protein effect of the target protein and control of protein levels. The control of the protein levels provided by the present disclosure provides treatment for a disease state or condition, which is regulated by the target protein by reducing the level of the protein in a cell (e.g., a patient's cell). In certain embodiments, the method comprises administering an effective amount of a compound as described herein, optionally with a pharmaceutically acceptable excipient, carrier, adjuvant, another biologically active agent, or a combination thereof.

[1030] In another embodiment, the present description provides a method for treating or improving a disease, disorder or symptom thereof in a subject or patient (e.g., an animal, such as a human), the method comprising administering to a subject in need thereof a composition comprising an effective amount (e.g., a therapeutically effective amount) of a compound described herein or a salt form thereof, and a pharmaceutically acceptable excipient, carrier, adjuvant, another biologically active agent or a combination thereof, wherein the composition is capable of effectively treating or improving the disease, disorder or symptom thereof in the subject.

[1031] In another aspect, the present description provides methods of identifying the effects of degradation of a protein of interest in a biological system using compounds according to the present disclosure.

[1032] In another embodiment, the present disclosure relates to a method of treating a human patient in need of treatment for a disease state or condition modulated by a protein, wherein degradation of the protein produces a therapeutic effect in the patient, the method comprising administering to the patient in need thereof an effective amount of a compound according to the present disclosure, optionally in combination with another biologically active agent. The disease state or condition can be a disease caused by a microbial agent or other exogenous agent (e.g., a virus, bacteria, fungus, protozoa, or other microorganism), or can be a disease state caused by overexpression of a protein, which results in the disease state and / or condition.

[1033] The term "disease state or condition" is used to describe any disease state or condition in which protein dysregulation occurs (i.e., the amount of protein expressed in a patient is elevated) and in which degradation of one or more proteins in the patient can provide beneficial therapy or relief of symptoms to a patient in need thereof. In some cases, the disease state or condition can be cured.

[1034] Disease states or conditions that can be treated using the compounds according to the present disclosure include, for example, asthma, autoimmune diseases such as multiple sclerosis, various cancers, ciliopathies, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorders, obesity, refractive errors, infertility, Angelman syndrome, Canavan disease, celiac disease, Charcot-Marie-Tooth disease, cystic fibrosis, Duchenne muscular dystrophy, hemochromatosis, hemophilia, Klinefelter syndrome, neurofibromatosis, phenylketonuria, polycystic kidney disease (PKD1) or 4 (PKD2), Prader-Willi syndrome, sickle cell disease, Tay-Sachs disease, Turner syndrome.

[1035] The term "neoplasia" or "cancer" is used throughout this specification to refer to the pathological process that leads to the formation and growth of cancerous or malignant tumors (i.e., abnormal tissue that grows by cell proliferation), which is generally faster than normal tissue and continues to grow after the stimulus that initiated the new growth has ceased. Malignant tumors exhibit partial or complete lack of structural organization and functional coordination with normal tissue, and most invade surrounding tissues, metastasize to several sites, and may recur after attempted removal and lead to death of the patient unless adequately treated. As used herein, the term neoplasia is used to describe all cancerous disease states and includes or encompasses pathological processes associated with malignant hematogenous, ascites, and solid tumors. Exemplary cancers that can be treated with the compounds of the present invention, alone or in combination with at least one additional anticancer agent, include squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, intestinal cancer, breast cancer, cervical cancer, colon cancer, esophageal cancer, head cancer, kidney cancer, liver cancer, lung cancer, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, stomach cancer; leukemia; benign lymphoma, malignant lymphoma, Burkitt's lymphoma, non-Hodgkin's lymphoma, benign melanoma, malignant melanoma, myeloproliferative disorders, sarcoma, Ewing's sarcoma, angiosarcoma, Kaposi's sarcoma, liposarcoma, myeloid sarcoma, peripheral neuroepithelial tumor, synovial tumor, sarcoma ... Sarcoma, glioma, astrocytoma, oligodendroglioma, ependymoma, glioblastoma, neuroblastoma, neurocytoma, ganglioglioma, medulloblastoma, pineal cell tumor, meningioma, meningiosarcoma, neurofibroma and schwannoma, prostate cancer, uterine cancer, testicular cancer, thyroid cancer, astrocytoma, gastric cancer, melanoma, carcinosarcoma, Hodgkin's disease, Wilms' tumor, teratocarcinoma, T-lineage acute lymphoblastic leukemia (T-ALL), T-lineage lymphoblastic lymphoma (T-LL), peripheral T-lymphocytic lymphoma, adult T-cell leukemia, Pre-B ALL, lymphoma, Pre-B lymphocytic neoplasm, large B-cell lymphoma, B-cell ALL, Philadelphia chromosome-positive ALL, Philadelphia chromosome-positive CML, follicular lymphoma, intravascular large B-cell lymphoma, B-cell leukemia, chronic myeloid leukemia, non-small cell lung cancer.

[1036] The term "biologically active agent" is used to describe an agent, other than a compound according to the present disclosure, that is used in combination with the compounds of the present invention as an agent having biological activity to help achieve the intended therapy, inhibition and / or prevention / prophylaxis for which the compounds of the present invention are used. Preferred biologically active agents as used herein include those agents that have pharmacological activity similar to that of the compounds of the present invention used or administered, and include, for example, anticancer agents, antiviral agents, particularly including anti-HIV agents and anti-HCV agents, antimicrobial agents, antifungal agents, and the like.

[1037] The term "additional anticancer agent" is used to describe an anticancer agent that can be combined with the compounds according to the present disclosure to treat cancer. These agents include, for example, everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, FLT-3 inhibitors, VEGFR inhibitors, EGFR TK inhibitors, Aurora kinase inhibitors, PIK-1 modulators, Bcl-2 inhibitors, HDAC inhibitors, c-MET inhibitors, PARP inhibitors, Cdk inhibitors, EGFR TK inhibitors, IGFR-TK inhibitors, anti-HGF antibodies, PI3 kinase inhibitors, AKT inhibitors, mTORC1 / 2 inhibitors, JAK / STAT inhibitors, checkpoint-1 or -2 inhibitors, focal adhesion kinase inhibitors, MAP kinase (MEK) inhibitors, VEGF capture antibodies, pemetrexed, erlotinib, dasatinib, nilotinib, decatanib, panitumumab, amrubicin, ogavuzumab, Lep-ETU, noratriptide, AZD2171, batabulin, ofatumumab, zalimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, tesimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC8490, cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdR1 KRX-0402, methionone, LY317615, neuradiab, vitespan, Rta 744, Sdx102, talampanel, atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, liposomal doxorubicin, 5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709, celecoxib; PD0325901, AZD-6244, capecitabine, L-glutamic acid, N-[4-[2- (2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrozole, exemestane, letrozole, DES (diethylstilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11,CHIR-258); 3-[5-(methylsulfonylpiperidinylmethyl)-indolyl-quinolone, vatalanib, AG-013736, AVE-0005, goserelin acetate, leuprorelin acetate, triptorelin pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-165, HKI-272, erlotinib, lapatinib, canertinib, ABX-EGF antibody, Erbitux, EKB-569, PKI-166, GW-572016, lonafarnib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, cinnamaldehyde Diacylanilide hydroxamic acid, valproic acid, trichostatin A, FK-228, SU11248, sorafenib, KRN951, amine glutethimide, arnsacrine, anagrelide, L-asparaginase, Bacillus Calmette-Guérin (BCG) vaccine, doxorubicin, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone acetate, cytarabine, dacarbazine, actinomycin D, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, Gleevec, gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprorelin, levamisole, lomustine, dichloromethane, Melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozotocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, hexamethylmelamine, floxuridine, 5-deoxyuridine, cytosine arabinoside, 6-mercaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxane, marimastat, COL-3, neivastat, BMS- 275291, squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene, idoxyfene, spironolactone, finasteride, cimetidine, trastuzumab, denileukin, gefitinib, bortezomib, paclitaxel, paclitaxel without hydrogenated castor oil, docetaxel, epothilone B, BMS-247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipenoxifene, ERA-923, arzoxifene, fulvestrant, acolbifene, lasofoxifene, idoxyfene, TSE-424, HMR-3339, ZK186619, topotecan,PTK787 / ZK222584, VX-745, PD 184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate ate), prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all-trans retinoic acid, ketoconazole, interleukin-2, megestrol acetate, immune globulin, nitrogen mustard, methylprednisolone, ibritumomab tiuxetan), androgens, decitabine, hexamethasone, bexarotene, tositumomab, arsenic trioxide, cortisone, etidronate, mitotane, cyclosporine, daunorubicin liposomal, Edwina asparaginase, strontium 89, casopitant, netupitant, NK-1 receptor antagonists, palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa, darbepoetin alfa, and mixtures thereof.

[1038] The term "anti-HIV agent" or "another anti-HIV agent" includes, for example, nucleoside reverse transcriptase inhibitors (NRTIs), other non-nucleoside reverse transcriptase inhibitors (i.e., those not representative of the present disclosure), protease inhibitors, fusion inhibitors, and the like, exemplary compounds of which may include, for example, 3TC (lamivudine), AZT (zidovudine), (-)-FTC, ddI (didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir disoproxil fumarate (PMPA), D-D4FC (Reverset), D 4T (stavudine), Racivir, L-FddC, L-FD4C, NVP (nevirapine), DLV (delavirdine), EFV (efavirenz), SQVM (saquinavir mesylate), RTV (ritonavir), IDV (indinavir), SQV (saquinavir), NFV (nelfinavir), APV (amprenavir), LPV (lopinavir), fusion inhibitors such as T20, etc., their fusions and mixtures, including anti-HIV compounds currently in clinical trials or development.

[1039] Other anti-HIV agents that can be co-administered with the compounds according to the present disclosure include, for example, other NNRTIs (i.e., in addition to the NNRTIs according to the present disclosure) that can be selected from nevirapine (BI-R6-587), delavirdine (U-90152S / T), efavirenz (DMP-266), UC-781 (N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-furancarboxamide, etravirine (TMC125), treviridine (Ly300046.HCl), MKC-442 (imivirine, coactinon), HI-236, HI-240, HI-280, HI-281, rilpivirine (TMC-278), MSC-127, HBY 097, DMP266, Baicalin (TJN-151) ADAM-II (3',3'-dichloro-4',4"-dimethoxy-5',5"-bis(methoxycarbonyl)-6,6-diphenylhexenoic acid methyl ester), 3-bromo-5-(1-5-bromo-4-methoxy-3-(methoxycarbonyl)phenyl)hept-1-enyl)-2-methoxybenzoic acid methyl ester (Alkenyldiarylmethane analog, Adam analog), (5-chloro-3-(phenylsulfinyl)-2'-indolecarboxamide), AAP-BHAP (U-104489 or PNU-104489), caprovirine (AG-1549, S-1153), ativiridine (U-87201E), aurintricarboxylic acid (SD-095345), 1-[(6-cyano-2-indolyl)carbonyl]-4-[ 3-(Isopropylamino)-2-pyridyl]piperazine, 1-[5-[[N]-(methyl)methylsulfonylamino]-2-indolylcarbonyl-4-[3-(isopropylamino)-2-pyridyl]piperazine, 1-[3-(ethylamino)-2-[pyridyl]-4-[(5-hydroxy-2-indolyl)carbonyl]piperazine, 1-[(6-formyl-2-indolyl)carbonyl]-4-[3-(isopropylamino)-2-pyridyl]piperazine, 1-[[5-(methylsulfonyloxy)-2-indolyl)carbonyl]-4-[3-(isopropylamino)-2-pyridyl]piperazine, U88204E, bis(2-nitrophenyl)sulfone (NSC 633001), calanolide A (NSC675451), calanolide B, 6-benzyl-5-methyl-2-(cyclohexyloxy)pyrimidin-4-one (DABO-546), DPC 961, E-EBU, E-EBU-dm, E-EPSeU, E-EPU, phosphonoformic acid (Foscavir), HEPT (1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymidine), HEPT-M (1-[(2-hydroxyethoxy)methyl]-6-(3-methylphenyl)thio)thymidine), HEPT-S (1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)- 2-thiothymine), malusin P, L-737,126, Michelamine A (NSC650898), Michelamine B (NSC649324), Michelamine F, 6-(3,5-dimethylbenzyl)-1-[(2-hydroxyethoxy)methyl]-5-isopropyluracil, 6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil, NPPS, E-BPTU (NSC 648400), oltipraz (4-methyl-5-(pyrazinyl)-3H-1,2-dithiolene-3-thione), N-{2-(2-chloro-6-fluorophenethyl)-N'-(2-thiazolyl)thiourea (PETT Cl, F derivative), N-{2-(2,6-difluorophenethyl)-N'-[2-(5-bromopyridyl)]thiourea (PETT derivative), N-{2-(2,6-difluorophenethyl)-N'-[2-(5-methylpyridyl)]thiourea {PETT pyridyl derivatives], N-[2-(3-fluorofuryl)ethyl]-N'-[2-(5-chloropyridyl)]thiourea, N-[2-(2-fluoro-6-ethoxyphenethyl)]-N'-[2-(5-bromopyridyl)]thiourea, N-(2-phenethyl)-N'-(2-thiazolyl)thiourea (LY-73497), L-697,639, L-697,593, L-697,661, 3-[2-(4,7-difluorobenzoxazol-2-yl)ethyl}-5-ethyl-6-methyl(pyridine-2(1H)-thione (2-pyridine) ketone derivatives), 3-[[(2-methoxy-5,6-dimethyl-3-pyridyl)methyl]amine]-5-ethyl-6-methyl(pyridine-2(1H)-thione, R82150, R82913, R87232, R88703, R89439 (Loviride), R90385, S-2720, suramin sodium, TBZ (thiazolobenzimidazole, NSC625487), thiazoloisoindol-5-one, (+)(R)-9b-(3,5-dimethylphenyl-2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-one, tevirapine (R86183), UC-38 and UC-84, etc.

[1040] Where applicable, the term "pharmaceutically acceptable salt" is used throughout this specification to describe a salt form of one or more compounds described herein that is used to increase the solubility of the compound in the gastric fluid of the patient's gastrointestinal tract in order to promote dissolution and bioavailability of the compound. Where applicable, pharmaceutically acceptable salts include salts derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include salts derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium, magnesium and ammonium salts, as well as numerous other acids and bases well known in the pharmaceutical art. Sodium and potassium salts are particularly preferred as neutralized salts of the phosphates according to the present disclosure.

[1041] The term "pharmaceutically acceptable derivative" is used throughout this specification to describe any pharmaceutically acceptable prodrug form (e.g., esters, amides, other prodrug groups) that, when administered to a patient, directly or indirectly provides a compound of the invention or an active metabolite of a compound of the invention.

[1042] General synthetic methods

[1043] The synthetic realization and optimization of bifunctional molecules as described herein can be carried out in a step-by-step or modular manner. For example, if a suitable ligand is not immediately available, identifying compounds that bind to the target molecule can involve high-throughput or medium-throughput screening activities. It is not uncommon for an initial ligand to require iterative design and optimization cycles to improve suboptimal aspects, as determined by appropriate in vitro and pharmacological and / or ADMET assays. Part of the optimization / SAR activity will be to probe the position of the ligand for tolerant substitution and possibly for the attachment of the chemical linkers previously mentioned herein. Where crystallographic or NMR structural data are available, these can be used to focus such synthetic tasks.

[1044] In a very similar manner, ligands for E3 ligases, i.e. ULM / ILM / VLM / CLM / ILM, can be identified and optimized.

[1045] With PTMs and ULMs (e.g., VLMs and / or CLMs), one skilled in the art can use known synthetic methods for their combination with or without a linker moiety. The linker moiety can be synthesized with a range of compositions, lengths, and flexibilities and functionalized so that the PTM and ULM groups can be sequentially attached to the distal end of the linker. Thus, libraries of bifunctional molecules can be realized and analyzed in in vitro and in vivo pharmacology and ADMET / PK studies. As with the PTM and ULM groups, the resulting bifunctional molecules can be subjected to iterative design and optimization cycles to identify molecules with desired properties.

[1046] In some cases, protecting group strategies and / or functional group interconversions (FGIs) may be required to facilitate the preparation of the desired materials. Such chemical processes are well known to synthetic organic chemists and many of them can be found in textbooks such as "Greene's Protective Groups in Organic Synthesis" by Peter G.M.Wuts and Theodora W.Greene (Wiley), and "Organic Synthesis: The Disconnection Approach" by Stuart Warren and Paul Wyatt (Wiley).

[1047] Solution 1

[1048]

[1049] Compounds of formula I (commercially available or readily prepared using standard reaction techniques known to those skilled in the art) can be reacted with compounds of formula II (also commercially available or readily prepared by those skilled in the art) in a solvent such as DMSO or DMF, in a base such as triethylamine or DIEA, with heating to produce compounds of formula III. In this case, X on compound II can be a leaving group such as a halogen, and Q6 and Q7 are such that the selective displacement shown here is advantageous. A non-limiting example is where X=Cl and Q6 and Q7 are both N. Compounds of formula III can produce heterobifunctional degradable compounds of formula V by reacting with compounds of formula IV in the presence of a base such as DIEA, in a solvent such as DMSO, with heating. Compounds of formula IV are higher order building blocks where the ULM, linker, and portion of the PTM form a complete subunit. Where represents a 4-8 membered cyclic amine or a spirocyclic amine (any 2-ring combination of 4,4; 4,5; 4,6; 5,4; 5,5; 5,6; 6,4; 6,5; and 6,6), optionally including a second N therebetween if >2 carbons. L' can be a bond, a linker, or part of a linker.

[1050] Option 2

[1051]

[1052] Certain compounds of Formula I in Scheme I have a double bond between Q8 and Q9, and have Q8 = CH and Q9 = COCH2CONHCH3. They can be prepared using the procedures described and / or adapted in Kerres et al., 2017, Cell Reports 20, 2860-2875, as shown in Scheme II. When G1 is NO2, the compound of Formula VI can be dissolved in a solvent such as DMF, treated with a base such as, but not limited to, K2CO3, and reacted with R PTM1 -X alkylation, in which case X can be a leaving group such as, but not limited to, iodine or bromine. Typically, R PTM1 -X is commercially available or readily prepared by one skilled in the art. Alternatively, R PTM1 The boronic acid analogue of the formula VI is reacted by a Chan-Lam coupling reaction to form a compound of formula VI (reviewed in Chen et al., 2020, Advanced Synthesis and Catalysis 62 (16), 3311-3331), wherein the boronic acid and the compound of formula VI are mixed with a copper salt such as Cu (OAc) 2 and a base such as Na 2 CO 3 in a solvent such as and heated. In this case, it is preferred to have G1 = H and to carry out the nitration as shown in the third step of Scheme 2 using KNO 3 under acidic conditions. The skilled person will recognize that when using R PTM1When alkylating 5-nitroisatin with -X (VI with G1=NO2), the nitration step is skipped because the compound of formula VIII is produced directly. The compound of formula VIII can be reacted with TMS-diazomethane under basic conditions (see Duplanier et al., 2009, J. Med. Chem. 52, 3576-3585 and references cited therein) to provide the ring-expanded compound of formula IX. The hydroxyl group of the compound of formula X can be exposed by treating the compound of formula IX with BBR3. The compound of formula I can be obtained in two additional steps by alkylating the hydroxyl group of X with 2-haloacetamide and then reducing the nitro group. Many methods are available to those skilled in the art to achieve nitro group reduction.

[1053] Option 3

[1054]

[1055] Compounds of formula I in Scheme 1 wherein a double bond exists between Q8 and Q9 and Q8 = CH and Q9 = COCH2CONHCH3 can also be obtained using the method shown in Scheme 3. Compounds of formula XII (commercially available or readily prepared by methods known to those skilled in the art) can be treated with nitric acid in sulfuric acid to form compounds of formula XIII. Compounds of formula XIII can be heated in a sodium bromate / HBr mixture to give compounds of formula XIV. Similarly, as shown in Scheme 2, under basic conditions, the reaction mixture is reacted with R PTM1 -X alkylates the compound of formula XIV to give the compound of formula XV. This compound is heated with Brett Phos Palladacycle Gen4 in a mixture of dioxane, water and KOH to give the compound of formula X. The last two steps are shown in Scheme 2.

[1056] Option 4

[1057]

[1058] Compared to Scheme I, in some cases it is preferred to form the heterobifunctional degradable compound of Formula V in two steps. This is illustrated in Scheme 4, where the compound of Formula III can be reacted with the compound of Formula XVI under basic conditions to form the compound of Formula XVII. For the compound of Formula XVI, represents a 4-8 membered cyclic amine or spirocyclic amine (any 2-ring combination of 4,4; 4,5; 4,6; 5,4; 5,5; 5,6; 6,4; 6,5; and 6,6), optionally including a second N between them if >2 carbons. L may be absent, a bond, a linker, or part of a linker. L" represents a linker formed after the compound of formula XVII and the compound of formula XVIII are linked, and contains all or part of L and L'. If L is absent, X1 can represent the second bridged ring secondary amine described above, or if L = a bond, a linker, or a portion of a linker, X1 can be an exocyclic amine (primary, secondary, and optional portion of a 4-8 membered ring or a 2-ring spirocycle as described above) or an alcohol. If X1 is an amine or alcohol, one skilled in the art will understand that as part of the compound of formula XVII, it can act as a nucleophile in a subsequent reaction with the compound of formula XVIII (Scheme 12) to produce a heterobifunctional degradable compound of formula V, in which case the compound of formula XVIII has X2 as a leaving group, a non-limiting example of which is a halide or tosylate, and produces a compound of formula V under conditions well known to those skilled in the art, such as combining XVII and XVIII in a solvent in the presence of a suitable base with or without heating. Additionally, when X1 is an amine, X2 can be an aldehyde, and the compound of formula V can be further reacted with the compound of formula XVIII in the presence of a suitable base. Formed under original alkylation conditions (Scheme 10). Its non-limiting example is to react in MeOH in the presence of a mild reducing agent such as Na(AcO)3BH and a catalytic amount of acid. The technician will also understand that when X1 is an alcohol, it can also be further activated to form a sulfonate, such as tosylate, mesylate, etc. In this case, X2 of XVIII can be an amine or an alcohol, and the compound of formula V can be formed under appropriate alkaline conditions known to those skilled in the art. If X1 or X2 is an alcohol or an amine, it may be connected with a protecting group, such as TBDMS or BOC, which will need to be removed to complete the conversion to V. In addition, if X1 is an alcohol, when L1 of formula XVIII is a bond and X2 is a phenolic hydroxyl group, the compound of formula XVII can react with the compound of formula XVIII under Mitsunobu conditions. The non-limiting example of Mitsunobu reaction conditions is to treat a cooling solution of the compound of formula VII and the compound of formula VIII in THF with DIAD and PH3P (Scheme 15).

[1059] Option 5

[1060]

[1061] Compounds of formula XVII from Scheme 4 (wherein Q6 = C-NO2 and Q7 = CH) can also be formed as described in T. Yasui et al., 2017, Bioorganic & Medicinal Chemistry 25, 4876-4886 and as shown in Scheme 5. Commercially available compounds of formula XIX, wherein X is a halogen such as Cl, Br or I, can be reacted with an amine or alcohol (in a solvent such as DMF, in the presence of a base such as DIEA or NaH, respectively) to produce compounds of formula XX. Compounds of formula VII can be prepared from compounds of formula XX by Pd-catalyzed amination with compounds of formula I. A non-limiting example of these conditions is heating a solution of compounds of formula XX and I in anhydrous DME in the presence of a palladium catalyst such as Pd2(dba)3, a ligand such as BINAP and a base such as K2CO3 under an inert gas such as argon.

[1062] Option 6

[1063]

[1064] Certain compounds of the present invention can be prepared as shown in Scheme 6. In this case, the PTM is linked to the linker-ULM subunit via an alkyne. The alkyne-containing moiety XXI is installed using a Sonogashira reaction. A typical but non-limiting example of these conditions is heating a solution of compounds of Formula III and Formula XXI in anhydrous DMF in the presence of TEA, CuI, and Pd(PPh)3 under an inert atmosphere to form a compound of Formula XXII. L represents a linker, or a fragment of a linker, and if L contains an amine, either of which may carry a protecting group such as BOC. The skilled person will understand that such protection needs to be removed before completing the conversion to the heterobifunctional degradable compound of Formula XXIII. In the compound of Formula XVIII, X2 can be a leaving group such as, but not limited to, a halide or tosylate, and L' can be a linker or a fragment of a linker. Thus, the deprotected compound of Formula XXII can be reacted with the compound of Formula XVIII to prepare the heterobifunctional degradable compound of Formula XXIII. The skilled artisan will recognize that the compound of formula XXII may contain an electrophile or leaving group on L, and X2 of the compound of formula XVIII may be a nucleophile, such as an amine.

[1065] Option 7

[1066]

[1067] Certain compounds of the present invention have a VHL ligand as its ULM, and these compounds can be prepared as shown in Scheme 7. Compounds of formula XXIV (commercially available or readily prepared using standard reaction techniques known to those skilled in the art) can be reacted with compounds of formula XXV under basic conditions such as NaH and a suitable solvent such as DMF to produce compounds of formula XXVI. PG is a suitable protecting group, such as tert-butoxycarbonyl. Compounds of formula XXVI can be converted to compounds of formula XXVII using conditions suitable for removing the protecting group, such as when PG is tert-butoxycarbonyl, using hydrogen chloride in 1,4-dioxane in dichloromethane. Compounds of formula XXVII are then reacted with compounds of formula III (wherein Q6=Q7=N, X=Cl) under basic conditions, such as in DIEA base or an equivalent, in a suitable solvent such as DMSO, with heating to obtain compounds of formula XXVIII. Compounds of formula III can be prepared as described in Schemes 1-3. The ester functionality of the compound of Formula XXVIII can be cleaved with a base, such as NaOH or LiOH, in a suitable solvent mixture, such as 1:1 MeOH:water or 1:1:1 THF:MeOH:water, to form the compound of Formula XXIX. The heterobifunctional degradable compound of Formula XXXI can be prepared by reacting the compound of Formula XXIX with the compound of Formula XXX under amide coupling conditions, such as HOBt or EDCI, with a suitable base, such as DIEA, and a suitable solvent, such as DMF. Compounds of Formula XXX are well documented in the literature, and those skilled in the art are capable of preparing them.

[1068] Option 8

[1069]

[1070] Other compounds of the present invention whose VHL ligand is ULM can be represented by compounds of formula XLI in Scheme 8. These compounds can be prepared by converting compounds of formula XXXII (commercially available or readily prepared using standard reaction techniques known to those skilled in the art) into monotosylate XXXIII using tosyl chloride, Ag2O, and KI in a suitable solvent (such as DCM) according to the method of Bouzide et al. [Tet. Lett. 2001, 42, 8781-8783]. The monoester XXX can be protected on the other hydroxyl group with a suitable protecting group such as THP. The protected monoester XXXIV can be reacted with a compound of formula XXXV in the presence of a base such as NaH and in a suitable solvent such as DMF to produce compounds of formula XXXVI. Compounds of formula XXXVIII can be prepared by first removing the protecting group of XXXVI under acidic conditions, such as 4M HCl in dioxane, and then heating the product (compound of formula XXXVII) and a compound of formula III (wherein Q6=Q7=N, X=Cl) in the presence of a base such as DIEA in a suitable solvent such as DMSO to produce compounds of formula XXXVIII. The heterobifunctional degradable compound of formula XLI can be prepared by first activating the hydroxyl group of the compound of formula XXXVIII to a tosylate ester under suitable conditions, such as tosyl chloride and DMAP in pyridine, to prepare the compound of formula XXXIX. Then, the compound of formula XXXIX and the compound of formula XL are heated in the presence of a base, such as K2CO3, in a suitable solvent, such as DMF, to prepare the heterobifunctional degradable compound of formula XLI.

[1071] Option 9

[1072]

[1073] As shown in Scheme 9, a degrader molecule having a cerebellin ligand as a ULM can be prepared. A compound of Formula XLII (commercially available or readily prepared by one skilled in the art) can be reacted with a compound of Formula XXXIX under alkaline conditions, such as K2CO3 or DMF, by heating to yield a heterobifunctional degradative compound of Formula XLII.

[1074] Plan 10

[1075]

[1076] Other examples where ULM is a ligand for cerebellin can be prepared as shown in Scheme 10. For compounds of Formula XLIV, L is a bond, or an acyclic, cyclic, or heterocyclic portion of a PTM optionally including a linker or a portion of a linker, and is a 4- to 8-membered cyclic amine or spirocyclic amine (any 2-ring combination of 4,4; 4,5; 4,6; 5,4; 5,5; 5,6; 6,4; 6,5; and 6,6), optionally including a second nitrogen atom between them if >2 carbon atoms. To form the heterobifunctional degradable compound of Formula XLIV, reductive alkylation conditions, such as sodium triacetoxyborohydride, acetic acid, dichloromethane, methanol, at 30°C, are used to react with the compound of Formula XLIV and the compound of Formula XLV. The compound of Formula XLV has Y═CO or CH, L′ is absent or is a linker or part of a linker, and can be prepared by methods readily available to those skilled in the art.

[1077] Plan 11

[1078]

[1079] In some cases, the reactivity shown in Scheme 10 can be reversed. As shown in Scheme 11, the compound of Formula XLVII can be reductively alkylated onto the compound of Formula XLVIII to form the heterobifunctional degradable compound of Formula XLIX. Here, L can be a bond, an acyclic, cyclic, heterocyclic, or spiro-heterocyclic PTM moiety, L' can be a bond, a linker, or a portion of a linker, and is a 4-8 membered cyclic amine or spirocyclic amine (any 2-ring combination of 4,4; 4,5; 4,6; 5,4; 5,5; 5,6; 6,4; 6,5; and 6,6), optionally including a second N therebetween if >2 carbons.

[1080] Plan 12

[1081]

[1082] In other cases, heterobifunctional degradable compounds can be formed by nucleophilic substitution reactions as shown in Scheme 12. Here, L and As previously described for compounds of Formula XLVII. For compounds of Formula L, Y is CO or CH, L' can be a linker or a portion of a linker, and X is a leaving group such as, but not limited to, bromine or O-toluenesulfonate. In some cases, as will be apparent to a skilled practitioner, when X is F, L' can also be zero. Heterobifunctional degradable compounds of Formula LI can be formed by combining compounds of Formula XLVII with L in the presence of a base such as alkali, in a solvent such as DMSO. DIEA with or without heating as desired.

[1083] Plan 13

[1084]

[1085] In other cases, it is preferred to use compound XLVIII to form a heterobifunctional degradative compound of formula LII, wherein the cerebellin ligand, linker, and PTM portion form a complete subunit as shown in Scheme 13. The conditions for this reaction generally require a solvent such as DMSO, a base such as DIEA, and heating. Compounds of formula XLVIII can be prepared by methods known and available to those skilled in the art.

[1086] Plan 14

[1087]

[1088] Degrader molecules of Formula LV can be formed by coupling compounds of Formula LIII, where L is an acyclic, cyclic, heterocyclic, or spiro-heterocyclic moiety as described above, and X' is H or a sulfonate moiety that forms an active ester with O, such as a tosylate. When X'=H, a Mitsunobu reaction as described above can be used to form compounds of Formula LV. When O-X' together are a sulfonate, compounds of Formula LIII can be reacted with compounds of Formula LIV in the presence of a base such as KCO in a solvent such as DMF.

[1089] Plan 15

[1090]

[1091] Heterobifunctional compounds of formula LVIII can be prepared from compounds of formula LVI and LVII using click chemistry (reviewed in Thirumurigan et al., 2013, Chem. Rev. 113, 7, 4905-4979) by methods well known to those skilled in the art, wherein L is an acyclic, cyclic, heterocyclic, or spiro-heterocyclic moiety terminated with an alkynyl group as described above, and wherein an azide-terminated linker (L') has been attached to the ULM by methods well known to those skilled in the art. A non-limiting example of click chemistry conditions is stirring a DMSO solution of compounds of formula LVI and LVII in the presence of CuI and DIEA.

[1092] Synthesis process

[1093] Step 1: Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-hydroxyisoindoline-1,3-dione

[1094]

[1095] To a solution of 3-aminopiperidine-2,6-dione (4.1 g, 24.7 mmol, 1.50 equiv., HCl salt) in acetic acid (45 mL) was added sodium acetate (4.1 g, 49.4 mmol, 3.00 equiv.), and the mixture was stirred at 25 ° C for 1 hour. 4-Hydroxyphthalic acid (3.0 g, 16.5 mmol, 1.00 equiv.) was then added to the mixture and heated to 120 ° C and stirred for another 11 hours. The mixture was concentrated, poured into water (20 mL), and then filtered. The crude product was purified by column chromatography (dichloromethane: methanol = 50: 1 to 10: 1) to give 2- (2,6-dioxo-3-piperidinyl) -5-hydroxy-isoindoline-1,3-dione (3.9 g, 14.3 mmol, 86% yield) as a colorless solid. LC / MS(ESI)m / z:275[M+1] + ; 1 H-NMR (400MHz, CDCl3) δ11.19-10.94(m,2H),7.75(d,J=8.0Hz,1H),7.20-7.08(m,2H),5.08(dd,J=5.2,12.8Hz,1H),3.34(br s,1H),2.95-2.81(m,1H),2.64-2.55(m,1H),2.08-1.98(m,1H).

[1096] Synthesis of 6-((2,5-dichloropyrimidin-4-yl)amino)-1-methyl-3-(2-oxopropoxy)quinolin-2(1H)-one (intermediate for preparing exemplary compounds 179, 164, 187, 165, 169, and 170):

[1097] Step 1: Preparation of 1-methyl-5-nitroindolin-2,3-dione

[1098]

[1099] To a mixture of 5-nitroindolin-2,3-dione (5 g, 26.04 mmol) and K2CO3 (14.1 g, 29.94 mmol) in DMF (10.0 mL) was added CH3I (4.1 g, 28.64 mmol) dropwise. The mixture was stirred at room temperature for 3 hours. After quenching with H2O (20 mL), the mixture was extracted with ethyl acetate (100 mL). The organic phase was concentrated under vacuum to give the desired product (2.2 g) as a black solid. LC / MS (ESI) m / z: 207.1 [M+1] + .

[1100] Step 2: Preparation of 3-hydroxy-1-methyl-6-nitroquinolin-2(1H)-one

[1101]

[1102] To a solution of 1-methyl-5-nitroindolin-2,3-dione (100 mg, 0.485 mmol) and TMSCH2N2 (110.8 mg, 0.971 mmol) in DCM (10 mL) was added dropwise Sc(OTf)3 (24.1 mg, 0.0485 mmol) at 0°C. The mixture was stirred at room temperature for 3 hours. After quenching with H2O (5 mL), the mixture was extracted with ethyl acetate (50 mL). The organic phase was concentrated under vacuum to give the desired product (50 mg) as a colorless oil. LC / MS (ESI) m / z: 221.1 [M+1] + .

[1103] Step 3: Preparation of 1-methyl-6-nitro-3-(2-oxopropoxy)quinolin-2(1H)-one

[1104]

[1105] Into a 100mL round-bottom flask was placed a solution of 3-hydroxy-1-methyl-6-nitro-1,2-dihydroquinolin-2-one (600.0mg, 2.7mmol, 1.0 equivalent), K2CO3 (1.1g, 0.1mmol, 3.0 equivalent), and 1-bromopropan-2-one (441.8mg, 3.2mmol, 1.2 equivalent) in DMF (5mL). The resulting mixture was stirred at room temperature for 2 hours. The reaction was then quenched by adding 20mL of water. The resulting mixture was extracted with ethyl acetate (20mL x 2). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was applied to a silica gel column and eluted with ethyl acetate / petroleum ether (1:1). This gave 295.0mg (39%) of 1-methyl-6-nitro-3-(2-oxopropoxy)-1,2-dihydroquinolin-2-one as a yellow solid. LC / MS(ESI)m / z:277.05[M+1] + .

[1106] Step 4: Preparation of 6-amino-1-methyl-3-(2-oxopropoxy)quinolin-2(1H)-one

[1107]

[1108] In a 100mL round-bottom flask, under a nitrogen atmosphere, Pd / C (10%, 20.0mg) was added to a solution of 1-methyl-6-nitro-3-(2-oxopropoxy)-1,2-dihydroquinolin-2-one (295.0mg, 1.1mmol, 1.0 equivalent) in MeOH (3mL) and DMF (3mL). The flask was then evacuated and flushed with hydrogen. Under a hydrogen atmosphere, the reaction mixture was hydrogenated at 40°C for 2 hours using a hydrogen balloon and then filtered through a celite pad. The filtrate was concentrated under reduced pressure. This gave 245.0mg (93%) of 6-amino-1-methyl-3-(2-oxopropoxy)-1,2-dihydroquinolin-2-one as a yellow solid.

[1109] Step 5: Preparation of 6-((2,5-dichloropyrimidin-4-yl)amino)-1-methyl-3-(2-oxopropoxy)quinolin-2(1H)-one

[1110]

[1111] Into a 20 mL sealed tube was placed 6-amino-1-methyl-3-(2-oxopropoxy)-1,2-dihydroquinolin-2-one (245.0 mg, 0.9 mmol, 1.0 equivalent), DIEA (385.4 mg, 2.9 mmol, 3.0 equivalent), 2,4,5-trichloropyrimidine (181.3 mg, 0.9 mmol, 1.0 equivalent) in DMF (3 mL). The resulting solution was stirred in an oil bath at 100 ° C for 2 hours. The reaction was then quenched by adding 20 mL of water. The resulting mixture was extracted with ethyl acetate (20 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was applied to a silica gel column and eluted with ethyl acetate. This gave 210.0 mg (54%) of 6-[(2,5-dichloropyrimidin-4-yl)amino]-1-methyl-3-(2-oxopropoxy)-1,2-dihydroquinolin-2-one as a yellow solid. LC / MS (ESI) m / z: 393.00 [M+1] + .

[1112] Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (intermediate for preparing exemplary compounds 26, 164, 187, 165, 169 and 170):

[1113] Step 1: Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione

[1114]

[1115] A mixture of 4-fluorophthalic acid (1.0 g, 5.4 mmol) and CDI (1,1'-carbonyldiimidazole) (1.9 mg, 11.9 mmol) in acetonitrile (20 ml) was stirred at room temperature for 1 hour. 3-aminopiperidine-2,6-dione hydrochloride (894 mg, 5.4 mmol) was added to the stirred solution. The mixture was stirred at 70 ° C overnight. The cooled reaction mixture was concentrated under reduced pressure to give a crude residue, which was stirred in water (30 ml) for 1 hour. The mixture was filtered to give a crude residue, which was dried in an oven at 50 ° C to give 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (1.4 g, yield 90%) as an off-white solid. LC / MS (ESI) m / z: 277.1 [M+1] + ; 1 H-NMR(400MHz,DMSO-d6)δ2.03-2.11(m,1H),2.50-2.63(m,2H),2.85-2.94(m,1H),5.15-5.20(m ,1H),7.66-7.78(m,1H),7.86(dd,J=7.6,2.4Hz,1H),8.02(dd,J=8.4,4.4Hz,1H),11.16(s,1H).

[1116] Synthesis of 2-((6-((2,5-dichloropyrimidin-4-yl)amino)-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)oxy)-N-methylacetamide (intermediate for preparing exemplary compounds 26, 191, 51, 56, and 104):

[1117] Step 1: Preparation of N-methyl-2-((1-methyl-6-nitro-2-oxo-1,2-dihydroquinolin-3-yl)oxy)acetamide

[1118]

[1119] A mixture of 3-hydroxy-1-methyl-6-nitroquinolin-2(1H)-one (727 mg, 3.30 mmol), 2-bromo-N-methylacetamide (604.7 mg, 4.03 mmol), and Cs2CO3 (2.15 g, 6.58 mmol) in DMF (10 mL) was stirred at room temperature for 12 hours. The reaction was quenched with MeOH (20 mL). The mixture was filtered through celite and the filtrate was concentrated to give a colorless oily product (220 mg). LC / MS (ESI) m / z: 292.1 [M+1] + .

[1120] Step 2: Preparation of 2-((6-amino-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)oxy)-N-methylacetamide

[1121]

[1122] A mixture of N-methyl-2-((1-methyl-6-nitro-2-oxo-1,2-dihydroquinolin-3-yl)oxy)acetamide (220 mg, 0.75 mmol) and Pd / C (100 mg) in MeOH / DMF (10 mL) was stirred at room temperature under H₂ for 3 hours. The mixture was filtered through celite and the filtrate was concentrated to give the product as a black solid (150 mg). LC / MS (ESI) m / z: 262.2 [M+23] + .

[1123] Step 3: Preparation of 2-((6-((2,5-dichloropyrimidin-4-yl)amino)-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)oxy)-N-methylacetamide

[1124]

[1125] To a solution of 2-((6-amino-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)oxy)-N-methylacetamide (100 mg, 0.38 mmol) and 2.4,5-trichloropyrimidine (83 mg, 0.46 mmol) in DMF (4 mL) and MeOH (4 mL) was added triethylamine (77.4 mg, 0.76 mmol), and the mixture was heated to 70 ° C and maintained for 12 hours. After cooling to room temperature, the reaction mixture was concentrated in vacuo and the residue was dissolved in water. The resulting precipitate was collected by filtration, washed with Et2O and dried in vacuo to give the product (140 mg). LC / MS (ESI) m / z: 408.1 [M+1] + .

[1126] Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (intermediate for preparing exemplary compound 191)

[1127] Step 1: Preparation of 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione

[1128]

[1129] Into a 100 mL round-bottom flask was placed a solution of 4-hydroxy-1,3-dihydro-2-benzofuran-1,3-dione (1 g, 6.09 mmol, 1.00 equiv) in HOAc (30 mL), 3-aminopiperidine-2,6-dione hydrochloride (1.1 g, 6.71 mmol, 1.10 equiv), and NaOAc (750 mg, 9.15 mmol, 1.50 equiv). The resulting solution was stirred at 120°C for 12 hours. The reaction mixture was cooled. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 100 mL of water. The resulting solution was extracted with 3 x 100 mL of dichloromethane, and the organic layers were combined. The resulting mixture was washed with 1 x 20 mL of brine. The mixture was dried over anhydrous sodium sulfate. The residue was applied to a silica gel column using dichloromethane / methanol (20:1). This gave 350 mg (21%) of 2-(2,6-dioxopiperidin-3-yl)-4-hydroxy-2,3-dihydro-1H-isoindole-1,3-dione as a white solid. LC / MS (ESI) m / z: 273 [M-1] + ; 1 H-NMR(300MHz,DMSO-d6)δ11.154(b,1H),11.139(s,1H),7.692-7.625(m,1H),7.325-7.234( m,2H),5.100-5.039(m,1H),2.947-2.825(m,1H),2.611-2.445(m,2H),2.036-2.002(m,1H).

[1130] Synthesis of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (intermediate for preparing exemplary compound 51)

[1131] Step 1: Preparation of 4-(4-methylthiazol-5-yl)benzonitrile

[1132]

[1133] Into a 1-L round-bottom flask purged and maintained with an inert nitrogen atmosphere was placed a solution of 4-bromobenzonitrile (20 g, 109.88 mmol, 1.00 equiv) in DMA (250 mL), 4-methyl-1,3-thiazole (21.88 g, 220.67 mmol, 2.00 equiv), Pd(OAc)2 (743 mg, 3.31 mmol, 0.03 equiv), and KOAc (21.66 g, 220.71 mmol, 2.00 equiv). The resulting solution was stirred at 150°C for 5 hours. The reaction mixture was cooled in a water / ice bath and diluted with 1 L of water. The resulting solution was extracted with 3 x 300 mL of ethyl acetate. The combined organic layers were washed with 3 x 300 mL of water and 1 x 300 mL of brine, then dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash distillation with a combination of ethyl acetate and petroleum ether (1:100-1:5). This gave 20 g (91%) of 4-(4-methyl-1,3-thiazol-5-yl)benzonitrile as a beige solid.

[1134] Step 2: Preparation of (4-(4-methylthiazol-5-yl)phenyl)formamide

[1135]

[1136] A solution of 4-(4-methyl-1,3-thiazol-5-yl)benzonitrile (35 g, 174.77 mmol, 1.00 equiv) in tetrahydrofuran (1000 mL) was placed in a 3L, 3-neck round-bottom flask purged and maintained with an inert nitrogen atmosphere. LiAlH4 (20 g, 526.32 mmol, 3.00 equiv) was then added portionwise at 0°C over 10 minutes. The resulting solution was stirred at 60°C in an oil bath for 3 hours. The reaction was cooled to 0°C with a water / ice bath and then quenched by adding 20 mL of water, 20 mL of NaOH (15%) and 60 mL of water. The resulting solution was diluted with 200 mL of ethyl acetate. The solid was filtered off. The filtrate was dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was applied to a silica gel column using dichloromethane / methanol (10:1). This gave 20 g (56%) of [4-(4-methyl-1,3-thiazol-5-yl)phenyl]formamide as a yellow oil.

[1137] Step 3: Preparation of tert-butyl (2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carboxylate

[1138]

[1139] A 50 mL round-bottom flask was charged with a solution of (2S,4R)-1-[(tert-butoxy)carbonyl]-4-hydroxypyrrolidine-2-carboxylic acid (2.7 g, 11.68 mmol, 1.20 equiv) in N,N-dimethylformamide (30 mL), DIEA (2.52 g, 19.50 mmol, 1.20 equiv), HATU (4.47 g, 11.76 mmol, 1.20 equiv), and [4-(4-methyl-1,3-thiazol-5-yl)phenyl]formamide (2 g, 9.79 mmol, 1.00 equiv). The resulting solution was stirred at 25°C overnight. The reaction was then quenched by the addition of 20 mL of water and extracted with 3 x 20 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was applied to a silica gel column using dichloromethane / methanol (20:1). This gave 1 g (24%) of tert-butyl (2S,4R)-4-hydroxy-2-([[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]carbamoyl)pyrrolidine-1-carboxylate as a yellow solid.

[1140] Step 4: Preparation of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride

[1141]

[1142] Into a 1000 mL round-bottom flask was placed a solution of tert-butyl (2S,4R)-4-hydroxy-2-([[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]carbamoyl)pyrrolidine-1-carboxylate (45 g, 107.78 mmol, 1.00 equiv) and hydrogen chloride (13.44 L) in dioxane (300 mL). The resulting solution was stirred at 20°C for 2 hours. The solid was collected by filtration. This yielded 37.3 g (98%) of (2S,4R)-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide hydrochloride as a yellow solid.

[1143] Step 5: Preparation of tert-butyl (S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate

[1144]

[1145] A 1000 mL round-bottom flask was charged with a solution of (2S)-2-[[(tert-butoxy)carbonyl]amino]-3,3-dimethylbutanoic acid (15.73 g, 68.01 mmol, 1.20 equiv) in N,N-dimethylformamide (500 mL), DIEA (29.2 g, 225.94 mmol, 4.00 equiv), HATU (25.9 g, 68.12 mmol, 1.20 equiv), and (2S,4R)-2-amino-5-chloro-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pentanamide (20 g, 56.52 mmol, 1.00 equiv). The resulting solution was stirred at 20° C. for 16 hours. The reaction was then quenched by the addition of 200 mL of water and extracted with 3×100 mL of ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was applied to a silica gel column using ethyl acetate / petroleum ether (2:1). This gave 15.2 g (51%) of tert-butyl N-[(2S)-1-[(2S,4R)-4-hydroxy-2-([[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate as a yellow solid.

[1146] Step 6: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride

[1147]

[1148] In a 500 mL round-bottom flask, a solution of tert-butyl N-[(2S)-1-[(2S,4R)-4-hydroxy-2-([[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate (12 g, 22.61 mmol, 1.00 equiv) in dioxane (20 mL) and a solution of hydrogen chloride (3.584 L) in dioxane (80 mL) were placed. The resulting solution was stirred at 25°C for 2 h. The solid was collected by filtration. This gave 5.1 g (48%) of (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide hydrochloride as a yellow solid. LC / MS (ESI) m / z: 431 [M+1] + ; 1H-NMR(400MHz,CD3OD)δ9.84-9.82(s,1H),7.58-7.54(m,4H),4.71-4.41(m,4H),4.13-4.08(m ,1H),3.86-3.71(m,2H),3.36(s,1H),2.60-2.58(s,3H),2.35-2.07(m,2H),1.19-1.12(m,9H).

[1149] Synthesis of (2S,4R)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)-1-(3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (intermediate for preparing exemplary compound 56)

[1150] Step 1: Preparation of 2-(3-methylisoxazol-5-yl)acetic acid

[1151]

[1152] Under nitrogen, n-butyl lithium (2.5 M, 77 mL, 1.25 eq) was added dropwise to a solution of 3,5-dimethylisoxazole (15 g, 154.46 mmol, 15 mL, 1 eq) in tetrahydrofuran (150 mL) at -78 ° C. The mixture was stirred at -55 ° C for 30 minutes, then carbon dioxide was bubbled into the mixture for 30 minutes, and the mixture was stirred at 25 ° C for 1 hour. The mixture was quenched with saturated ammonium chloride solution (50 mL) and extracted with ethyl acetate (50 mL). The aqueous phase was adjusted to pH = 2 with aqueous hydrochloric acid (2 M), and the mixture was extracted with ethyl acetate (50 mL, three times). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 2-(3-methylisoxazol-5-yl)acetic acid (10 g, 70.86 mmol, 46% yield) as a brown solid. 1 H-NMR (400MHz, DMSO-d6) δ12.74(br s,1H),6.24(s,1H),3.83(s,2H),2.20(s,3H).

[1153] Step 2: Preparation of methyl 2-(3-methylisoxazol-5-yl)acetate

[1154]

[1155] To a solution of 2-(3-methylisoxazol-5-yl)acetic acid (10 g, 70.86 mmol, 1 equivalent) in methanol (100 mL) at 0°C was added thionyl chloride (12.65 g, 106.29 mmol, 7.71 mL, 1.5 equivalents), and the mixture was stirred at 50°C for 4 hours. The mixture was concentrated to obtain a crude product. The crude product was diluted with ethyl acetate (200 mL), washed with water (200 mL), then with saturated aqueous sodium bicarbonate (50 mL), and then with brine (50 mL). The organic phase was dried over anhydrous water, filtered, and the filtrate was concentrated to obtain methyl 2-(3-methylisoxazol-5-yl)acetate (10 g, 64.45 mmol, 91% yield) as a brown oil. 1 H-NMR (400MHz, CDCl3) δ6.11(s,1H),3.80(s,2H),3.76(s,3H),2.30(s,3H).

[1156] Step 3: Preparation of methyl 3-methyl-2-(3-methylisoxazol-5-yl)butanoate

[1157]

[1158] To a solution of methyl 2-(3-methylisoxazol-5-yl)acetate (10 g, 64.45 mmol, 1 eq) in tetrahydrofuran (100 mL) was added sodium hydride (3.87 g, 96.68 mmol, 60% purity, 1.5 eq) at 0° C., followed by the addition of 2-iodopropane (13.15 g, 77.34 mmol, 7.74 mL, 1.2 eq) at 0° C., and the mixture was stirred at 25° C. for 2 hours. Additional 2-iodopropane (2.55 g, 15.00 mmol, 1.5 mL) was added, and the mixture was stirred at 25° C. for 10 hours. The mixture was quenched with aqueous hydrochloric acid (1 M, 300 mL), and the mixture was extracted with ethyl acetate (200 mL, three times). The organic phase was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated to give methyl 3-methyl-2-(3-methylisoxazol-5-yl)butanoate (13 g) as a brown oil.

[1159] Step 4: Preparation of 3-methyl-2-(3-methylisoxazol-5-yl)butanoic acid

[1160]

[1161] To a solution of methyl 3-methyl-2-(3-methylisoxazol-5-yl)butanoate (12.7 g, 64.39 mmol, 1 eq) in methanol (90 mL) and water (60 mL) was added sodium hydroxide (12.88 g, 321.96 mmol, 5 eq) and the mixture was stirred at 25 °C for 2 hours. The mixture was concentrated to remove methanol, and the residue was diluted with water (200 mL) and extracted with ethyl acetate (200 mL). The aqueous phase was adjusted to pH = 3 with aqueous hydrochloric acid solution (2 M), and the mixture was extracted with dichloromethane (200 mL, three times), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give a crude product as a brown oil. The crude product was purified by flash preparative HPLC to remove the acetonitrile fraction. The residue was extracted with dichloromethane (300 mL × 5), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give the product 3-methyl-2-(3-methylisoxazol-5-yl)butanoic acid (7.5 g, 40.94 mmol, 63% yield) as a white solid. 1 H-NMR (400MHz, DMSO-d6) δ6.26 (s, 1H), 3.58 (d, J = 8.7Hz, 1H), 2.33-2.23 (m, 1H), 2.21 (s, 3H), 0.95 (d, J = 6.7Hz, 3H), 0.82 (d, J = 6.8Hz, 3H).

[1162] Step 5: Preparation of 2-hydroxy-4-(4-methylthiazol-5-yl)benzonitrile

[1163]

[1164] To a solution of 4-bromo-2-hydroxybenzonitrile (15 g, 75.75 mmol, 1 eq) and 4-methylthiazole (20.28 g, 204.53 mmol, 19 mL, 2.7 eq) in N-methylpyrrolidone (150 mL) were added potassium acetate (22.30 g, 227.25 mmol, 3 eq) and palladium acetate (1.70 g, 7.58 mmol, 0.1 eq). The mixture was stirred at 110°C under nitrogen for 6 hours. The mixture was quenched with water (500 mL), and the aqueous phase was extracted with ethyl acetate (300 mL x 3). The combined organic phases were washed with brine (200 mL, twice), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Methyl tert-butyl ether (500 mL) was then added to the mixture, and the organic phase was washed with water (100 mL) and brine (100 mL, twice). The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1 to 1 / 1) to obtain 2-hydroxy-4-(4-methylthiazol-5-yl)benzonitrile (11 g, 50.87 mmol, 67% yield) as a yellow solid.

[1165] Step 6: Preparation of 2-(aminomethyl)-5-(4-methylthiazol-5-yl)phenol

[1166]

[1167] To a solution of 2-hydroxy-4-(4-methylthiazol-5-yl)benzonitrile (11 g, 50.87 mmol, 1 eq) in tetrahydrofuran (150 mL) was added lithium aluminum hydride (7.72 g, 203.46 mmol, 4 eq) at 0°C, and the mixture was stirred at 50°C for 3 hours. The mixture was quenched with water (8 mL) at 0°C, followed by the addition of 15% aqueous sodium hydroxide solution (8 mL), followed by water (8 mL) and anhydrous sodium sulfate (30 g). The mixture was stirred at 25°C for 30 minutes and filtered. Dichloromethane / methanol (4 / 1, 50 mL) was added to the solid, and the mixture was stirred at 25°C for 1 hour, filtered, and the filtrates were combined and concentrated to give 2-(aminomethyl)-5-(4-methylthiazol-5-yl)phenol (7 g, 31.78 mmol, 62% yield) as a brown solid. 1 H-NMR (400MHz, DMSO-d6) δ8.82(s,1H),6.90(d,J=7.5Hz,1H),6.52(d,J=1.6Hz,1H),6.25(dd,J=1.7,7.5Hz,1H),3.59(s,2H),2.41(s,3H).

[1168] Step 7: Preparation of tert-butyl (2S,4R)-4-hydroxy-2-((2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carboxylate

[1169]

[1170] To a solution of 2-(aminomethyl)-5-(4-methylthiazol-5-yl)phenol (7 g, 31.78 mmol, 1 eq) and (2S,4R)-1-tert-butoxycarbonyl-4-hydroxy-pyrrolidine-2-carboxylic acid (7.35 g, 31.78 mmol, 1 eq) in dimethylformamide (70 mL) was added diisopropylethylamine (12.32 g, 95.33 mmol, 16.60 mL, 3 eq) followed by HATU (13.29 g, 34.95 mmol, 1.1 eq) and the mixture was stirred at 25 °C for 2 hours. Additional (2S,4R)-1-tert-butoxycarbonyl-4-hydroxy-pyrrolidine-2-carboxylic acid (7.35 g, 31.78 mmol, 1 eq) and HATU (12.08 g, 31.78 mmol, 1 eq) were added, and the mixture was stirred for 5 hours at 25° C. The mixture was diluted with water (300 mL), extracted with ethyl acetate (300 mL, twice), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give a brown oily crude product, which was dissolved in tetrahydrofuran / water (2 / 1, 150 mL), lithium hydroxide (3 g) was added, and the mixture was stirred for 1 hour at 25° C. The mixture was diluted with water (300 mL) and adjusted to pH 7 with aqueous hydrochloric acid (0.5 M). The mixture was extracted with ethyl acetate (300 mL, twice). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by silica gel chromatography (2-10% methanol in dichloromethane) to obtain tert-butyl (2S,4R)-4-hydroxy-2-[[2-hydroxy-4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-1-carboxylate (6.9 g, 15.92 mmol, 50% yield) as a yellow oil. LC / MS (ESI) m / z: 434.1 [M+1]. + .

[1171] Step 8: Preparation of (2S,4R)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

[1172]

[1173] To a solution of tert-butyl (2S,4R)-4-hydroxy-2-[[2-hydroxy-4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-1-carboxylate (6.9 g, 15.92 mmol, 1 equiv) in methanol (30 mL) was added hydrochloric acid / dioxane (4 M, 30 mL, 7.54 equiv), and the mixture was stirred at 25°C for 20 minutes. The mixture was concentrated to give a yellow solid product, which was triturated with ethyl acetate and petroleum ether (1:1, 20 mL). The mixture was filtered and the solid was dried on a rotary evaporator to give the product (2S,4R)-4-hydroxy-N-[[2-hydroxy-4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (4.83 g, 13.06 mmol, 82% yield, hydrochloric acid) as a yellow solid. 1 H-NMR(400MHz,DMSO-d6)δ10.03(br s,1H),9.11-8.95(m,2H),8.66(br s,1H),7.20(d,J=7.9Hz,1H),7.04(d,J=1.3Hz,1H),6.90(dd,J=1.7,7.8Hz,1H),4.44(br s,1H),4.40-4.26(m,3H),3.41-3.27(m,1H),3.13-3.02(m,1H),2.46(s,3H),2.33(br dd,J=7.5,12.7Hz,1H),1.96-1.85(m,1H),1.33-1.24(m,1H).

[1174] Step 9: Preparation of (2S,4R)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)-1-(3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide

[1175]

[1176] To a solution of (2S,4R)-4-hydroxy-N-[[2-hydroxy-4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (4.83 g, 13.06 mmol, 1 eq, hydrochloride) in dimethylformamide (60 mL) was added diisopropylethylamine (5.06 g, 39.18 mmol, 6.82 mL, 3 eq), followed by 3-methyl-2-(3-methylisoxazol-5-yl)butanoic acid (2.39 g, 13.06 mmol, 1 eq) and HATU (5.46 g, 14.36 mmol, 1.1 eq), and the mixture was stirred at 25° C. for 2 hours. The mixture was diluted with water (200 mL) and extracted with ethyl acetate (300 mL, twice). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give a crude product. The crude product was purified by preparative HPLC to remove the acetonitrile fraction, and the residue was extracted with dichloromethane (300 mL×5). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give the product (2S, 4R)-4-hydroxy-N-[[2-hydroxy-4-(4-methylthiazol-5-yl)phenyl]methyl]-1-[3-methyl-2-(3-methylisoxazol-5-yl)butanoyl]pyrrolidine-2-carboxamide (4.0 g, 8.02 mmol, 61% yield) as a white solid. 1 H-NMR(400MHz,CD3OD)δ8.85(s,1H),7.39-7.23(m,1H),6.98-6.86(m,2H),6.31-6.06(m,1H),4.65-4.28(m,4H),3.94-3.4 8(m,3H),2.52-2.45(m,3H),2.42-2.31(m,1H),2.26-2.15(m,4H),2.13-2.03(m,1H),1.08-1.01(m,3H),0.92-0.81(m,3H).

[1177] Synthesis of 2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy)acetaldehyde (intermediate for preparing exemplary compound 74):

[1178] Step 1: Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(2-(2-hydroxyethoxy)ethoxy)isoindoline-1,3-dione

[1179]

[1180] In N 2To a solution of tert-butyl 3-hydroxy-3-(phenylethynyl)pyrrolidine-1-carboxylate (2 g, 7.29 mmol) in THF (10 mL) was added sodium 2,2'-oxodietholate (959 mg, 8.75 mmol), DIAD (5.9 g, 29.16 mmol) and Ph3P (7.65 g, 29.16 mmol). The mixture was stirred at room temperature for 1 hour. The mixture was quenched with water (15 mL) and extracted with EA (15 mL). The combined filtrate was concentrated to give a crude product, which was chromatographically purified by column chromatography using PE:EA=10:1 to 3:1 to give the desired product (1.2 g, 45.4% yield) as a yellow solid. LC / MS (ESI) m / z: 363.1 [M+1] + .

[1181] Step 2: Preparation of 2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy)acetaldehyde

[1182]

[1183] To a solution of 2-(2,6-dioxopiperidin-3-yl)-5-(2-(2-hydroxyethoxy)ethoxy)isoindoline-1,3-dione (300 mg, 0.83 mmol) in MeCN (10 mL) was added IBX (278 mg, 0.99 mmol) at room temperature. The mixture was heated to 80 °C for 2 hours. The mixture was filtered and concentrated to give the product (300 mg) as a yellow oil. LC / MS (ESI) m / z: 361.2 [M+1] + .

[1184] Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-(piperazin-1-yl)isoindoline-1,3-dione hydrochloride (intermediate for preparing exemplary compound 104):

[1185] Step 1: Preparation of tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-carboxylate

[1186]

[1187] To a s...

Claims

1. A bifunctional compound having the following chemical structure: ULM-L-PTM, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof, in: (a) ULM is a small molecule E3 ubiquitin ligase binding moiety that binds an E3 ubiquitin ligase selected from Von Hippel-Lindau (VLM) and cerebellum (CLM); (b) the PTM is a small molecule comprising a B-cell lymphoma 6 protein (BCL6) targeting moiety; and (c) The L is a bond or a chemical linking moiety connecting the ULM and the PTM.

2. The compound according to claim 1, wherein PTM is represented by the following formula: in: Each R PTM1 are independently: H; halogen (e.g., Cl or F); -CN; -OH; -NO2; -NH2; optionally substituted straight or branched alkyl (e.g., optionally substituted straight or branched C1-C6 alkyl or optionally substituted straight or branched C1-C4 alkyl or C1-C8 alkyl optionally substituted with OH or isopropyl); O-optionally substituted straight or branched C1-C4 alkyl; optionally substituted C1-C4 alkynyl; optionally substituted C1-C4 alkynyl hydrocarbon; optionally substituted straight or branched hydroxyalkyl (e.g., optionally substituted straight or branched C1-C7 hydroxyalkyl); optionally substituted alkylcycloalkyl (e.g., including optionally substituted C1-C6 alkyl, optionally substituted C3-C10 cycloalkyl; or both); optionally substituted alkyl-aryl (e.g., including optionally substituted straight or branched C1-C6 alkyl, optionally substituted 5-10 membered heteroaryl, or both); optionally substituted alkyl-heteroaryl alkyl (e.g., including optionally substituted straight or branched C1-C6 alkyl, optionally substituted 5-10 membered heteroaryl, or both); optionally substituted alkyl-heteroaryl (e.g., including C1-C6 alkyl, optionally substituted 5 or 6 membered heteroaryl, optionally substituted with C1-C4 alkyl; heteroaryl is selected from oxazol-4-yl, 1,3,4-triazol-2-yl and imidazol-1-yl; or a combination thereof); optionally substituted -NH-alkyl-heteroaryl (e.g., optionally substituted straight or branched C1-C5 alkyl, optionally substituted 5-8 membered heteroaryl, optionally substituted C1-C4 alkyl, N-CH2-pyrazol-4-yl, or a combination thereof); optionally substituted alkoxy (e.g., optionally substituted straight or branched C1-C6 alkyl or -OCH3); optionally substituted O-heterocyclyl (e.g., including optionally substituted 3-12 or 4-7 membered heterocyclyl; optionally substituted heterocycloalkyl; optionally substituted C 3-12 monocyclic or bicyclic heterocycloalkyl; optionally substituted by at least one OH, C1-C5 alkyl (e.g., methyl), =O, NH2, or a combination thereof; or a combination thereof); optionally substituted S-heterocyclyl (e.g., including optionally substituted 4-7 membered heterocyclyl; optionally substituted heterocycloalkyl; optionally substituted by at least one C1-C4 alkyl (e.g., methyl), =O, or a combination thereof; or a combination thereof); optionally substituted (eg, optionally substituted with straight or branched C1-C4 alkyl; -(CH2) u CO(CH2) v CH3, -COCH3 or -CH2CH2COCH3, wherein each u and v are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -O(CH2) u CO(CH2) v CH3, -O(CH2) u CH((CH2) x CH3)(CH2) w CO(CH2) v CH3, -O-CH2COCH3, -O-CH2COCH2CH3, -O-CH(CH 3) COCH3, -OCH2COCH3 or -OCH2(CH3)COCH3, wherein each u, v, w and x are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -(CH2) u CO(CH2) v NR PTM1a R PTM2a 、-CONR PTM1a R PTM2a 、-CH2CONR PTM1a R PTM2a 、-CH2CH2CONR PTM1a R PTM2a , -CONHCH3 or -CH2CONHCH3, wherein each u and v are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -O(CH2) u CO(CH2) v NR PTM1a R PTM2a 、-O(CH2) u CH((CH2) x CH3)(CH2) w CO(CH2) v NR PTM1a R PTM2a 、-O-CH(CH3)CONR PTM1a R PTM2a 、-O-CH2CONR PTM1a R PTM2a or -OCH2C(O)NHOCH3, wherein each u, v, w and x are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -(CH2) u CHCH(CH2) w CO(CH2) v NR PTM1a R PTM2a or -CHCHCONR PTM1a R PTM2a , wherein each u, v and w are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -NH-(CH2) u CO(CH2) v NR PTM1a R PTM2a or -NH-CH2CONR PTM1a R PTM2a , wherein each u and v are independently selected from 1, 2, 3, 4 or 5); fluoroalkoxy (e.g., mono-, di- and / or trifluoroalkoxy); optionally substituted monocyclic or bicyclic cycloalkyl (e.g., optionally substituted 3-12 membered cycloalkyl; optionally substituted with at least one of OH, =O, linear or branched C1-C6 alkyl (e.g., methyl, ethyl or butyl) or NH2; or a combination thereof); optionally substituted hydroxycycloalkyl; optionally substituted aryl (e.g., optionally substituted C5-C10 aryl, any optionally substituted 5-7 membered aryl; optionally substituted with at least one halogen or C1-C3 alkyl (e.g., methyl or ethyl); or a combination thereof), optionally substituted heteroaryl (e.g., optionally substituted 5-10 membered heteroaryl, optionally substituted 5-7 membered heteroaryl; optionally substituted 5 membered heteroaryl; optionally substituted with at least one halogen or C1-C3 alkyl (e.g., methyl or ethyl); or a combination thereof), which is optionally connected to Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14, Q15, Q16, Q17, Q18, Q19, Q20, Q210, Q221, Q23, Q24, Q25, Q26, Q27, Q28, Q29, Q30, Q31, Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41, Q42, Q43, Q44, Q45, Q46, Q47, Q48, Q49, Q50, Q51, Q52, Q53, Q54, Q55, Q56, Q57, Q58, Q59, Q60, Q61, Q62, Q63, Q64, Q65 11 , Q 12 , Q 13 , Q 14 , or Q 15 (e.g., optionally via an optionally substituted -(CH2) u O(CH2) v O(CH2) x - or a combination thereof and optionally connected to Q 16 at least one of ); an optionally substituted monocyclic or bicyclic heterocyclyl (e.g., an optionally substituted 3-12 membered heterocyclyl; a C3-C12 monocyclic or bicyclic heterocycloalkyl, an azetidin-1-yl, a pyrrolidin-1-yl, a piperidin-1-yl, a piperazin-1-yl or a morpholin-4-yl or a homopiperazin-1-yl, each optionally substituted with OH, a straight or branched C1-C5 alkyl (methyl, ethyl or butyl) or NH2), which is optionally connected to Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14, Q15, Q16, Q17, Q18, Q19, Q20, Q21, Q22, Q23, Q24, Q25, Q26, Q27, Q28, Q29, Q30, Q31, Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41, Q42, Q43, Q44, Q45, Q46, Q47, Q48, Q49, Q50, Q51, Q52, Q53, Q54, Q55, Q56, Q57, Q58, Q59, Q60, Q61, Q62, Q63, Q74, Q75 11 , Q 12 , Q 13 , Q 14 or Q 15 (e.g., optionally via an optionally substituted -(CH2) u O(CH2) v O(CH2) x - or both and optionally connected to Q 16 at least one of ); Each t1 is independently selected from 1, 2, 3, 4 or 5; Each t2 is independently selected from 0, 1, 2, 3, 4 or 5; Each R PTM1a and R PTM2a are independently H, optionally substituted C1-C4 alkyl (e.g., CH3 or CH2CH 3) , optionally substituted C1-C4 alkoxy (eg, -OCH2 or -CH2CH3), CH2OCH3 or R PTM1a and R PTM2a Join together to form a 3-10 membered ring; Q6, Q7, Q8, Q9, Q 11 , Q 12 , Q 13 , Q 14 and Q 15 are each independently N, O or C, each optionally replaced by one or more independently selected R PTM1 (e.g., 1, 2, or 3 independently selected R PTM1 , depending on the valence) substitution; Q 16 for CH; X is O, S or CH2; is a single bond or a double bond; n is an integer from 0 to 10; and PTM The point of attachment to the linker group or ULM is indicated.

3. The compound according to claim 1 or 2, wherein the PTM has a chemical structure selected from the following: in: R PTM5 is H, optionally substituted straight or branched alkyl (e.g., optionally substituted straight or branched C1-C6 alkyl or isopropyl or C1-C4 alkyl-NH(C1-C3 alkyl) or C1-C4 alkyl-N(C1-C3 alkyl)2), optionally substituted -alkyl-aryl (e.g., optionally substituted C1-C6 alkyl, optionally substituted C5-C10 aryl, or both), optionally substituted -alkyl-heteroaryl (e.g., optionally substituted C1-C6 alkyl, optionally substituted C5-C10 heteroaryl, or both), optionally substituted -alkyl-heteroaryl (e.g., optionally substituted C1-C6 alkyl, optionally substituted C5-C10 heteroaryl, or both), optionally substituted -alkyl-heteroaryl (e.g., optionally substituted C1-C6 alkyl, optionally substituted C5-C10 heteroaryl, or both), optionally substituted -alkyl-heteroaryl (e.g., optionally substituted aryl, or both), optionally substituted aryl (e.g., optionally substituted C5-C10 aryl), optionally substituted heteroaryl (e.g., optionally substituted C5-C10 heteroaryl), optionally substituted cycloalkyl (e.g., optionally substituted C3-C10 cycloalkyl), optionally substituted -alkyl-cycloalkyl (e.g., optionally substituted C1-C6 alkyl, optionally substituted C3-C10 cycloalkyl, or both), optionally substituted heterocyclyl (e.g., optionally substituted C3-C10 heterocyclyl); Q6 is N, CH, C(NO2) or C(CN); Q7 and Q 14 are each independently N or CH; X PTM1 is H or F; X PTM2 is H, Cl, F or CN; Q8 and Q9 is a single bond, a double bond, where When Q8 and Q9 are connected by a single button: Q8 is CH2, O, CH(R PTM3 )、N(R PTM3 ) or N(CH3); and Q9 is CH2, O, CH(R PTM3 )、N(R PTM3 )、N(CH 3) 、N(CH2CH2CONHCH3 ) or N(CH2CH2COCH3); When Q8 and Q9 are connected by a double bond: Q8 is CH, C(R PTM3 ),N(R PTM3 ), N or optionally substituted C(NH-alkyl-heteroaryl) (such as optionally substituted C1-C5 alkyl, optionally substituted 5-7 membered heteroaryl, or both); Q9 is CH, C(R PTM3 ), N or N(R PTM3 );and R PTM3 is: -OH; optionally substituted straight or branched alkyl, optionally substituted alkoxy (e.g., optionally substituted with straight or branched C1-C4 alkyl or -OCH3); optionally substituted (eg, optionally substituted with straight or branched C1-C4 alkyl; -(CH2) u CO(CH2) v CH3, -COCH3 or -CH2CH2COCH3, wherein each u and v are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -O(CH2) u CO(CH2) v CH3, -O(CH2) u CH((CH2) x CH3)(CH2) w CO(CH2) v CH3, -O-CH2COCH3, -O-CH2COCH2CH3, -O-CH(CH 3) COCH3, -OCH2COCH3 or -OCH2(CH3)COCH3, wherein each u, v, w and x are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -(CH2) u CO(CH2) v NR PTM1a R PTM2a 、-CONR PTM1a R PTM2a 、-CH2CONR PTM1a R PTM2a 、-CH2CH2CONR PTM1a R PTM2a , -CONHCH3 or -CH2CONHCH3, wherein each u and v are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -O(CH2) u CO(CH2) v NR PTM1a R PTM2a 、-O(CH2) u CH((CH2) x CH3)(CH2) w CO(CH2) v NR PTM1a R PTM2a 、-O-CH(CH3)CONR PTM1a R PTM2a 、-O-CH2CONR PTM1a R PTM2a or -OCH2C(O)NHOCH3, wherein each u, v, w and x are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -(CH2) u CHCH(CH2) w CO(CH2) v NR PTM1a R PTM2a or -CHCHCONR PTM1a R PTM2a , wherein each u, v and w are independently selected from 1, 2, 3, 4 or 5); optionally substituted (e.g., optionally substituted with straight or branched C1-C4 alkyl; -NH-(CH2) u CO(CH2) v NR PTM1a R PTM2a or -NH-CH2CONR PTM1a R PTM2a , wherein each u and v are independently selected from 1, 2, 3, 4 or 5); optionally substituted -alkyl-heteroaryl (e.g., optionally substituted with C1-C4 alkyl; -(CH2) t2 - optionally substituted 5- or 6-membered heteroaryl; the heteroaryl being selected from oxazol-4-yl, 1,3,4-triazol-2-yl and imidazol-1-yl; and combinations thereof); optionally substituted -NH-alkyl-heteroaryl (e.g., optionally substituted with C1-C4 alkyl or a combination thereof, -NH-(CH2) t2 -(CH2)-(C1-C4)-alkyl, optionally substituted 5- or 6-membered heteroaryl, N-CH2-pyrazol-4-yl); optionally substituted alkyl-cycloalkyl or alkyl-heterocycloalkyl (e.g., optionally substituted C1-C4 alkyl, -(CH2)-(C1-C4)-alkyl, t2 - optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl); optionally substituted -NH-alkyl-cycloalkyl or -NH-alkyl-heterocycloalkyl (e.g., optionally substituted with C1-C4 alkyl, -NH-(CH2) t2 - optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl); optionally substituted -O-cycloalkyl or -O-heterocycloalkyl (e.g., optionally substituted 3-5 membered cycloalkyl or heterocycloalkyl; -O-(oxetane-3-yl)); optionally substituted -O-alkyl-cycloalkyl or -O-alkyl-heterocycloalkyl (e.g., O-(CH2) t2 - optionally substituted 3-5 membered cycloalkyl or heterocycloalkyl; optionally substituted by at least one of =O, OH and C1-C4 alkyl); optionally substituted S-heterocyclyl (e.g., including optionally substituted 4-7 membered heterocyclyl; optionally substituted heterocycloalkyl; optionally substituted by at least one C1-C4 alkyl (e.g., methyl), =O or a combination thereof; or a combination thereof); Each R PTM1a and R PTM2a are independently H, optionally substituted C1-C4 alkyl (e.g., CH3 or CH2CH 3) , optionally substituted C1-C4 alkoxy (eg, -OCH2 or -CH2CH3), CH2OCH3 or R PTM1a and R PTM2a Join together to form a 3-10 membered ring; Each t1 is independently selected from 1, 2, 3, 4 or 5; and Each t2 is independently selected from 0, 1, 2, 3, 4 or 5; Q 11 CH2, CHR PMT3 or NR PMT4 ; R PTM4 is a linear or branched C1-C8 alkyl group optionally substituted by OH; R PMT2 is H, OH, CN, optionally substituted straight or branched C1-C4 alkyl, optionally substituted -NH2 (e.g., -N(C1-C3 alkyl) or -NH(C1-C3 alkyl)), O-optionally substituted straight or branched C1-C4 alkyl, optionally substituted C1-C4 alkynyl, optionally substituted C1-C4 alkyne, optionally substituted monocyclic or bicyclic C3-C12 heterocyclyl (e.g., optionally substituted C3-C12 monocyclic or bicyclic heterocycloalkyl, such as C3-C12 monocyclic or bicyclic heterocycloalkyl, azetidin-1-yl, azetidin-1-yl-3-ol, pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl or morpholin-4-yl, homopiperazin-1-yl, each of which is optionally substituted with one or more of OH, linear or branched C1-C5 alkyl or NH2) or optionally substituted -OC 3-12 Monocyclic or bicyclic heterocyclic groups (eg, optionally substituted -OC 3-12 Monocyclic or bicyclic heterocycloalkyl, such as -OC 3-12 monocyclic or bicyclic heterocycloalkyl, which is optionally substituted with at least one OH, linear or branched C1-C5 alkyl or NH2) or an optionally substituted C3-C12 membered ring (e.g., an optionally substituted C3-C12 non-aryl membered ring, which is optionally substituted with one or more of OH, linear or branched C1-C5 alkyl or NH2), wherein when R PTM2 When it is a ring structure, it is optionally connected via R PTM2 C or N of the ring is covalently linked to Q 16 ;and The PTM The point of attachment to the linker group (L) or ULM is indicated.

4. The compound according to any one of claims 1 to 3, wherein at least one of the following is satisfied: (a) R of PTMIIa1, PTMIIa2, PTMIIb1, PTMIIb2, PTMIIc1, PTMIIc2, PTMIId1, PTMIId2, PTMIIIa1, PTMIIIa2, PTMIIIb1, PTMIIIb2, PTMIIIb3, PTMIIIc1, PTMIIIc2, PTMIIId1, PTMIIId2 PTM1 , or the associated positions of PTMII and PTMIII are selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl and hexyl; (b) R of PTMIIa1, PTMIIa2, PTMIIb1, PTMIIb2, PTMIIc1, PTMIIc2, PTMIId1, PTMIId2, PTMIIIa1, PTMIIIa2, PTMIIIb1, PTMIIIb2, PTMIIIb3, PTMIIIc1, PTMIIIc2, PTMIIId1, PTMIIId2 PTM2 , or the associated positions of PTMII and PTMIII are selected from: H, OH, NH2, -N(CH3)2, ethyl, in represents a bond that can be stereospecific ((R) or (S)) or non-stereospecific; (c) R of PTMIIa1, PTMIIa2, PTMIIb1, PTMIIb2, PTMIIc1, PTMIIc2, PTMIId1, PTMIId2, PTMIIIa1, PTMIIIa2, PTMIIIb1, PTMIIIb2, PTMIIIb3, PTMIIIc1, PTMIIIc2, PTMIIId1, PTMIIId2 PTM3 , or the associated positions of PTMII and PTMIII are selected from: in represents a bond that can be stereospecific ((R) or (S)) or non-stereospecific; and X PTM3 is selected from CH2, O and S; or (d) R of PTMIIa1, PTMIIa2, PTMIIb1, PTMIIb2, PTMIIc1, PTMIIc2, PTMIId1, PTMIId2, PTMIIIa1, PTMIIIa2, PTMIIIb1, PTMIIIb2, PTMIIIb3, PTMIIIc1, PTMIIIc2, PTMIIId1, PTMIIId2 PTM5 , or the associated positions of PTMII and PTMIII are selected from: H, methyl, CFH2, CF2H, ethyl, propyl, isopropyl, cyclopropyl, butyl, pentyl, hexyl, or (e) combinations thereof.

5. The compound according to any one of claims 1 to 4, wherein the PTM is represented by a chemical structure selected from the group consisting of: in represents a bond that can be stereospecific ((R) or (S)) or non-stereospecific.

6. The compound according to any one of claims 1 to 5, wherein VLM is a chemical structure represented by: in: X 1 , X 2 Each independently selected from the bond O, NR Y3 , CR Y3 R Y4 , C=O, C=S, SO and SO2; R Y3 , R Y4 Each is independently selected from H, a linear or branched C optionally substituted by one or more halogens 1-6 Alkyl, optionally substituted by 0-3 R P C 1-6 Alkoxy; R P is 0, 1, 2 or 3 independently selected from H, halo, -OH, C 1-3 Alkyl, C=O group; W 3 is selected from optionally substituted T, optionally substituted -TN(R 1a R 1b )X 3 , optionally substituted -TN(R 1a R 1b ), optionally substituted -T-aryl, optionally substituted -T-heteroaryl, optionally substituted -T-diheteroaryl, optionally substituted -T-heterocyclyl, optionally substituted -T-diheterocyclyl, optionally substituted -NR 1 -T-aryl, optionally substituted -NR 1 -T-heteroaryl or optionally substituted -NR 1 -T-heterocyclyl; X 3 C=O、R 1 , R 1a , R 1b ; R 1 , R 1a , R 1b Each is independently selected from H, a linear or branched C1-C6 alkyl group optionally substituted by one or more halo or -OH groups, R Y3 C=O、R Y3 C=S、R Y3 SO, R Y3 SO2、N(R Y3 R Y4 )C=O、N(R Y3 R Y4 )C=S、N(R Y3 R Y4 )SO and N(R Y3 R Y4 )SO2; T is selected from optionally substituted alkyl, -(CH2) n -group, straight or branched-(CH2) n -OC 1-6 alkyl or optionally substituted -(CH2) n -O-heterocyclyl, wherein each methylene group is optionally substituted by one or two selected from halogen, methyl, optionally substituted alkoxy, linear or branched C1-C6 alkyl optionally substituted by one or more halogens, C(O)NR 1 R 1a or NR 1 R 1a Substituents, or R 1 and R 1a connected to form an optionally substituted heterocyclic group, or an -OH group or an optionally substituted amino acid side chain; and n is 0 to 6, W 4 yes R 14a , R 14b are each independently selected from H, haloalkyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted hydroxyalkyl, optionally substituted alkylamine, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR 26 ,CONR 27a R 27b 、NHCOR 26 or NHCH3COR 26 ; and R 14a and R 14b The other one is H; or R 14a , R 14b together with the carbon atom to which they are attached, form an optionally substituted 3- to 5-membered cycloalkyl, heterocycloalkyl, spirocycloalkyl, or spiroheterocyclyl, wherein the spiroheterocyclyl is not an epoxide or an aziridine; W 5 is selected from optionally substituted phenyl or optionally substituted 5-10 membered heteroaryl (e.g., W 5 optionally substituted with one or more [such as 1, 2, 3, 4 or 5] halo, CN, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, hydroxy or optionally substituted haloalkoxy); and R 15 Selected from H, halogen, CN, OH, NO2, NR 14a R 14b , OR 14a ,CONR 14a R 14b NR 14a COR 14b 、SO2NR 14a R 14b NR 14a S02R 14b , optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloheteroalkyl; and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM'), or a chemical linker moiety that couples at least one PTM or ULM' or both to the ULM.

7. A compound according to any one of claims 1 to 6, wherein VLM is a chemical structure represented by: in: W 3 is selected from optionally substituted aryl, optionally substituted heteroaryl or R9 and R 10 are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl or haloalkyl, or R9, R 10 and the carbon atom to which they are attached form an optionally substituted cycloalkyl group; R 11 is selected from optionally substituted heterocyclyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted aryl, R 12 is selected from H or optionally substituted alkyl; R 13 is selected from H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl or optionally substituted aralkyl; R 14a , R 14b are each independently selected from H, haloalkyl, optionally substituted alkyl, optionally substituted alkoxy, aminomethyl, alkylaminomethyl, alkoxymethyl, optionally substituted hydroxyalkyl, optionally substituted alkylamine, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, CONR 27a R 27b 、CH2NHCOR 26 or (CH2)N(CH3)COR 26 ; and R 14a and R 14b The other one is H; or R 14a , R 14b together with the carbon atom to which they are attached, form an optionally substituted 3- to 6-membered cycloalkyl, heterocycloalkyl, spirocycloalkyl, or spiroheterocyclyl, wherein the spiroheterocyclyl is not an epoxide or an aziridine; W 5 is selected from optionally substituted phenyl or optionally substituted 5-10 membered heteroaryl (e.g., W 5 optionally substituted with one or more [such as 1, 2, 3, 4 or 5] halo, CN, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, hydroxy or optionally substituted haloalkoxy), R 15 Selected from: H; halogen; CN; OH; NO2; NR 14a R 14b ;OR 14a ;CONR 14a R 14b NR 14a COR 14b ; SO2NR 14a R 14b NR 14a S02R 14b ; optionally substituted alkyl; optionally substituted haloalkyl; optionally substituted haloalkoxy; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted cycloalkyl; or optionally substituted cycloheteroalkyl; Each R 16 independently selected from CN, halo, optionally substituted alkyl, optionally substituted haloalkyl, hydroxyl or optionally substituted haloalkoxy; o is 0, 1, 2, 3, or 4; R 18 is independently selected from H, halogen, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy, or a linker; and p is 0, 1, 2, 3 or 4, wherein the dashed line indicates the site of attachment of at least one PTM or a chemical linker moiety that couples at least one PTM to the ULM.

8. A compound according to any one of claims 1 to 5, wherein the VLM has a chemical structure selected from the following: in: R1 is H, ethyl, isopropyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl or haloalkyl; R 14a is H, haloalkyl, optionally substituted alkyl, methyl, fluoromethyl, hydroxymethyl, ethyl, isopropyl or cyclopropyl; R 15 is selected from H, halogen, CN, OH, NO2, optionally substituted heteroaryl, optionally substituted aryl; optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted cycloalkyl or optionally substituted cycloheteroalkyl; X is C, CH2 or C=O R3 is absent or optionally substituted 5 or 6 membered heteroaryl; and The dashed line indicates the attachment site of the chemical linker moiety that couples the PTM to the ULM.

9. The compound according to any one of claims 1 to 5, wherein the CLM comprises a group according to the following chemical structure: in: ULM-g R 1’ is an optionally substituted C1-C6 alkyl, an optionally substituted -(CH2) n OH, optionally substituted -(CH2) n SH, optionally substituted (CH2) n -O-(C1-C6)alkyl, optionally substituted (CH2) n -WCOCW-(C0-C6)alkyl containing an epoxide moiety WCOCW, wherein each W is independently H or C1-C3 alkyl, optionally substituted -(CH2) n COOH, optionally substituted -(CH2) n C(O)-(C1-C6 alkyl), optionally substituted-(CH2) n NHC(O)-R″, optionally substituted -(CH2) n C(O)-N(R″)2, optionally substituted-(CH2) n OC(O)-N(R”) c2 、-(CH2O) n H, optionally substituted -(CH2) n OC(O)-(C1-C6 alkyl), optionally substituted-(CH2) n C(O)-O-(C1-C6 alkyl), optionally substituted-(CH2O) n COOH, optionally substituted -(OCH2) n O-(C1-C6 alkyl), optionally substituted-(CH2O) n C(O)-(C1-C6 alkyl), optionally substituted-(OCH2) n NHC(O)-R″, optionally substituted -(CH2O) n C(O)-N(R″)2, -(CH2CH2O) n H, optionally substituted -(CH2CH2O) n COOH, optionally substituted -(OCH2CH2) n O-(C1-C6 alkyl), optionally substituted-(CH2CH2O) n C(O)-(C1-C6 alkyl), optionally substituted-(OCH2CH2) n NHC(O)-R″, optionally substituted-(CH2CH2O) n C(O)-N(R″)2, optionally substituted-SO2R S , optionally substituted S(O)R S , NO2, CN or halogen (F, Cl, Br, I, preferably F or Cl); Each R" of ULM-g is independently H or C1-C6 alkyl which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups (preferably fluorine); ULM-g R S is C1-C6 alkyl, optionally substituted aryl, heteroaryl or heterocyclic group or -(CH2) m N(R″)2 group; X and X' of ULM-g are each independently C=O, C=S, -S(O), S(O)2, (preferably X and X' are both C=O); ULM-g R 2’ is optionally substituted -(CH2) n -(C=O) u (NR”) v (SO2) w Alkyl, optionally substituted -(CH2) n -(C=O) u (NR1) v (SO2) w N(R")2 group, optionally substituted -(CH2) n -(C=O) u (NR1) v (SO2) w -aryl, optionally substituted-(CH2) n -(C=O) u (NR”) v (SO2) w -heteroaryl, optionally substituted-(CH2) n -(C=O) v NR”(SO2) w -heterocyclic, optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -alkyl, optionally substituted -NR"-(CH2) n -C(O) u (NR1) v (SO2) w -N(R")2, optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -NR"C(O)R", optionally substituted -NR"-(CH2) n -(C=O) u (NR”) v (SO2) w -aryl, optionally substituted -NR"-(CH2) n -(C=O) u (NR”) v (SO2) w -heteroaryl or optionally substituted -NR"-(CH2) n -(C=O) v NR”(SO2) w -heterocycle, optionally substituted -X R2’ -alkyl; optionally substituted -X R2 '-aryl; optionally substituted -X R2 '-heteroaryl; optionally substituted-X R2 '-heterocyclyl; optional substituents; ULM-g R 3’ is optionally substituted alkyl, optionally substituted -(CH2) n -(O) u (NR”) v (SO2) w -alkyl, optionally substituted -(CH2) n -C(O) u (NR”) v (SO2) w -N(R")2, optionally substituted -(CH2) n -C(O) u (NR”) v (SO2) w -NR"C(O)R", optionally substituted -(CH2) n -C(O) u (NR”) v (SO2) w -C(O)N(R")2, optionally substituted -(CH2) n -C(O) u (NR”) v (SO2) w -aryl, optionally substituted-(CH2) n -C(O) u (NR”) v (SO2) w -heteroaryl, optionally substituted-(CH2) n -C(O) u (NR”) v (SO2) w -heterocyclic, optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -alkyl, optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -N(R")2, optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -NR"C(O)R", optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -aryl, optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -heteroaryl, optionally substituted -NR"-(CH2) n -C(O) u (NR”) v (SO2) w -heterocyclic, optionally substituted -O-(CH2)n-(C=O) u (NR”) v (SO2) w -alkyl, optionally substituted -O-(CH2)n-(C=O) u (NR”) v (SO2) w -N(R")2, optionally substituted -O-(CH2)n-(C=O) u (NR”) v (SO2) w -NR"C(O)R", optionally substituted -O-(CH2)n-(C=O) u (NR”) v (SO2) w -aryl, optionally substituted -O-(CH2) n -(C=O) u (NR”) v (SO2) w -heteroaryl or optionally substituted -O-(CH2) n -(C=O) u (NR”) v (SO2) w -heterocyclyl; -(CH2) n -(V) n’ -(CH2) n -(V) n’ -alkyl, optionally substituted -(CH2) n -(V) n’ -(CH2) n -(V) n’ -aryl, optionally substituted-(CH2) n -(V) n’ -(CH2) n -(V) n’ -heteroaryl, optionally substituted-(CH2) n -(V) n’ -(CH2) n -(V) n’ -heterocyclyl, optionally substituted-(CH2) n -N(R 1’ )(C=O) m’ -(V) n’ -alkyl, optionally substituted -(CH2) n -N(R 1’ )(C=O) m’ -(V) n’ -aryl, optionally substituted-(CH2) n -N(R 1’ )(C=O) m’ -(V) n’ -heteroaryl, optionally substituted-(CH2) n -N(R 1’ )(C=O) m’ -(V) n’ -heterocyclyl, optionally substituted -X R3’ -alkyl; optionally substituted -X R3 '-aryl; optionally substituted -X R3 '-heteroaryl; optionally substituted-X R3 '-heterocyclyl; optional substituents; ULM-g R 1N and R 2N are each independently H, C1-C6 alkyl optionally substituted with one or two hydroxyl groups and up to three halogen groups, or optionally substituted -(CH2) n -Aryl, -(CH2) n -heteroaryl or -(CH2) n -heterocyclic group; V of ULM-g is O, S or NR”; ULM-g R 1’ Each independently is H or C1-C3 alkyl; ULM-gX R2’ and X R3’ each independently optionally substituted -CH2) n -、-CH2) n -CH(X v )=CH(X v )-(cis or trans), -CH2) n -CH≡CH-, -(CH2CH2O) n - or C3-C6 cycloalkyl, wherein X v is H, halogen or optionally substituted C1-C3 alkyl; Each m of ULM-g is independently 0, 1, 2, 3, 4, 5, 6; Each m' of ULM-g is independently 0 or 1; Each n of ULM-g is independently 0, 1, 2, 3, 4, 5, 6; Each n' of ULM-g is independently 0 or 1; Each u of ULM-g is independently 0 or 1; Each v of ULM-g is independently 0 or 1; Each w of ULM-g is independently 0 or 1; and ULM-g R 1’ , R 2’ , R 3’ Any one or more of X, X and X' are optionally modified to be covalently bonded to the PTM group via a linker group or a pharmaceutically acceptable salt or stereoisomer thereof.

10. The compound of any one of claims 1 to 5, wherein the CLM is selected from thalidomide, lenalidomide, pomalidomide, an analog thereof, an isostere thereof, or a derivative thereof.

Citation Information

Cited By

  • PROTACs compounds for targeted degradation of BCL6 and application of PROTACs compounds

    CN121159515A